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ABSTRACT
Multiple sclerosis (MS) is a complex neurological disorder characterized by
the interactions between heightened inflammation, oxidative stress and
neurodegeneration. We and others have previously demonstrated that
proteasome dysfunction and its consequences are also important factors in the
pathology of both MS and its rodent model, experimental autoimmune
encephalomyelitis (EAE). While proteasome subunit alterations in EAE have been
observed, the underlying mechanisms are poorly understood. The first goal of this
dissertation was to characterize the mechanisms that regulate proteasome
expression and composition in neural cells in EAE and in vitro.
Immunohistochemical analysis of the EAE spinal cord shows changes in
proteasome composition in neurons and astrocytes. Molecular and biochemical
methods revealed that constitutive proteasome (c-20S) mRNA and protein levels
are reduced while immune-proteasome (i-20S) and 11S regulator expression is
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augmented in EAE. This altered composition is most likely due to two processes,
the first of which is a decline in two transcription factors upstream of c-20S
subunits: nuclear factor (erythroid-derived 2) like-1 (Nfe2l1/Nrf1) – which regulates
proteasome gene expression – and one of its regulators, pre-B cell leukemia
homeobox domain 1 (PBX1). The second is a heightened signal transducer and
activator of transcription 1 (STAT-1) / interferon regulatory factor 1 (IRF-1)
signaling, which mediates the displacement of constitutive subunits for inducible
subunits. Differentiated N2a neurons and C6 astrocytes in vitro display similarly
elevated i-20S and 11S levels when exposed to CIII, a pro-inflammatory cytokine
cocktail (i.e., interferon-g, interleukin-1b and tumor necrosis factor-a). Surprisingly,
neither exhibit changes in PBX1 / Nrf1 or in c-20S-specific subunit mRNA.
Altogether, these data imply that proteasome subunit displacement caused by
elevated STAT-1 / IRF-1 is the main mechanism dictating proteasome composition
in cultured neurons and astrocytes.
The second goal of this dissertation was to understand how reactive
astrocytes participate in neuroinflammation – recent evidence suggests that there
are different neurotoxic (A1) and neurotrophic (A2) reactivities. Because A1
astrocytes have been found in the lesions of MS patients, we expanded this idea
to our own models. We found A1-reactive astrocytes in the EAE spinal cord, and
two pro-inflammatory cytokine-induced reactivities in differentiated C6 astrocytes.
The first type (A1-reactive) express heightened NF-kB, complement C3 and Nrf2,
while the levels of these constituents in the second (pan-reactive) type are
reduced. Furthermore, inhibition of active NF-kB in A1-reactive astrocytes results
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in abrogated expression of Nrf2 and complement C3, suggesting that both the
astrocytic response to inflammation and Nrf2 expression are connected to NF-kB
signaling.
The findings presented in this dissertation shed light on the signaling
mechanisms responsible for proteasome regulation in an animal model of MS.
They also reveal the differences in these mechanisms and proteasome
composition in neurons and astrocytes, as well as diverse reactions by astrocytes
during inflammation. We hope that these studies will not only increase our
understanding of the pathophysiological processes underlying MS, but also
provide the basis for developing new therapeutic approaches to treat this
debilitating neurological disorder.
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Chapter 1 – General Introduction
Multiple sclerosis
Multiple sclerosis (MS) is the most common demyelinating disease in
humans and the most frequent neurological disorder affecting young adults
according to the Centers for Disease Control. In 2010, over 700,000 people in the
US were estimated to have MS – women were more likely to be diagnosed than
men and there was a higher prevalence in people residing in northern regions in
the country compared to southern regions (Wallin et al., 2019). MS is considered
to be an autoimmune disease of unknown etiology characterized by severe central
nervous system (CNS) inflammation, demyelination, oligodendrocyte cell death
and neuronal damage (Lassmann et al., 2007). These neuropathologies lead to
various symptoms including decreasing mobility, vision impairment and cognitive
deficits among many others.
The time-course of the disease varies according to where a patient falls on
the spectrum of MS (Lublin et al., 2014). Considering the onset of disease,
clinically isolated syndrome is diagnosed by the appearance of demyelination and
lesions in the brain as the result of inflammation. If the disease remains active, the
patient then typically develops oscillating phases of remission and relapse – this
is considered relapsing-remitting MS. About 80-90% of patients suffer from this
form, making it the most common MS type (Lassmann et al., 2012). The disease
often continues into secondary progressive MS, in which the periods between
remission and relapse shorten while the CNS begins to degenerate, and the
patient experiences a continuous neurological decline. In about 10% of cases, the
1

disease progresses from the onset without any relief in symptoms – this is
considered primary progressive MS. There is currently no cure for MS and most
therapies are directed at reducing the intensity and number of relapses.
Experimental autoimmune encephalomyelitis
The molecular and cellular mechanisms underlying tissue damage in MS
are explored using a variety of animal models, but the most common is
experimental autoimmune encephalomyelitis (EAE) (Gold et al., 2006). EAE is
typically induced in rodents using a myelin protein, such as myelin oligodendrocyte
glycoprotein (MOG) or its encephalitogenic peptide (Mendel et al., 1995), along
with an immune system enhancer (i.e. Freund’s adjuvant). These injections
generate a CNS-specific, demyelinating, autoimmune disorder in the animals
similar to MS (Bizzozero and Zheng, 2009). Although EAE is not a perfect model,
it shares a number of clinical and pathological features with MS and is routinely
used to test therapeutic approaches (Baxter, 2007). The spinal cord is the most
affected CNS region in EAE and is pathologically characterized by perivenular
infiltration of lymphocytes, macrophage/microglial activation, demyelination and
axonal damage (Kuerten et al., 2007). Another prominent pathological
characteristic of MS and EAE is astrogliosis and glial scarring (Brosnan and Raine,
2013) – astrocytes in diseased or damaged tissue are often described as reactive
since they undergo changes in their phenotype (i.e. become hypertrophic) along
with altered molecular signaling in response to the CNS microenvironment
(Sofroniew, 2009).
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Astrocyte Reactivity
Recently, the study of reactive astrocytes and their function in the CNS has
taken a large and complex step forward. Because reactive astrocytes, along with
reactive microglia, are often considered to be “first responders” during CNS injury
or disease, it is clear that discovering the mechanisms behind their variable
functions is essential to understanding their interactions with the rest of the CNS
(Anderson et al., 2014; Sofroniew, 2009). The most common marker for reactive
astrogliosis is glial fibrillary acidic protein (GFAP) – which was first characterized
during a study of MS lesions – although not all astrocyte populations express it to
the same extent (Eng et al., 2000; Sofroniew and Vinters, 2010). These cells play
critical roles that include participating in CNS development, synapse formation,
blood flow regulation and cellular metabolism as well as responding to stressors
like inflammation and oxidative stress (Sofroniew and Vinters, 2010).
Historically, astrocyte reactions to stress have been generalized down to
reactive or non-reactive based on the amount GFAP they express (Liddelow and
Barres, 2017). However, detectable gene expression changes within astrocytes
allow for new phenotypic classifications (Zamanian et al., 2012). For example, two
distinct types of astrocytes – neuroinflammatory and hypoxic – are generated in
vivo using lipopolysaccharide (LPS) injections or middle cerebral artery occlusion
(MCAO), respectively. Both share common reactive markers, such as GFAP and
vimentin, as well as markers unique to their specific reactivities. The MCAO
astrocytes tend to express more neurotrophic genes, as opposed to the LPS
astrocytes which express more inflammatory, neurotoxic genes (Zamanian et al.,
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2012). These two types were named A1 (i.e. neurotoxic) and A2 (i.e. neurotrophic)
astrocytes, similar to the designations of reactive microglia (Fig. 1.1; Liddelow et
al., 2017; Martinez and Gordon, 2014). In addition, this same group discovered
that the A1 phenotype, characterized by elevated expression of complement C3,
could be induced in vitro using either a combination of immune molecules (e.g.,
complement C1q, interleukin-1a, and tumor necrosis factor-a) or medium from
LPS-activated microglia (Liddelow et al., 2017). Culture medium from the A1reactive astrocytes causes the death of neurons and oligodendrocytes, implying
that A1 astrocytes release harmful substances into the CNS microenvironment. In
addition, optic nerve crush injury in vivo stimulates A1 reactivity and increases cell
death of damaged retinal ganglion cells, and this effect is prevented by genetic
ablation of A1 inducing cytokines. The above studies introduced the idea that
astrocyte reactivity, particularly in the A1 subtype, is important in the context of
CNS injury and disease.

A1 astrocytes

Neurotoxic

A1+A2+An

Mixed Effects

Immune Signaling
Complement Pathway
Antigen Presentation
Cell Cycle Arrest/Death

A2 astrocytes

Neurotrophic
Growth Factors
Metabolism
Transcription Factors
Cell Cycle Signaling

Figure 1.1– Continuum of astrocyte reactivity (adapted from Liddelow and Barres,
2017) including two major types (A1 and A2), as well as undiscovered types (An),
and the corresponding pathways that are upregulated in each type (Zamanian et al.,
2012).
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Role of reactive astrocytes in neurodegenerative disease
The ground-breaking study by the Barres laboratory not only discovered
what triggers A1 reactivity, but also determined that this phenotype could be found
in diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD),
amyotrophic lateral sclerosis (ALS) and MS (Liddelow et al., 2017). The authors
suggested that A1 astrocytes may contribute to these pathologies through the
release of neurotoxic factors as well as the loss of normal astrocytic functions, like
synapse maintenance and phagocytosis. Likewise, other groups have found that
the number of A1 reactive astrocytes rise during aging and that blockage of this
cell type – through complement C3 receptor inhibition – can ameliorate pathogenic
features in animal models of AD and PD (Clarke et al., 2018; Lian et al., 2016; Yun
et al., 2018). Heightened complement C3 was also discovered in optic nerve
astrocytes of EAE animals (Tassoni et al., 2019), denoting the presence of A1reactive astrocytes in this disease.
Many of these studies also implicate the upregulation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB) in A1-reactive astrocytes
as a primary contributor to disease progression, since this factor can bind to the
C3 promoter following its activation by tumor necrosis factor-a or TNF-a (Lian et
al., 2015). Genetic deletion of astrocytic NF-kB abrogates symptom severity and
disease time-course in EAE animals (Brambilla et al., 2009, 2014). A similar
protective effect of NF-kB ablation was discovered in animal models of ischemia
and spinocerebellar ataxia type 3 (Dvoriantchikova et al., 2009; Li et al., 2018).
Moreover, a connection between astroglial NF-kB expression and MS has also
5

been documented. One example is that astrocytes with heightened NF-kB
expression have been localized to MS lesions. This particular set of MS patients
have a genetic variant in the NFKB1 locus that has been associated with an
elevated risk of developing the disease (Ponath et al., 2018). It is important to note,
however, that inflammatory signaling through NF-kB is not the only mechanism by
which astrocytes contribute to MS and EAE, as these cells can also cause
oxidative damage through NADPH oxidase activation or nitric oxide production
(Brambilla, 2019; Mossakowski et al., 2015).
Oxidative stress in MS and EAE
Both MS and EAE are multi-dimensional diseases with inflammatory and
degenerative features, as well as high levels of reactive oxygen species (ROS)
that contribute to cell death in the CNS. Elevated and chronic oxidative stress
conditions can cause protein oxidation and aggregation, lipid peroxidation, axonal
degeneration and apoptosis. Furthermore, protein oxidation leads to irreversible
modifications, like carbonylation, which has been demonstrated in the brains of MS
patients (Bizzozero et al., 2005). Under normal conditions, these damaged
proteins are degraded by cellular proteases (Bizzozero, 2008). These include the
proteasome – the major, ubiquitously expressed proteolytic enzyme complex –
various mitochondrial proteases and lysosomal proteinases. The widespread
expression of these proteases helps to combat protein dysfunction and
aggregation under oxidative stress conditions throughout cellular compartments.
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Structure and function of proteasomes
The proteasome is a highly conserved proteolytic complex in charge of the
degradation of most proteins in the cytoplasmic and nuclear compartments. This
proteolytic machinery degrades not only damaged proteins to maintain healthy
cellular environments, but also ubiquitinated proteins that are involved in signaling,
immunity and apoptosis (Kumar Deshmukh et al., 2019; Rechsteiner, 2005). The
20S core proteasome is comprised of four rings made up of seven subunits each,
with the two inner rings formed by β-subunits and the two outer rings formed by
the α-subunits (Fig. 1.2; Huber et al., 2012). Of the seven β-subunits, only three
contain proteolytic active sites: β1, β2 and β5 have caspase-like, trypsin-like and
chymotrypsin-like activity which cleave after acidic, basic and hydrophobic
residues, respectively (Coux et al., 1996).

11S Regulator (PA28)

β subunits (1 of each per ring)
β1: caspase (#)
β2: trypsin ($)
β5: chymotrypsin (*)

Inflammation
(IFN-g)
# $

# $

Oxidative Stress
(ROS)
Constitutive 20S
*

*

βi subunits (1 of each per ring)
β1i: caspase (#)
β2i: trypsin ($)
β5i: chymotrypsin (*)

Immune 20S

⍺ subunit
Core β subunit
Catalytic β subunit
Inducible β subunit

Figure 1.2 – Constitutive 20S proteasome and immuno 20S proteasome structures,
including the a and b rings for each complex as designated by the key at the bottom.
Thick arrow indicates the trigger of displacement of constitutive b-subunits by inducible bsubunits. The specific catalytic activities of the relevant b-subunits are represented by the
following symbols: caspase-like (#), trypsin-like ($) and chymotrypsin-like (*). The 11S
regulator or PA28 composition is also shown, with dark pink being PA28a and light pink
being PA28b subunits, which can bind to both 20S proteasomes. Adapted from JohnstonCarey et al., (2015).

7

The α-subunits can recruit other regulatory or co-activator caps, such as the
11S (i.e. PA28) and 19S (i.e. PA700), that bind to one or both ends of the 20S
particle (Pickering and Davies, 2012). The 11S particle – a hexamer of alternating
PA28a and b subunits – associates with the 20S upon high levels of oxidative
stress as well as phosphorylation of the 20S. This activator seems to be necessary
for more efficient degradation of oxidized proteins in both the cytoplasm and the
nucleus following low doses of hydrogen peroxide (Pickering and Davies, 2012).
In contrast, the 19S activator binds to the 20S core to form the 26S proteasome,
thus providing ATPase activity as well as substrate selection for degradation of
poly-ubiquitinated proteins (Tomko and Hochstrasser, 2013). Another regulator,
proteasome inhibitor 31 kilodalton (PI31), has been shown to inhibit peptide
generation for antigen presentation (Zaiss et al., 2002). However, with or without
regulators, the 20S proteasome can still function in an ATP-independent manner
– unlike the 26S proteasome which needs ATP in order to degrade its ubiquitinated
substrates (Raynes et al., 2016).
Upon activation of the immune response by inflammation, the three catalytic
b-subunits of the 20S proteasome (β1, β2 and β5) are substituted for the
respective inducible subunits (β1i, β2i and β5i) (Aki et al., 1994; Hussong et al.,
2010; Lundh et al., 2017). This process, called subunit displacement, leads to the
replacement of constitutive 20S proteasome (c-20S) for the inducible or immuno20S proteasome (i-20S) (Früh et al., 1994). The i-20S is thought to be the dominant
proteasome form during immune responses, compared to the c-20S and 26S
proteasomes (Pickering et al., 2010). In addition, it was recently demonstrated that
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the 11S regulator preferentially binds to the i-20S as opposed to the c-20S,
whereas the 19S does not prefer one over the other (Fabre et al., 2015). On the
other hand, PI31 was shown to prefer binding to the c-20S.
Transcriptional regulation of proteasome expression
Because proteasomes respond to changes in the environment, their
expression is tightly regulated by a variety of signaling pathways. Of these,
inflammation and oxidative stress are two of the more common inducers.
Inflammatory cytokines, particularly interferon gamma (IFN-g) - highly expressed
in both MS and EAE - have been shown to increase i-20S proteasomes. IFN-g is
also able to induce the chaperone proteasome maturation protein (POMP) in vitro,
thereby facilitating the formation of immunoproteasomes (Heink et al., 2005). All
three inducible subunits contain interferon-stimulated response elements (ISRE)
in their promoters that are responsive to IFN-g through indirect signaling pathways
(Fig. 1.3). When IFN-g binds to its receptors, the receptors dimerize and activate
the associated Janus kinases (Jak) to phosphorylate signal transducer and
activator of transcription 1 (STAT-1). In turn, phosphorylated STAT-1 can dimerize
and translocate into the nucleus to activate another transcription factor, interferon
regulatory factor 1 or IRF-1 (Castro et al., 2018; Wang et al., 2010). IRF-1 has
been found to increase expression of all inducible subunits in concert with
phosphorylated STAT-1 (Chatterjee-Kishore et al., 1998; Foss and Prydz, 1999;
Heink et al., 2005). IFN-g has also been demonstrated to upregulate the subunits
of the 11S regulator (Ahn et al., 1995).
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Inducible Proteasome Genes
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Figure 1.3 – Pathway of IRF-1 activation by IFN-g/STAT-1 signaling (adapted from
Castro et al., 2018). Two IFN-g receptors, IFN-gR1 (blue) and IFN-gR2 (red), have
attached JAK1 (blue rectangles) and JAK2 (red rectangles). Following phosphorylation of
each other, STAT-1 docks and is phosphorylated. As a dimer, it then translocates to the
nucleus to activate IRF-1 transcription through binding of the interferon-g activated
sequence (GAS) site. IRF-1 is then expressed and localizes to the nucleus where it binds
ISRE-containing genes. Note that the IRF-1 promoter can also bind and be activated by
NF-kB p65/p50.

Inflammation is not the only trigger of inducible and 11S regulator subunit
expression. Extensive research has shown that two nuclear factor (erythroidderived 2)-like transcription factors, Nrf1 and Nrf2, play a role in activation of these
subunits under conditions of oxidative stress. These factors bind to electrophile
response elements (EpRE) in the promoters of the genes they regulate – indeed,
all proteasome and proteasome regulator subunit genes contain these sequences
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nearby their transcription start sites (Baird et al., 2017). However, the specific
localization of the sequence within the genome is more consistent with Nrf1 binding
rather than Nrf2. This notion is supported by previous studies showing that Nrf1 is
the primary regulator of proteasome subunit gene expression. A form of Nrf1 found
in humans, TCF11, induces 26S proteasome gene expression following
proteasome inhibition (Steffen et al., 2010). In mouse cells, proteasome inhibition
causes Nrf1-mediated synthesis of new subunits, since cells in which Nrf1 is
knocked out are not able to produce new subunits (Radhakrishnan et al., 2010).
Furthermore, limited proteasome inhibition increases Nrf1 and its various active
forms, which then triggers transcription of the 26S proteasome subunits (Sha and
Goldberg, 2014). Specific knockout of Nrf1 in the neurons of mouse brains causes
direct abrogation of 20S a- and b-subunit expression without oxidative stress
playing a major role (Lee et al., 2011), demonstrating the importance of Nrf1 in
proteasome expression.
In comparison to Nrf1, Nrf2 seems to be more important during periods of
high oxidative stress (Zhang and Xiang, 2016). The 20S proteasome becomes
elevated under oxidative stress as a result of increased Nrf2 signaling in both
invertebrates and mammals (Pickering et al., 2013). This heightened expression
of 20S proteasomes can be due to Nrf2 activation induced by not only electrophilic
agents – such as dimethyl fumarate and tert-butyl hydroquinone (tBHQ) – that can
react with nucleophilic thiol groups but also various oxidants (Kwak et al., 2003;
Lipton et al., 2016). For example, during hydrogen peroxide-induced oxidative
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stress, elevated Nrf2 increases both 20S and 11S proteasomal subunit expression
(Pickering et al., 2012).
Proteasome dysfunction in disease
Disruption of the processes that govern protein homeostasis (i.e.,
proteostasis) caused by proteasome impairment is a common problem in many
pathologies, but particularly in neurodegenerative disease. Because many of these
diseases often present with accumulation of mutant or damaged proteins, any
change in proteasome function could play a role in the pathology. a-Synuclein, a
major player in PD, is known to disrupt proteasome chymotrypsin-like activity in
both rat pheochromocytoma PC12 and human neuroblastoma SHSY-5Y cell lines
– which have noradrenergic and dopaminergic phenotypes, respectively (Zondler
et al., 2017). Reduced proteasome function has also been discovered in the CNS
of patients with Huntington’s disease (HD), leading to increases in ubiquitinated
proteins (Seo et al., 2004). Furthermore, overexpression of 11S subunits in
fibroblasts from HD patients cannot rescue the abrogated proteasome activity.
Proteasome dysfunction has also been associated with ALS. In vitro studies have
shown that acute proteasome inhibition causes superoxide dismutase 1 (SOD-1)
to change its conformation to the more toxic, aggregation-prone form commonly
found in ALS (Kitamura et al., 2014). Similarly, in the SOD-1G93A mouse model
of familial ALS, proteolytic activity of the proteasome is reduced by 50% in the
lumbar spinal cord where 20S levels are decreased in motor neurons (Kabashi et
al., 2004). Changes in proteasomes, including decreased activity, have also been
found in AD (Keller et al., 2000). Isolated 26S proteasomes from mice with
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tauopathy have lower proteolytic activity and are directly connected to tau proteins
(Myeku et al., 2016). Indeed, tau aggregates reduce the activity of proteasomes
isolated from mice without the disease. This coincides with a previous study
indicating that the protein substrates in AD are the most likely culprit behind
decreased proteasome activity, rather than dysfunction of the proteasome itself
(Gillardon et al., 2007). Altogether, changes in either proteasome activity or levels
seem to be a common facet of neurodegenerative pathology.
Proteasomes have been theorized to play a role in MS for the past decade,
including in our own work. Autoantibodies directed towards multiple proteasome
subunits have been found in the serum and cerebral spinal fluid of MS patients
(Mayo et al., 2002). Moreover, a mutation in the b1i gene has been connected to
a lower risk of MS development as well as higher production of a non-immunogenic
myelin peptide (Mishto et al., 2010). Knockout of this same gene in mice causes
proteasome activity to substantially decrease in the brain concurrent with higher
levels of carbonylated proteins (Ding et al., 2006). Similarly, knockout of the β5i
subunit in EAE mice leads to faster onset of more severe symptoms and significant
accumulation of poly-ubiquitinated proteins in their brain tissue (Seifert et al.,
2010). Our lab has discovered that the activity of the 20S proteasome is
significantly diminished in both the gray matter and white matter of MS brains
(Zheng and Bizzozero, 2011). In addition, both the cerebella and spinal cords of
animals with EAE show similar reductions in activity (Zheng and Bizzozero, 2010a,
2010b) as well as high levels of both oxidized and aggregated protein species
(Bizzozero and Zheng, 2009; Dasgupta et al., 2013).
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Nrf transcription factors: antioxidant response under normal and disease
conditions
The antioxidant response system present in most cells is highly regulated
via a family of transcription factors that belong to the cap’n collar basic leucine
zipper (CNC-bZIP) family. There are two major designations within this family: the
BTB and CNC homology (Bach) proteins and the Nrf proteins. Nrf1 and Nrf2 are
known to be ubiquitously expressed throughout tissues and cell types, while NFE2 p45 and Nrf3 are more tissue specific (Tebay et al., 2015). A common function
of all the CNC-bZIP transcription factors is their ability to heterodimerize with small
musculoaponeurotic fibrosarcoma (sMaf) proteins and bind to promoter
sequences referred to as antioxidant response elements (ARE) or electrophile
response elements (EpRE) (Itoh et al., 1997). These sequences can be found in
promoters of antioxidant genes as well as genes related to the GSH conjugation
phase of drug metabolism (i.e., phase II xenobiotic genes) in which drugs are made
more water soluble (Tebay et al., 2015). Nrf1 is known to activate genes similarly
to Nrf2 in the presence of stressors like ROS and proteasome inhibition; however,
due to multiple Nrf1 isoforms, it can also competitively inhibit Nrf2 from binding or
inhibit EpRE activation altogether (Kim et al., 2016). Nrf3 has been shown to
respond to stress signals like inflammatory cytokines TNF-a and IFN-g (Chénais
et al., 2005; Kitaya et al., 2007), both of which are prominent in MS and EAE. Due
to the large number of genes that are targeted by the Nrf family, loss of function in
any of these factors could be catastrophic.
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Nrf1 forms and functions
Nrf1 is important for basal control of the antioxidant pathways as well as
responses to endoplasmic reticulum stress (Zhang and Xiang, 2016). Knockout
studies have revealed that of the three Nrfs, only Nrf1 leads to embryonic lethality
in mice when deleted and can cause neurodegeneration in neuronal-specific
knockouts (Lee et al., 2011). Nrf1 may also compensate for the loss of both Nrf2
and Nrf3 (Derjuga et al., 2004). However, due to multiple transcripts of its gene –
Nfe2l1 – as well as alternative splicing, Nrf1 is an incredibly complex protein with
many different forms and accompanying activities (Fig. 1.4). In rodents and
humans, the full form of Nrf1 is a 120-kilodalton (kDa) protein called Nrf1a that is
glycosylated under basal conditions and translocates to and lodges in the
endoplasmic reticulum (ER) membrane (Wang and Chan, 2006). Full length, or
p120, Nrf1 is deglycosylated to the p95 form and released into the cytoplasm
where it undergoes progressive cleavage to result in many shorter forms, like the
activating p85 (Zhang and Hayes, 2013).
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Figure 1.4 – Localization and production of the various forms of Nrf1 (adapted from
Bugno et al., 2015). Following its transcription, full-length Nrf1/p120 is localized to the ER
as a transmembrane protein and glycosylated (red u-shapes). In the absence of stress
p120 is eliminated by proteasomal degradation. Oxidative stress and/or ER stress activate
Nrf1, whereby it is deglycosylated and cleaved into the various forms listed. Additionally,
some forms (e.g., Nrf1b, Nrf1g or Nrf1d) are considered to be alternatively translated. The
EpRE activating capability of each isoform is indicated by the color of the name: strong
activators (green), weak activators (blue) and dominant negative inhibitors (red). The
various Nrf1 isoforms translocate to the nucleus, heterodimerize with a sMaf protein and
activate transcription of genes such as proteasome subunits or antioxidant proteins.

Although there is some disagreement as to how some of the shorter forms
arise – whether it is due to proteolytic processing or alternative translation initiation
– there are a number of shorter forms that still maintain Nrf1’s EpRE binding
activity. One of these is a supposedly alternatively translated form has a molecular
weight of 55-65 k, depending upon the gel composition. This shorter form, called
LCR-F1 or Nrf1b, is considered to be a weak EpRE activator but may have differing
activity depending upon the stress signal (Zhang et al., 2014a). For instance, one
group found that the p65 form of Nrf1 could act as an EpRE repressor by blocking
Nrf2 from binding to the promoters of its target genes (Wang et al., 2007). Finally,
two shorter forms that can be generated either by cleavage of Nrf1b or by
alternative splicing are Nrf1g/p36 and Nrf1d/p25. These smaller proteins are
considered to be dominant negative inhibitors of EpRE activators (Zhang et al.,
2014a).
Nrf2 role in cellular function and disease
Though all of the CNC-bZIP factors can bind to EpRE, Nrf2 is the best
studied of these and controls the activation of over 200 stress response genes
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(Chorley et al., 2012). These genes are not only related to the antioxidant
response, but are also present in autophagy, cytoprotection, metabolism,
inflammation, mitochondrial dysfunction and many other processes. Because of
the vast regulatory reach of Nrf2, deletion of its gene (Nfe2l2) has significant
repercussions including mitochondrial dysfunction, reduced glutathione (GSH)
levels, increased susceptibility to chemically induced carcinogenesis and
augmented neuronal death in models of neurodegenerative disease (Tebay et al.,
2015).
In EAE, the disease is much more severe and has an earlier onset in mice
lacking Nrf2 as compared to wild-type mice (Johnson et al., 2010). Moreover, EAE
can be treated effectively using dimethyl fumarate (DMF), which increases Nrf2
levels in the CNS and reduces the levels of oxidized proteins and demyelination
(Linker et al., 2011). DMF has not only been used to treat EAE, but is also currently
being used to treat MS patients (Fox et al., 2012; Linker et al., 2011). When Nrf2
is activated in astrocytes, specifically, it has been shown to promote
neuroprotection in various models of neurological disorders, like PD and ischemia
(Bell et al., 2011; Vargas and Johnson, 2009). Neurons are known to have very
little intrinsic Nrf2 and minimal capacity to produce antioxidants, thus they rely
heavily on astrocytic Nrf2 signaling (Baxter and Hardingham, 2016). Furthermore,
in the demyelinating cuprizone mouse model of MS, Nrf2 activation via Kelch-like
ECH associated protein 1 (Keap1) knockdown in astrocytes led to a decrease in
demyelination and increased protection of oligodendrocytes (Draheim et al., 2016).
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Control of Nrf2 levels via translational and post-translational regulation
Nrf2 levels are tightly regulated both translationally and post-translationally
(Fig. 1.5; Bryan et al., 2013). An internal ribosome entry site (IRES) is present in
the 5’ untranslated region of Nfe2l2 mRNA, indicating that this protein can undergo
cap-independent translation (Li et al., 2010). Under conditions like oxidative stress,
the IRES allows the 40S ribosome to bind Nfe2l2 mRNA via phosphorylation of
eukaryotic initiation factor 2 alpha (eIF2a) (Klann and Dever, 2004). IRESdependent translation of Nrf2 also seems to be redox sensitive and can balance
out with degradation at basal levels (Li et al., 2010). Cap-independent translation
is contingent upon the kinases responsible for phosphorylating eIF2a at serine 51,
such as general control non-derepressible (GCN), haem-regulated initiation factor
2a kinase (HRI), eIF2a kinase 3 (PERK) and protein kinase RNA-regulated (PKR)
(Klann and Dever, 2004).
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Figure 1.5 – Scheme representing regulation of Nrf2 by translational and posttranslational mechanisms. Phosphate groups are the p-labeled pink circles while
ubiquitin groups are the Ub-labeled orange circles.

Following translation, Nrf2 is bound by Keap1, which is responsible for
maintaining basal levels of Nrf2 through degradation (Regoli and Giuliani, 2014).
Once bound by Keap1, Nrf2 is ubiquitinated by Keap1’s binding partners, Cullin-3
(Cul3) and RING-box 1 (Kobayashi et al., 2004). The ubiquitinated Nrf2 is then
transported to the proteasome where it is degraded; due to this tight regulation,
Nrf2 protein has a very short half-life (~30 minutes) (Nguyen et al., 2009). Other
Keap1 binding partners act oppositely to Cul3 and instead prevent the
sequestration of Nrf2 by Keap1. Sequestosome 1 (p62), phosphoglycerate mutase
5 (PGAM5) and parkin 7 (DJ-1) all can attach to the Nrf2 binding site on Keap1
and therefore promote the release and activation of Nrf2 (van Horssen et al., 2010;
Komatsu et al., 2010; Lo and Hannink, 2008). Similarly, the cyclin dependent
kinase inhibitor p21 can directly block Keap1-mediated degradation of Nrf2 by
binding to Nrf2 at the same site that Keap1 would normally attach (Chen et al.,
2009). Once a stressor has been detected, such as ROS or electrophilic
compounds that react to thiol groups on Keap1, Nrf2 is released from Keap1 by
phosphorylation of serine 40 (Bloom and Jaiswal, 2003).
Nrf2 can also be degraded independently of Keap1 via the activity of
glycogen synthase kinase 3b (GSK-3b). GSK-3b can phosphorylate and activate
Fyn kinase to phosphorylate Nrf2 and signal its shuttling from the nucleus (Jain
and Jaiswal, 2007). Levels of GSK-3b and its active phosphorylated form are
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unaltered in EAE (Morales Pantoja et al., 2016), which rules out GSK-3b
interference in Nrf2 nuclear translocation and subsequent degradation.
Transcriptional regulation of Nrf signaling
While both Nrf1 and Nrf2 pathways can crosstalk with a number of different
transcription factors, this dissertation will focus on those that may be critical to the
regulation of proteasome expression and to the behavior of astrocytes. These are
the mammalian (or mechanistic) target of rapamycin (mTOR) and the pre-B-cell
leukemia homeobox-1 transcription factor (PBX1) for Nrf1, and NF-kB for Nrf2.
As a member of the phosphatidylinositol 3-kinase (PI3K) family, mTOR
participates in a wide variety of cellular functions mostly focused on cell growth,
survival and proliferation. Specifically, mTOR can be found in two protein
complexes (mTORC), mTORC1 and mTORC2, where it acts as the catalytic
component. mTORC1 is particularly responsible for regulating metabolic
processes that contribute to cellular growth, which also include protein
homeostasis (Saxton and Sabatini, 2017). One of the downstream targets of
mTORC1 is the sterol responsive element binding protein (SREBP) family of
transcription factors, which activate fatty acid and cholesterol synthesis
(Porstmann et al., 2008). This is one example of a pathway that has been
implicated in Nrf1 activation as well as subsequent proteasome upregulation (Fig.
1.6). Genetic overactivation of mTORC1 or cellular exposure to growth factors is
sufficient to upregulate Nrf1 gene and protein expression, thereby increasing gene
expression of both 20S and 19S subunits (Zhang et al., 2014b). In addition,
knockdown of SREBP1, specifically, results in decreased Nfe2l1 expression. This
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transcriptional regulation of Nrf1 and proteasome gene expression could be
responsible for maintenance of amino acid levels during periods of cellular growth
through enhanced protein degradation.
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Figure 1.6 — Pathway of Nrf1 activation by mTORC1/SREBP1 (adapted from Zhang
and Manning, 2015). mTORC1 activates transcription of SREBP1, which localizes to the
ER membrane and upon activation, it migrates to the Golgi and is cleaved. The cleaved
SREBP1 travels to the nucleus and binds to genes with a sterol regulatory element (SRE)
– this activates transcription of Nfe2l1.

Another protein that is thought to act upstream of Nrf1 is the homeobox
protein PBX1. Besides playing a critical role in the development of tissue and
organs (Capellini et al., 2011), PBX1 is also important in the differentiation and
survival of midbrain dopaminergic neurons (Villaescusa et al., 2016). This study –
using chromatin immunoprecipitation (ChIP) in combination with next generation
sequencing – discovered that PBX1 can bind to genomic locations proximal to the
Nfe2l1 transcription start site, suggesting Nfe2l1 as a possible PBX1 target.
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Furthermore, patients with PD – in which there is considerable damage to these
neurons in the substantia nigra – have lower levels of both PBX1 and Nfe2l1 in this
particular neuronal population. Overall, the above literature provides evidence that
mTOR and PBX1 are important in the transcriptional regulation of Nrf1 in
pathological conditions.
In terms of Nrf2 crosstalk partners that could play a role in disease, one of
the most prominent and best studied is NF-kB (Fig. 1.7). NF-kB is a complex of
transcription factors that is primarily responsible for pro-inflammatory signaling
during immune responses (Oeckinghaus et al., 2011). Activation of NF-kB occurs
when immune components, such as TNF-a or interleukin-1b (IL-1b), bind to their
respective receptors and signal activation of the IkB kinase (IKK) complex. This
complex phosphorylates the IkB protein, which basally binds and sequesters two
NF-kB proteins: p50 and p65 or RelA. Once released by phosphorylated IkB, p50
and p65 translocate to the nucleus where they activate genes with kB binding sites.
These genes include those of cytokines, chemokines, adhesion molecules and
various transcription factors (Pahl, 1999). In addition, oxidative stress has been
demonstrated to induce NF-kB activation through its upstream regulatory
pathways (Kabe et al., 2005).
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Figure 1.7 – Canonical NF-kB activation by IL-1b and TNF-a (adapted from
Oeckinghaus et al., 2011) and potential crosstalk with Nrf2 (adapted from Cuadrado
et al., 2014). Binding of IL-1b and TNF-a to their receptors, IL-1R (green) and TNFR
(orange), respectively, activates a signaling cascade that leads to phosphorylation and
activation of the IKK complex. This complex then phosphorylates IkB to release p65/p50
into the cytosol. While IkB is poly-ubiquitinated and degraded by the proteasome, the NFkB dimer localizes to the nucleus and activates genes with kB sites. This includes Nfe2l2,
as it contains these sites – however, other mechanisms have been theorized to activate
Nrf2, such as IKK phosphorylation of Keap1 or normal activation of Nrf2 by reactive
oxygen species.

It has been suggested that NF-kB regulates Nrf2 at the transcriptional level,
since the Nfe2l2 promoter has several kB binding sites in the murine and human
sequences (Nair et al., 2008; Rushworth et al., 2012). In support of this idea are
the findings (1) that silencing p50 and p65 expression in vitro results in lower Nrf2
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expression, and (2) that LPS treatment of both human peripheral monocytic THP1 cells and normal monocytes leads to p50 and p65 binding of the Nfe2l2 promoter
(Rushworth et al., 2012). This study also found that p65 binds the kB site near the
transcription start site of the Nfe2l2 locus in lymphoblastoid cells treated with TNFa. Furthermore, another study observed that macrophages exposed to iron-coated
silica nanoparticles – which cause oxidative stress – upregulate the nuclear
translocation of both NF-kB and Nrf2, thereby prompting the expression of Nrf2
target genes (Zhang et al., 2017). This group also found that NF-kB inhibition with
the compound SN50 reduces the magnitude of both the Nrf2 elevation and that of
its targets.
There also appears to be a reciprocal regulation of NF-kB expression by
Nrf2, suggesting crosstalk between the two signaling pathways. It has been
theorized that Nrf2 can inhibit NF-kB signaling indirectly through activation of heme
oxygenase 1 (HO-1), a Nrf2 target (Banning and Brigelius-Flohé, 2005; Soares et
al., 2004). Likewise, Nrf2 overexpression produced by treatment with the
electrophilic agent sulforaphane decreases both NF-kB activation and the
induction of cell death following cytokine exposure, most likely by reducing
oxidative stress (Song et al., 2009). Another hypothesis suggests that when Nrf2
is activated, it can trigger transcription of the autophagy adaptor protein p62. In
doing so, Nrf2 / p62 signals for the degradation of IkB – indirectly activating NF-kB
– as well as enhancing Nrf2 release through degradation of Keap1 (Stępkowski
and Kruszewski, 2011). Finally, one study found that knocking out Nrf2 causes a
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rise in NF-kB and its signaling (Cuadrado et al., 2014). Overall, it seems that the
crosstalk between NF-kB and Nrf2 is complex, but most likely context dependent.
Under basal or stress conditions, both Nrf1 and Nrf2 are vital regulators of
their own specific pathways (Ohtsuji et al., 2008; Yang et al., 2005), but they have
also been shown to crosstalk with each other. For example, Nrf1 and Nrf2 appear
to compete with one another for EpRE-containing genes, depending upon the
context. Nrf1 – in particular, Nrf1 p65 – outcompetes Nrf2 for binding sites when
both are overexpressed in unstimulated human bronchial epithelial cells (Chepelev
et al., 2013). Additionally, knockout of Nrf1a leads to a significant increase in Nrf2
expression, due to the resulting reduction of proteasomes and their degradation of
Nrf2 (Qiu et al., 2018). The same study also found that reduction of Nrf2 causes a
decrease in Nrf1 mRNA and protein levels. These findings indicate the presence
of a complex feedback loop between the two transcription factors as well as
intricate relationships with other crosstalk partners.
Goal of Dissertation
The primary focus of our laboratory’s work is to identify the pathological
mechanisms underlying nervous system damage in MS and the pertinent animal
model EAE. Previous studies have revealed that there is a high degree of oxidative
stress in both MS and EAE, which leads to the oxidation of many cellular
components including proteins. These damaged proteins accumulate due to a
failure of the proteolytic systems that normally remove them. Our lab has
demonstrated not only that protein oxidation in the form of carbonyls causes
protein aggregation and cell death, but also that the proteasome is impaired in both
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EAE and MS. The main goals of this dissertation are to 1) determine what
upstream signaling could be affecting proteasome expression in EAE, and 2)
investigate the specific effects of neuroinflammation on this signaling and its
consequences in vitro. The general hypothesis of this dissertation is that
heightened inflammatory signaling during EAE contributes to dysregulated
antioxidant signaling, thereby resulting in altered cellular proteolytic systems and
varied astrocytic reactivity.
Aim 1
The first aim of this dissertation investigates the expression of proteasome
subunits in neural cells and how they are regulated in EAE. In chapter 2, we first
show that there is extensive inflammation and oxidative stress in the spinal cords
of mice with MOG peptide-induced EAE over the course of the disease. Most
importantly, expression of constitutive proteasome and Nrf1 – one of the main
transcription factors responsible for c-20S proteasome expression – are
diminished in the diseased animals. This could be due to a decrease in one of its
own upstream regulators, PBX1, but not to a reduction in mTOR signaling. In
contrast, the expression of i-20S and 11S rises in EAE, which is most likely the
result of augmented STAT-1 / IRF-1 activation. We conclude that the differential
expression of constitutive and immunoproteasomes in EAE spinal cords,
particularly in astrocytes and neurons, is probably caused by a combination of
subunit displacement and reduced Nrf1 signaling.
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Aim 2
The second aim explores the regulation of proteasome expression in
cultured neurons and astrocytes under inflammatory conditions. Differentiated
mouse neuro2a neuroblastoma cells (N2a) – which take on a dopaminergic
phenotype – and rat C6 glioma cells were exposed to a mixture of pro-inflammatory
cytokines that are elevated in EAE. In both cell types, treatment with the IFNg/TNF-a/IL-1b mixture leads to changes in proteasome expression similar to those
observed in EAE – heightened i-20S and 11S expression and decreased c-20S
expression. However, Nrf1 expression is unchanged upon cytokine exposure,
suggesting that, in culture, subunit displacement is the only mechanism
responsible for the reduced levels of c-20S particles. While the rise in i-20S
expression is due to increased p-STAT-1 signaling, pharmacological inhibition of
NF-kB – which also diminishes IRF-1 – in astrocytes has no effect on the cytokineinduced changes in proteasome expression. These findings indicate that STAT-1
can activate i-20S subunit and 11S subunit expression by itself.
Aim 3
The final aim of this dissertation studies NF-kB signaling and its effect on
Nrf2 expression and cellular reactivity in astrocytes. Results show that A1-reactive
astrocytes, characterized by elevated complement C3 and GFAP expression, are
indeed present in the EAE spinal cord in the vicinity of inflammatory lesions.
Furthermore, we discovered that differentiated C6 cells exposed to proinflammatory cytokines generate two different phenotypes that we categorized
based on their expression of C3 and NF-kB. The first is an A1-reactive phenotype
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that expresses high levels of both C3 and NF-kB. Interestingly, there exists a
subpopulation of astrocytes – named pan-reactive – that upon cytokine treatment
displays unchanged levels of NF-kB compared to control cells. These pan-reactive
cells also have diminished levels of Nrf2 compared to A1-reactive astrocytes,
which have elevated Nrf2 expression. In both cell types, changes in the amount of
Nrf2 protein follow those of the mRNA levels and are most likely due to differential
NF-kB expression. Indeed, pharmacological inhibition of NF-kB signaling in A1
cells leads to a corresponding decrease in the amount of Nrf2 protein. This druginduced downregulation of NF-kB in A1-reactive astrocytes also causes a fall in
C3 mRNA expression, causing the cells to behave more like pan-reactive, whose
NF-kB signaling is unresponsive to the cytokine mixture.
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Abstract
The goal of this study was to determine if subunit displacement and/or
alterations in proteasome biosynthesis could explain the changes observed in the
levels of constitutive proteasomes (c-20S) and immunoproteasomes (i-20S) in the
spinal cords of mice with experimental autoimmune encephalomyelitis (EAE). To
this end, EAE was induced in C57BL/6 mice by immunization with MOG35-55
peptide. Spinal cords were collected at different times during the disease course
and used for western blotting, RNA analysis and immunohistochemistry. The
results show that, as expression of i-20S and the activator PA28 rise in EAE, there
is a concomitant decline in that of c-20S at the mRNA and protein level. These
changes are observed in neurons and astrocytes but not oligodendrocytes. The
increased amounts of the i-20S-specific subunit b5i and PA28a/b in EAE correlate
with the levels of IFN-g and its downstream effectors p-STAT-1 and IRF-1, but not
with those of NF-kB. This suggests the STAT-1/IRF-1 pathway is solely
responsible for the induction of these subunits. The decrease in the mRNA and
protein levels corresponding to the c-20S-specific subunit b5 may also be due to
reduced expression of the nuclear factor (erythroid-derived 2)-like-1 (Nrf1 or
Nfe2l1), specifically Nrf1a and Nrf1b. Low Nfe2l1 mRNA expression is unlikely
caused by reduced mTOR signaling but could be the result of diminished pre-Bcell leukemia homeobox-1 transcription factor (PBX1) levels. Together, these
findings suggest that a combination of subunit displacement and reduced Nrf1
expression may be responsible for c-20S impairment in EAE. The present work
provides insights into the dynamics of proteasome expression in the CNS of EAE
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mice and is the first to explore Nrf1 signaling in an inflammatory demyelinating
disorder.
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Introduction
Proteasomes are large protein complexes that carry out the majority of
intracellular proteolysis, and thus play an essential role in regulating cell function
and maintaining homeostasis (Rechsteiner and Hill, 2005). The core of these
complexes, the 20S proteasome, is made of two outer rings of seven a subunits
(a1-a7) and two inner rings of seven β subunits (β1-β7) (Ethen et al. 2007). Each
β ring has three proteolytic sites, which display caspase-like (β1), trypsin-like (β2)
and chymotrypsin-like (β5) activities (Coux et al. 1996). Exposure of cells to
cytokines, such as interferon-g (IFN-g), leads to the replacement of the catalytic β1,
β2 and β5 subunits in the constitutive 20S particle (c-20S) by the inducible β1i, β2i
and β5i subunits, forming the immunoproteasome 20S particle (i-20S) (Aki et al.
1994). While immunoproteasomes were initially thought to be present exclusively
in immune cells - where they participate in the generation of peptides for antigen
presentation - they are now known to be expressed in most tissues and to play
roles that are unrelated to the immune system (Seifert et al. 2010; Hussong et al.
2010). Under physiological conditions, a fraction of the 20S particle pool is bound
to various regulators, which significantly affect its catalytic activity and substrate
specificity. One of these activators, PA28 (11S), is also induced by IFN-g and
attaches to the i-20S particle forming a complex (11S/i-20S/11S). This complex
produces more peptides of the correct length for the major histocompatibility
complex class 1 antigen processing (Rivett and Hearn, 2004). PA700 (19S), the
other major activator, binds to the end of 20S core particles to form the 26S
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proteasome, which recognizes and hydrolyzes abnormal and misfolded proteins
conjugated with polyubiquitin chains (Braun et al., 1999).
While little is known about how proteasome and immunoproteasome
expression is controlled under basal conditions, more information is available on
how levels of proteasomes are regulated under stress conditions. For example,
IFN-g augments the transcription of the immunoproteasome-specific b subunits
(Aki et al., 1994) via binding of STAT-1-dependent interferon regulatory factor-1
(IRF-1) to IFN-g regulatory elements in the promoter regions of these genes (Foss
and Prydz, 1999). In cells containing both c-20S and i-20S particles, a rise in the
content of inducible subunits is accompanied by a reduction in the amounts of
constitutive subunits by a well characterized process known as subunit
displacement (Früh et al., 1994). In addition to post-translational downregulation
of constitutive proteasomes in inflammatory conditions, the promoter regions of the
genes that encode for the constitutive proteasome subunits and the 11S and 19S
activators have electrophile response elements (EpRE) that bind nuclear factor–
erythroid-2–related factors (Pickering et al., 2012) These proteins belong to the
cap‘n’collar subfamily of basic-region leucine zipper transcription factors, and
include Nrf1 (Nfe2l1), Nrf2 (Nfe2l2), Nrf3 (Nfe2l3) and the p45 subunit (Motohashi
et al., 2002). Both Nrf1 and Nrf2 form heterodimers with small Maf proteins that
bind to EpRE and activate transcription (Venugopal and Jaiswal 1998; Biswas and
Chan 2010). The amount of Nrf1 augments upon endoplasmic reticulum stress and
mild proteasome inhibition by a post-translational mechanism (Bugno et al., 2015;
Xiang et al., 2018), whereas Nrf2 levels increase following oxidative stress
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(Kobayashi et al., 2004). While both transcription factors have the potential to
increase proteasome subunit expression, Nrf1 alone is required for the
upregulation of proteasome genes in response to proteasome inhibition
(Radhakrishnan et al., 2010). Additionally, Nrf1 deletion in neuronal cells causes
proteasome impairment due to down-regulation of proteasomal genes that encode
the catalytic subunits (Lee et al., 2011). Thus, Nrf1 seems to be more important
than Nrf2 for promoting constitutive proteasome synthesis.
Experimental autoimmune encephalomyelitis (EAE) is a well-established
animal model for CNS autoimmune disorder, recapitulating a number of clinical
and pathological features of multiple sclerosis (MS) (Gold et al., 2000). Several
EAE models exist that mimic the different clinical courses of MS. MOG35-55 peptideinduced EAE in the C57BL/6 mouse, the animal model used in this study, is
characterized by the presence of inflammatory lesions in the CNS that are present
mostly in the spinal cord and the cerebellum (Kuerten et al., 2007). Our laboratory
was the first to demonstrate that the peptidase activity of the proteasome is altered
in MS brains (Zheng and Bizzozero, 2011) and EAE cerebella (Zheng and
Bizzozero, 2010). Furthermore, we discovered that the changes in the levels of the
three catalytic subunits of c-20S and i-20S proteasomes account for all the
fluctuations of proteasomal peptidase activities during the disease course of EAE
(Zheng et al., 2012). The goal of the present study was to determine if subunit
displacement and/or alterations in proteasome biosynthesis could explain the
changes in the levels of proteasomes and their activators observed in the spinal
cords of EAE animals during the inflammatory phase. The results show that, as
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expression of i-20S and PA28 rise in EAE, there is a concomitant decline in that of
c-20S at the mRNA and protein level. Interestingly, these changes are observed
in neurons and astrocytes but not oligodendrocytes. The increase in the amount
of the i-20S-specific subunit b5i and PA28a/b in EAE correlate with the levels of
IFN-g and its downstream effectors STAT-1 and IRF-1. Finally, we show that the
decrease in the c-20S-specific subunit b5 mRNA levels may also be due to
reduced Nrf1 expression. Together, these findings suggest that a combination of
subunit displacement and reduced Nrf1 expression may be responsible for c-20S
impairment in EAE. The present work provides insights into the dynamics of
proteasome expression in the CNS of EAE mice and is the first to explore Nrf1
signaling in an inflammatory demyelinating disorder.
Materials and Methods
Induction of experimental autoimmune encephalomyelitis
Housing and all procedures of the animals were in strict accordance with
the NIH Guide for the Care and Use of Laboratory Animals and approved by the
Institutional Animal Care and Use Committee (protocol #16-200424-HSC). Adult
female C57Bl/6 mice (8-week old) were purchased from Envigo (MGI:2161078,
previously Harlan Laboratories, Indianapolis, IN). Three to four arriving mice were
arbitrarily placed in standard ventilated cages for one week of habituation before
EAE induction. No randomization was performed to assign the cages to control or
the EAE group. All mice housed in the same cage received the same inoculation.
This is necessary because the weaker (EAE) mice could have trouble competing
against healthy (control) mice for accessibility to food and water. To induce EAE,
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mice (~20 g of body weight) received a subcutaneous injection (200 µl) into the
lower back area of custom synthesized MOG35-55 peptide (200 µg) (21st Century
Biochemicals; Marlborough, MA) in saline mixed with complete Freund's adjuvant
(CFA) (1:1) constaining of 4 mg/ml of heat killed Mycobacterium tuberculosis
H37Ra (cat #7001; Chondrex Inc; Redmond, WA). Control mice received saline
mixed with CFA without MOG peptide. Two and 48 h after EAE induction, all
animals received an intraperitoneal injection of 0.3 µg of pertussis toxin (PTX,
cat#180, List Biological Laboratories; Campbell, CA) in 100 µl of saline. Seven
days after disease induction, mice received a second immunization on the other
flank. This immunization protocol with 2 MOG peptide injections causes a
persistent type of EAE, allowing to compare changes that occur in the acute
(mostly inflammatory) and the chronic (mostly neurodegenerative) phase of the
disease. Food and water were placed on the cage floor to ensure access to
nourishment. No measures were taken to minimize possible pain after disease
induction because analgesic and anti-inflammatory drugs may affect the disease
course. Animals were weighed and examined daily for the presence of neurological
signs. Normally, mice that experience a loss of 30% in body weight or have very
severe symptoms (moribund stage) are euthanized and removed from the
experiment. However, in this study no animal reached that stage and therefore no
animal was excluded. A schematic timeline of the study design is depicted in Fig.
1. At various times during the course of the disease, 9 - 60 days post-immunization
(dpi), EAE and CFA-injected controls were euthanized by decapitation under
inhaled anesthesia of isoflurane (2-3% cat# 430024079, Piramal Critical Care Inc;
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La Vergne, TN). The spinal cords were removed using the hydraulic extrusion
method. The excised cervical and thoracic sections were flash-frozen for RNA
extraction or immediately homogenized in 20 mM sodium phosphate buffer pH 7.5
containing 1 mM EDTA, 0.1 mM neocuproine, 2 mM 4,5 dihydroxy-1,3 benzene
disulfonic acid, 1 mM dithiothreitol (DTT), 1x cOmplete™ protease inhibitor cocktail
(cat#11873580001; Sigma; St Louis, MO) and 1x PhosSTOP™ phosphatase
inhibitor (cat#04906845001; Sigma). Protein homogenates were stored at -80°C
until use. Protein concentration was determined with Bradford-based chemistry
using Bio-Rad protein assay dye reagent (cat#5000006; Bio-Rad Laboratories;
Hercules, CA) with bovine serum albumin as a standard. Lumbar spinal cord
sections were used for histological (hematoxylin and eosin staining) and
immunofluorescence analysis (see below). This region has more lesions than other
spinal cord areas making the pathological changes easy to assess. It is important
to note that blinding was not done from the beginning of the study due to the fact
that EAE mice exhibit neurological symptoms and thus can be easily identified.
However, tissue samples (RNA, protein lysates and histological sections) were
assigned with new serial numbers during all experimental procedures. Sample IDs
were only revealed to the investigator after data acquisition. This study was not
pre-registered.
Subcellular fractionation
Preparation of the crude nuclear fraction was carried out using a modified
nuclear extraction protocol adapted from Thermo-Fisher Scientific. Briefly, small
spinal cord sections were homogenized at 4˚C in 0.5 ml of hypotonic buffer solution
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(20 mM Tris-HCl pH 7.4 containing 10 mM NaCl, 3 mM MgCl2, 1 mM DTT, 1 mM
phenylmethylsulphonyl fluoride and 1x protease inhibitor cocktail) using a
glass/teflon Dounce tissue homogenizer (20 up/down strokes). Suspensions were
kept on ice for 15 min, mixed with 25 µl of 10% w/v Nonidet P-40 and centrifuged
at 3,000 g for 10 min. The supernatant (cytosolic fraction) and the pellet (crude
nuclear fraction) were collected, and proteins were solubilized in sodium dodecyl
sulfate (SDS) sample buffer and analyzed by western blotting.
Reverse transcription and qPCR
Snap-frozen

spinal

cord

tissues

were

homogenized

in

Trizol®

(cat#15596026, Invitrogen; Carlsbad, CA) reagent and total RNA extracted
following manufacturer's protocol. Complementary DNA (cDNA) was prepared
from DNase I-treated total RNA and synthesized using the SuperScript II FirstStrand Synthesis system (cat#18064022, Invitrogen). Quantitative RT-PCR was
conducted on the Applied Biosystems 7500 Fast Real-Time PCR System by
mixing 20 ng cDNA with 1 µM of gene-specific primers (Table 2.1) and amplified
with the Power SYBR Green PCR MasterMix (cat#4367659, Applied Biosystems,
Forster City, CA) using a preset program (50˚C for 10 min, 95˚C for 10 min and
then 40 cycles of 95˚C/15 sec and 60˚C/1 min). The relative mRNA expression
levels for the genes of interest were determined using the comparative 2-ΔCt
method (Livak and Schmittgen 2001) by normalizing the Ct values of target genes
to the geometric mean Ct of 4 house-keeping genes (Gapdh, Hprt1, Rplp0 and
Rn18s) (Table 2.1) (Vandesompele et al. 2002). In all cases, the normalized values
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from EAE mice were expressed as relative to the average from control animals.
The variations of control values are shown in the figures.
Western blot analysis
Proteins (5 μg) were separated by SDS–polyacrylamide gel electrophoresis
on 4-20% Mini-Protean TGX gels (cat#4561096; Bio-Rad Laboratories; Hercules,
CA) and were blotted to polyvinylidene difluoride membranes. Blots were blocked
with 3% (w/v) non-fat milk in phosphate-buffered saline solution containing 0.05%
(v/v) Tween 20 (PBS-T) and then incubated overnight at 4°C with the primary
antibodies listed in Table 2.2. Membranes were rinsed three times in PBS-T and
were incubated for 1 h with the corresponding horseradish peroxidase-conjugated
secondary antibodies (Table 2.2). Blots were developed by enhanced
chemiluminescence using the Western Lightning ECL™ kit (cat#NEL103; PerkinElmer, Boston, MA) and signals captured on blue X-ray films. Films were scanned
in a Hewlett Packard Scanjet 4050 and the images were quantified using the NIH
Fiji ImageJ 1.52 imaging analysis program (RRID:SCR_003070). Band intensities
were normalized by the intensity of the Coomassie blue stain in the respective
lanes or, in the case of the nuclear fractions, by the amount of histone H3. All the
antibodies used in this study were validated by the suppliers and detected bands
at the predicted molecular weights on western blots.
Immunofluorescence localization of proteasomes and immunoproteasomes
To assess cellular distribution of c-20S, i-20S and 11S particles in the
lumbar spinal cords of control and EAE mice, we performed double-label
immunofluorescence analyses using antibodies against β5, β5i, PA28b and
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various cell-specific markers on paraformaldehyde-fixed and paraffin-embedded
sections. All the antibodies used for immunohistochemistry are listed in Table 2.3.
Briefly, 5 µm-thick sections mounted to slides were deparaffinized and hydrated in
down-grade alcohol series. Antigen retrieval was performed in 10 mM sodium
citrate buffer (pH 6.0) with 0.05% Tween-20 using a heat-induced retrieval
method. Spinal cord sections were blocked in 4% normal goat serum and then
incubated with the primary antibodies at 4˚C overnight. The various cell types were
detected using mouse monoclonal antibodies against GFAP (glial fibrillary acidic
protein) for astrocytes, CA-II (carbonic anhydrase-II) for oligodendrocytes, NeuN
(neuronal nuclear antigen) for neurons and CD45 (cluster of differentiation 45) for
leukocytes (Table 2.3). Target proteins and cell-specific markers were covisualized with secondary antibodies conjugated to either a CyTM 3 fluorophore or
an Alexa Fluor® 488 that detect the respective antibody species (Table 2.3).
Immunofluorescence images were captured with a Leica TCS SP5 confocal
microscope system (Leica Microsystems Inc, Buffalo Grove, IL). Relative
fluorescence of b5 and b5i immunoreactivity was quantified with the Leica
Application Suite X (RRID:SCR_013673) using the histogram tool. To quantify the
relative expression level on the fluorescence-labeled confocal images, individual
regions of interest were delineated (hand draw tool) in the green, neural markerlabeled cells and returning the mean grey values in the red (b5 and b5i) channel.
For each animal, a total of 8 confocal images from each stained slide (5-50 labeled
cells/field) selected at random were analyzed. Values were expressed as the
average fluorescence. Data for oligodendrocytes and astrocytes come from both
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white matter and gray matter. Data for neurons derive from gray matter and also
include motor neurons.
Statistical Analysis
Animal numbers (study size) in each study group (dpi) was determined by
power analysis using G*Power 3.1 software (RRID:SCR_013726; Kiel University,
Germany) and the following parameters: two-tail analysis, effective size = 2.0, a =
0.05 and a power (1-b) = 0.8. The effective size was calculated assuming a
difference between means of 20% and a SD = 0.10, which was taken from similar
studies. Results were analyzed for statistical significance with the unpaired
Student’s t-test utilizing the GraphPad Prism® program 8.1 (RRID:SCR_002798;
GraphPad Software Inc.; San Diego, CA) after assessing the normality of the data
with the Shapiro-Wilk test. For data that did not follow a normal distribution,
statistical significance was determined with the nonparametric Mann-Whitney test.
Outliers in the data sets were identified using the GraphPad Prism® ROUT test
and assigning a Q value of 1% and were removed before the final statistical
analysis.
Results
Pro-inflammatory cytokine expression and oxidative stress are elevated in EAE
spinal cords
EAE was induced in female C57BL/6 mice by double immunization with
MOG35-55 peptide as explained in “Materials and Methods” and shown in Fig. 2.1.
Symptoms were graded according to the following scale: 0, no symptoms; 1, tail
weakness; 1.5, clumsy gait; 2, hind limb paresis; 2.5, partial hind limb dragging; 3,
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hind limb paralysis; 3.5, hind limb paralysis with fore limb paresis; 4, complete
paralysis; and 5, moribund. Neurological symptoms and spinal cord pathology start
at 14 dpi (7 days after the second injection with MOG peptide), reaching a
maximum after 21 dpi (Fig. 2.2a). CFA-injected animals (i.e. controls) do not
present any neurological sign or spinal cord damage. In this study, we used a total
of 26 control mice and 32 EAE mice. Except for the small sample size at 60 dpi (n
= 3), the number of mice in each of the other control and EAE groups ranged
between 5 and 8 (Fig. 2.1). This number is very close to the minimum of 6 mice
per group predetermined by power analysis using the parameters described in
“Materials and Methods”.
As shown in Fig. 2.2b, lymphocyte infiltration in the spinal cord (as detected
by staining the sections with hematoxylin and eosin) begins at 14 dpi reaching a
maximum at 21 dpi. In contrast, IFN-g mRNA expression in EAE is already high at
9 dpi (Fig. 2.2c) and remains elevated throughout the course of the illness. TNF-a
mRNA levels in EAE are significantly elevated at 21 dpi and thereafter (Fig. 2.2d),
while the temporal expression pattern of IL-1b mRNA is similar to that of IFN-g,
except for the values at 9 dpi (Fig. 2.2e). Glutathione levels in the diseased spinal
cord decline progressively starting at 21 dpi (Fig. 2.2f). Overall, these data indicate
the presence of significant inflammation and oxidative stress in the spinal cords of
EAE mice, which are expected to upregulate immunoproteasome and constitutive
proteasome expression, respectively.
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Reduced c-20S and increased i-20S expression in EAE spinal cords
We next measured the mRNA expression of the immunoproteasomespecific subunit b5i (Psmb8) as well as that of PA28b (Psme2), a component of
the 11S activator, in the spinal cord during the course of EAE (9 - 60 dpi). As
expected from the temporal mRNA expression pattern of IFN-g, TNF-a and IL-1b
in EAE (Fig. 2.2c-e), Psmb8 and Psme2 mRNA levels in the affected spinal cords
become significantly higher than those in controls at 14 dpi, reaching a maximum
between 21 dpi and 30 dpi to decrease thereafter (Fig. 2.3a,b). Similar results were
obtained for PA28a (Psme1) (data not shown). In contrast, the constitutive
proteasome-specific subunit b5 (Psmb5) mRNA expression diminishes in EAE
starting already at 9 dpi, with the difference being maximal at 14 dpi - 21 dpi and
declining after that period (Fig. 2.3c). Reduced b5 gene expression in EAE was an
unexpected finding since constitutive proteasomes are known to be induced by
oxidative stress, which is clearly demonstrated by the low glutathione levels in this
disorder (Fig. 2.2f).
The amounts of proteasomes and their activators in EAE mice at 30 dpi,
measured by western blot analysis of spinal cord proteins, is shown in Fig. 2.4a.
The levels of proteasome core particles (c-20S + i-20S), assessed with an antibody
that recognizes six of the seven 20S a-subunits (a1-3/5-7), increases in EAE by
75.7 ± 15.0% (p = 0.0043). However, a7-subunit (Psma7) mRNA expression is
unchanged in EAE (Fig. 2.4b), suggesting the occurrence of translational and/or
post-translational control mechanisms. Proteasome b5i, PA28a and PA28b
proteins are greatly augmented in EAE (Fig. 2.4a), which agrees with their
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increased gene expression (Fig. 2.4b). The amount of the b5 subunit is reduced
by 36.7 ± 7.8% (p = 0.0007) in EAE, which follows the 38% decrease in mRNA
expression. Levels of the 19S-specific Rpt5 subunit rise by 107 ± 41% (p = 0.0260)
while there is an 18% reduction in its mRNA levels (Psmc3).
Using the intensity values obtained by western blot analysis and purified c20S and i-20S proteasomes for calibration, we estimated the absolute amounts of
each proteasome core particle in control and EAE spinal cord homogenates. The
purity of the c-20S particle (positive for β1, β2 and β5 but not for their inducible
counterparts) and the i-20S (positive for β1i, β2i and β5i but not for their standard
counterparts) was demonstrated by western blotting in our previous publication
(Zheng et al., 2012). We found that in control spinal cords, ~86% of core particles
correspond to c-20S proteasome (4.67 pmol/mg protein) and the rest (~14%) to
the i-20S proteasome (0.73 pmol/mg protein). In contrast, only 33% of the
proteasomes in EAE spinal cords at 30 dpi corresponds to the constitutive form
(2.98 pmol/mg protein) while 67% (6.10 pmol/mg protein) was in the form of
immunoproteasomes. Based on these numbers, the total amount of proteasomes
(i.e. c-20S + i-20S) in EAE rises by 68%, which is close to the 75.7% increase
observed by western blot analysis using the a1-3/5-7 antibody (Fig. 2.4a).
Neurons and astrocytes display altered levels of constitutive- and immunoproteasomes
To ascertain whether the decrease in constitutive proteasome levels in EAE
takes place in all spinal cord cells or whether it is limited to a particular cell type
(neurons, astrocytes or oligodendrocytes), we conducted a double-label
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immunofluorescence confocal microscopy analysis. As shown in Fig. 2.5, images
from control and EAE spinal cords at 30 dpi reveal the presence of the c-20Sspecific subunit b5 in the cytoplasm of all three major cell types. Staining was more
intense in neurons (average intensity = 41) followed by oligodendrocytes (average
intensity = 25) and astrocytes (average intensity = 18). Quantification of the images
shows that b5 subunit labeling in EAE decreases by 47.0 ± 7.2 % (p = 0.0014) in
neurons and by 54.1 ± 15.0% (p = 0.0596) in astrocytes, while levels of this subunit
in oligodendrocytes are unchanged (p = 0.3853) (Fig. 2.7a). The reduced amount
of b5 in neurons and astrocytes, along with the decreased number of
oligodendrocytes in the EAE spinal cord (Hu et al., 2019), is likely the reason for
the 36.7% drop in b5 levels observed on western blots of total spinal cord proteins
(Fig. 2.4a).
The average b5i intensity for neurons, astrocytes and oligodendrocytes in
control spinal cords at 30 dpi are similar (Fig. 2.6). Quantification of the images
reveal that b5i subunit labeling in EAE increases by 117 ± 34% (p = 0.0059) in
neurons and by 94 ± 47% (p = 0.0749) in astrocytes, while levels of this subunit in
oligodendrocytes are unchanged (p = 0.3414) (Fig. 2.7b). It is noteworthy that gray
matter astrocytes have the same changes in proteasome composition in EAE as
those present in the white matter (data not shown). Similarly, EAE
oligodendrocytes do not display any changes in proteasome composition
regardless whether they are in gray or white matter (data not shown). It is also
interesting to mention that while b5 staining in control and EAE is exclusively
cytoplasmic, b5i (particularly in EAE) was also present in the nucleus. This agrees
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with a previous observation that IFN-g promotes the nuclear accumulation of
immunoproteasomes in human cervical epithelial HeLa and Hep2 cells (Fabunmi
et al., 2000). In addition to neural cells, the immunoproteasome-specific b5i subunit
is present in leukocytes located in the more peripheral regions of the spinal cord
(Fig. S2.1). In agreement with the western blot data, PA28 was barely expressed
in control spinal cords. In EAE, PA28 expression was present in inflammatory cells
(not shown) and astrocytes (Fig. S2.2).
Increased expression of immunoproteasomes is likely due to activation of
STAT-1 signaling pathway
It has been shown that IFN-g augments the transcription of the
immunoproteasome-specific subunits b1i, b2i and b5i (Aki et al., 1994) via binding
of STAT-1-dependent IRF-1 to IFN-g regulatory elements in the promoter regions
of these genes (Foss and Prydz, 1999). The expression of PA28 is also increased
by IFN-g (Groepttrup et al., 1995). In addition, immunoproteasome subunits have
NFkB response sequences within their promoters (Ferrington and Gregerson,
2012). As shown in Fig. 2.8a,b, the amount of phosphorylated STAT-1 (p-STAT-1)
and IRF-1 in the nuclear fraction increases dramatically in the EAE spinal cord
measured at 30 dpi, which clearly results from the ~18-fold rise in IFN-g expression
(Fig. 2.2c). In contrast, nuclear levels of NF-kB (p65 subunit) are unaltered in the
disease (Fig. 2.8c). In sum, these data strongly suggest that expression of i-20S
and PA28 particles in EAE is mainly the result of activation of the IFN-g / STAT-1 /
IRF-1 pathway.
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Abnormal Nfe2l1 (Nrf1) signaling may contribute to the reduced c-20S
expression in EAE
Nrf1 is a transcription factor that upregulates the expression of all the
proteasome subunit genes in a concerted manner, particularly during proteasome
impairment (Radhakrishnan et al., 2010; Lee et al., 2013). There are several Nrf1
isoforms that derive from (1) alternative splicing, (2) alternative initiation of
translation, and (3) posttranslational processing (e.g., glycosylation, proteolysis)
(Bugno et al., 2015; Xiang et al., 2018). We thought of the possibility that Nrf1
expression may be altered in EAE, which could result in decreased synthesis of
constitutive proteasomes. To that end, we first measured Nfe2l1 mRNA levels in
the spinal cord during the course of EAE using a set of primers that recognizes all
the transcripts. As shown in Fig. 2.9a, Nfe2l1 gene expression in EAE declines
starting at 9 dpi, with the difference being maximal between 14 and 21 dpi. It is
noteworthy that the temporal pattern of mRNA expression of Nfe2l1 is similar to
that of Psmb5 (Fig. 2.3). Western blot analysis of cytoplasmic fractions prepared
from control and EAE spinal cords at 30 dpi, reveal the presence of six Nrf1positive bands with molecular masses ranging from 25 kDa to 100 kDa (Fig. 2.9b).
Of all these bands, only the 55 kDa band (Nrf1b) is present in the nucleus and its
levels are reduced in EAE by 50.0 ± 10.0% (p = 0.0037) (Fig. 2.9c). When the films
corresponding to the nuclear fractions are exposed for a longer time, the 100 kDa
band (Nrf1a) becomes visible and its levels are also reduced in EAE (Fig. S2.3).
Double label-immunohistochemical analysis to identify the cells where Nrf1 is
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reduced were inconclusive due to the heterogeneous labeling of the nuclei in
control (mostly diffuse) and EAE (mostly punctuate) spinal cords (data not shown).
Aside from stress-related stimuli, Nfe2l1 expression is induced by growth
factors through mTORC1-activation of the sterol regulatory element-binding
protein 1 transcription factor (Zhang and Manning, 2015). However, we found that
the levels of phospho-mTOR are significantly elevated in EAE measured at 30 dpi,
implying that other factors may regulate Nrf1 transcription (Fig. 2.10a). One such
molecule is the pre-B-cell leukemia homeobox-1 transcription factor (PBX1), which
has been recently shown to directly induce Nrf1 gene expression (Villaescusa et
al., 2016). Interestingly, at 30 dpi, nuclear PBX1 levels are reduced in EAE spinal
cords by 51.7 ± 3.7% (p = 0.0004) (Fig. 2.10b), suggesting that this phenomenon
may underlie the Nfe2l1 deficit in the disease.
Proteasome composition is also altered in the cerebella, but not the cerebra, of
EAE mice.
Finally, we measured the expression of proteasomes and their activators in
the cerebra and cerebella of EAE mice. Lesions in the cerebellum are different,
both in location and intensity, than those in the spinal cord, while minimal
pathological changes are known to occur in the cerebrum (Kuerten et al., 2007).
As shown in Fig. 2.11, the patterns of expression of the proteasome subunits b5,
b5i and a, as well as the activator PA28a, in the EAE cerebellum are similar to
those found in the spinal cord; specifically, there is an increase in the levels of i20S and PA28 and a concomitant reduction in the amount of c-20S. However, the
magnitude of the changes in the diseased cerebellum is smaller than those in the
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spinal cord. For instance, b5i, a1-3/5-7 and PA28a subunit levels in the cerebella
of EAE mice rise by 53.6 ± 22%, 17.2 ± 4.4% and 271 ± 33%, respectively (Fig.
2.11), while amounts of these subunits in the EAE spinal cords increase by 1680
± 585%, 75.7 ± 15.0% and 686 ± 158%, respectively (Fig. 2.4a). Similarly, b5 levels
diminish by 25.2 ± 3.8% (p = 0.0211) in EAE cerebella versus 36.7 ± 7.8% in EAE
spinal cords. In contrast to the findings in the spinal cord, the amount of the 19S
subunit Rpt5 in the EAE cerebellum is unaltered. Analysis of EAE and control
cerebra revealed no changes in the levels of any of these proteasome subunits
except for a modest increase (68.7 ± 22.7%, p = 0.0174) in PA28a levels. In sum,
the magnitude of the changes in proteasome subunits in EAE are the highest in
the spinal cord, followed by the cerebellum and the cerebrum. This correlates with
the varying extents of inflammation and damage in these CNS areas. Interestingly,
Nrf1b levels are also reduced in the cerebellum but not the cerebrum (Fig. S2.4).
Thus, while subunit displacement is likely to account for some of the decrease in
the amounts of constitutive proteasomes in EAE, the contribution of Nrf1 deficiency
to this phenomenon could also be significant.
Discussion
In this study, we describe the changes in the expression of proteasome
particles and their activators in the spinal cords of EAE mice. The results clearly
show that (1) there is a rise in i-20S and PA28 expression and a decline in c-20S
expression in EAE, both at the mRNA and protein level; (2) among the three cell
types studied, the changes are observed in neurons and astrocytes but not
oligodendrocytes; (3) the increase in the amount of the i-20S-specific subunit b5i
49

and PA28a/b in EAE correlates with the levels of IFN-g, p-STAT-1 and IRF-1, but
not with those of NFkB, suggesting that STAT-1 and/or IRF-1 dimers are
responsible for induction of these subunits; (4) the decrease in the c-20S-specific
b5 subunit mRNA and protein levels may also be due to reduced expression of
Nrf1a and Nrf1b; and (5) impaired Nfe2l1 mRNA expression is unlikely due to
reduced mTOR signaling but could be the result of diminished PBX1 levels.
There is abundant biochemical and immunohistochemical data, including
those presented in this study, showing that inflammation is a major feature of the
EAE spinal cord. Local inflammation leads to the production of several proinflammatory cytokines, particularly IFN-g, which are known to upregulate
immunoproteasome subunits and the proteasome activator PA28 (Aki et al., 1994;
Groepttrup et al., 1995). In line with this notion, we found that the amount of i-20S
and PA28a/b, both mRNA and protein, is greatly elevated in EAE (Fig. 2.4). This
is not surprising as the promoter regions of the inducible proteasome subunits and
PA28 subunits contain binding sites for interferon consensus sequence-2 and
gamma interferon activated sequence elements that bind STAT-1 and IRF-1
(Chatterjee-Kishore et al., 2000), and the levels of both transcription factors are
elevated in the nuclear fractions from EAE spinal cords (Fig. 2.8). The promoter of
immunoproteasome and PA28 subunits also contain additional binding sites for
other transcription factors, including three regions of consensus sequence for NFkB binding (Ferrington and Gregerson, 2012). Interestingly, nuclear NF-kB levels
were unchanged in EAE, suggesting that IFN-g is regulating immunoproteasome
expression mostly via STAT-1 and IRF-1. The lack of increased NF-kB signaling
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in EAE was surprising since the nuclear levels of this transcription factor are known
to be up-regulated by pro-inflammatory cytokines like TNF-a (Hayden and Ghosh,
2014) and IL-1b (McDonald et al., 1997) as well as by oxidative stress (Morgan
and Liu, 2011), all of which are elevated in EAE (Fig. 2.2d-f). Perhaps NF-kB is
elevated in a small subset of cells like microglia or lymphocytes, and therefore
such an increase is not detected when one analyzes total spinal cord proteins.
Concomitant with the rise in the concentration of i-20S and 11S particles in
EAE, we discovered a reduction in the amount of c-20S, suggesting the
displacement of housekeeping proteasome subunits by immuno-subunits. In
support of this idea, we observed that neural cells in EAE spinal cords where β5i
expression is increased (i.e., neurons and astrocytes) have low β5 expression.
Similarly, EAE oligodendrocytes show no changes in either β5i or β5 expression.
Moreover, in the EAE cerebellum, where the increase in the amount of β5i is less
pronounced than that in the spinal cord, the reduction in β5 levels is smaller.
Proteasome subunit displacement is a well-characterized post-translational
process achieved by competition of the inducible subunits with the respective
constitutive subunits for a common assembly site within the 20S particle (Früh et
al., 1994). The preferential incorporation of all three immuno-subunits (β1i, β2i and
β5i) is assisted by the proteasome maturation protein (POMP). This protein binds
the pro-peptide of β5i with greater affinity than that of β5, resulting in preferred
formation of i-20S over c-20S particles (Heink et al., 2005). Interestingly, POMP
expression is upregulated by IFN-g (Burri et al., 2000), whose levels are
augmented in EAE (Fig. 2.2c). Furthermore, p-mTOR (Yun et al., 2016), which is
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also elevated in EAE (Fig. 2.10a), promotes the formation of immunoproteasomes
by making the immuno-subunits available to POMP via PRAS40 activation. Thus,
the conditions present in the EAE spinal cord enable the preferential formation of
i-20S over c-20S core particles.
It is important to note that immune cells and microglia may contribute to the
western blot and qPCR values determined in spinal cord homogenates. Indeed,
we found that CD45+ cells contain significant amounts of b5i (Fig. S2.1). Also, we
have previously shown that CD3+ cells and microglia in EAE cerebellum express
b5i (Zheng et al., 2012). However, even if microglia and immune cells were to
express only immunoproteasomes, that would not explain the decrease in the
levels of constitutive particles in EAE from 4.67 to 2.98 pmol/mg protein. Thus, the
data in the homogenates cannot be explained simply by the contribution of these
non-neural cells. Most importantly, the presence of immunoproteasomes in other
CNS cells does not change the fact that c-20S is being replaced with i-20S in EAE
neurons and astrocytes, as demonstrated by immunohistochemical analysis.
While subunit displacement is likely one important reason for the reduced
levels of constitutive proteasomes in EAE, it does not explain why Psmb5 mRNA
levels are also diminished in the disease (Figs. 2.3 and 2.4). STAT-3 has been
shown to increase Psmb5 mRNA and protein levels, and the amount of constitutive
proteasome (Vangala et al., 2014). However, phospho-STAT-3 levels are
augmented in EAE spinal cords (Hou et al., 2017), suggesting that reduction of
Psmb5 mRNA expression cannot not be attributed to impaired STAT-3 signaling.
The promoter regions of all the constitutive proteasome subunits and those that
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make up the 11S and 19S complexes have EpRE that can bind to and became
activated by Nrf1 and Nrf2 (Pickering et al., 2012). However, while both
transcription factors can increase proteasome subunit expression, only Nrf1 is
required for upregulation of proteasome genes in response to proteasome
inhibition (Radhakrishnan et al., 2010). Furthermore, late-stage deletion of Nrf1 in
neuronal cells leads to impaired proteasome function due to down-regulation of
proteasomal genes that encode the catalytic subunits (Lee et al., 2011). These
studies point to the critical role of Nrf1 in the biogenesis of constitutive
proteasomes and prompted us to explore the possibility that expression of this
transcription factor is diminished in EAE. In the present study, we discovered that
Nfe2l1 mRNA levels, utilizing a set of primers that measure all transcripts, are
reduced in EAE spinal cords with a temporal pattern similar to that of Psmb5
mRNA. The reason for diminished Nfe2l1 mRNA expression in EAE is unknown
but it does not appear to be the result of reduced mTOR signaling (Fig. 2.10a).
Interestingly, we found a decline in PBX1 content in EAE spinal cords, which could
underlie the reduced Nrf1 expression (Fig. 2.10b). PBX1 has been recently shown
to activate Nfe2l1 expression to promote neuronal survival (Villaescusa et al.,
2016). Furthermore, those studies also revealed that both PBX1 and Nrf1 are
absent in substantia nigra neurons from Parkinson’s disease patients, suggesting
an impaired PBX1-Nrf1 pathway in neurodegeneration.
The Nfe2l1 gene can yield multiple mRNA transcripts that can undergo
alternative initiation of translation generating distinct polypeptide isoforms. These
forms can also be modified by glycosylation and proteolytic cleavage, rendering
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several bands on SDS-gels with molecular masses ranging from 25 kDa to 140
kDa (Bugno et al., 2015; Xiang et al., 2018). The four major forms are the fulllength Nrf1 (Nrf1a, ~100 kDa on SDS-gradient gels), Nrf1b (~55 kDa), generated
through in-frame translation, Nrf1g (~36 kDa), produced by a separate in-frame
translation starting codon, and Nrf1d (~ 25 kDa) that seems to arise from
proteolytic cleavage of Nrf1g (Zhang et al., 2014; Bugno et al., 2015;). Nrf1a
exhibits a stronger transactivation activity than Nrf1b (Caterina et al., 1994;
Prieschl et al., 1998; Zhang et al., 2014), while Nrf1g/d are dominant-negative
forms that interfere with the functional association of Nrf1a or Nrf2 to small
musculoaponeurotic fibrosarcoma proteins and down-regulate the expression of
EpRE-containing genes (Zhang et al., 2014). Our present work reveals that Nrf1b
is the major Nrf1 species present in the nuclear fraction along with a small amount
of Nrf1a, and that the levels of both of these positive activators of proteasome
expression decline in EAE. A number of additional Nrf1-positive bands were
detected on western blots of the cytosolic fraction; these include the 85 kDa and
76 kDa species, which are considered proteolytic fragments of Nrf1a, a 46 kDa
form (Nrf1b2) that derives from Nrf1b cleavage, and a 25 kDa form that is likely to
be Nrf1d. However, none of these species are present in the nuclear fractions from
the spinal cords and thus were not quantified. It is important to note that most
studies in the literature assign functionality to Nrf1 isoforms based on their levels
in cell homogenates without determining whether or not they are present in the
nucleus.
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In summary, we have obtained evidence that two important mechanisms,
subunit displacement and impaired Nfe2l1 signaling, may be the cause for the
reduced amounts of constitutive proteasomes in neurons and astrocytes during
inflammatory

demyelination.

Because

constitutive

proteasomes

and

immunoproteasomes are equally effective at removing ubiquitinated (Nathan et al.,
2013) and oxidized proteins (Pickering et al., 2010; Zheng et al., 2012), it is fair to
conclude that the overall capacity of these cells to eliminate damaged proteins is
augmented in EAE and helps prevent the toxic protein accumulation at the peak
of the disease. In a previous study on proteasome composition in the EAE
cerebellum, we discovered that as the disease progresses from the inflammatory
to the neurodegenerative phase, immunoproteasome levels return to normal
without being counterbalanced by a rise in the amounts of constitutive
proteasomes (Zheng et al., 2012). This suggests that impaired synthesis of
constitutive proteasomes in chronic EAE, caused perhaps by deficient Nrf1
signaling, could be an important pathophysiological mechanism.
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Table 2.1 - List of mouse PCR primers used in the study
Proteasome subunits
Psmb5 / b5
Psmb8 / b5i
Psme1 / PA28a
Psme2 / PA28b
Psmc3 / Rpt5
Psma7 / a7

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5’-GATCTGTGGCTGGGATAAGAG-3’
5’-TCCATAACGCCGTAAGCATAC-3’
5’-GCTGCTTTCCAAACATGATGC-3’
5’-CCGAGTCCCATTGTCATCTAC-3’
5’-TCCATCCCGAAGCCCAA-3’
5’-CCTTTAAGAACGCATCCAACTC-3’
5’-TCATATCCCTGAGTCAGCTCT-3’
5’-TGCTTGTCTGTTTCCATCTCG-3’
5’-GATCATACCCGCCTCCAC-3’
5’-ATCATGCAGATCCACTCACG-3’
5’-ACAATGTCCTTTCCTCGAACA-3’
5’-GCCATCACCGTCTTCTCG-3’

Antioxidant Defense
Nfe2l1 / Nrf1

Forward
Reverse

5’-AGCCTTCTATCTCCTCTTCTGA-3’
5’-CTCACTTGCTGATGTATTTACTTCC-3’

Pro-inflammatory cytokines
Ifng / IFN-g
Tnf / TNF-a
Il1b / IL-1b

Forward
Reverse
Forward
Reverse
Forward
Reverse

5’-ACGGCACAGTCATTGAAAGC-3’
5’-TCACCATCCTTTTGCCAGTTC-3’
5’-GCCACCTCGCTCTTCTG-3’
5’-TGGTTTGCTACGACGTGGG-3’
5’-GGCTCATCTGGGATCCTCTC-3’
5’-ATCTTTTGGGGTCCGTCAACT-3’

House-keeping genes
Gapdh / GAPDH
Hprt1 / HPRT1
Rplp0 / RPLP0
Rn18s / 18S rRNA

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5’-TGTGATGGGTGTGAACCACGAGAA-3’
5’-GAGCCCTTCCACAATGCCAAAGTT-3’
5’-TGGGCTTACCTCACTGCTTT-3’
5’-CTAATCACGACGCTGGGACT-3’
5’-TCCAGGCTTTGGGCATCA-3’
5’-CTTTATCAGCTGCACATCACTCAGA-3’
5’-GCAATTATTCCCCATGAACG-3’
5’-GGCCTCACTAAACCATCCAA-3’
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Table 2.2- List of primary and secondary antibodies used for western blot analysis.

Primary
Antibodies
20S a1-3/5-7
20S b5
20S b5i
PA28a
PA28b
Rpt5
Nrf1
Histone-H3

Species/Clonality

Dilutions

Supplier

RRID

Mus / mAb
Rb / pAb
Rb / mAb
Rb / mAb
Rb / pAb
Rb / mAb
Rb / pAb
Rb / mAb

1:500
1:2000
1:2000
1:1000
1:1000
1:2000
1:1000
1:10000
1:2000 1:5000
1:2000
1:2000
1:2000
1:2000
1:5000

Enzo Life Science
Enzo Life Science
Cell Signaling Technology
Abcam
Abcam
Abcam
Proteintech
Cell Signaling Technology

AB_2052368
AB_2052392
AB_2744693
AB_2801483
AB_2050212
AB_2801479
AB_2267298
AB_10544537

Cell Signaling Technology

AB_10859369

Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Proteintech
Proteintech

AB_10949108
AB_10691552
AB_2773718
AB_10951860
AB_2721256

Dilutions

Supplier

RRID

1:10,000

Jackson
ImmunoResearch

AB_2307391

1:10,000

Jackson
ImmunoResearch

AB_10015289

NFkB (p65)

Rb /mAb

IRF-1
p-mTOR
p-STAT-1
PBX1
Lamin B1

Rb / mAb
Rb / mAb
Rb / mAb
Rb / pAb
Mus / mAb

Secondary
Species/Clonality
Antibodies
Peroxidaseconjugated anti- Goat / pAb
rabbit IgG
PeroxidaseGoat /pAb
conjugated antimouse IgG

Abbreviations: Mus, mouse; Rb, rabbit; mAb, monoclonal antibody; pAb, polyclonal antibody; RRID, research resource identifier
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Table 2.3- List of primary and secondary antibodies used for immunohistochemical analysis.

Primary
Antibodies
20S b5
20S b5i
PA28b
GFAP
CAII
NeuN
CD45

Species/Clonality
Rb / pAb
Rb / mAb
Rb / pAb
Mus / mAb
Mus / mAb
Mus / mAb
Rat / mAb

Dilutions
1:100
1:50
1:50
1:200
1:200
1:200
1:25

Supplier
Enzo Life Science
Cell Signaling Technology
Abcam
Sigma Aldrich
Santa Cruz Biotechnology
Millipore
Life Technology

Cat#
BML-PW8895
13635
ab91548
G3893
Sc-48351
MAB377
MCD4500

RRID
AB_2052392
AB_2744693
AB_2050212
AB_477010
AB_626796
AB_2298772
AB_10372515

Species/Clonality

Dilutions

Supplier

Cat#

RRID

Donkey / pAb

1:500

Jackson ImmunoResearch

711-165-152

AB_2307443

Alexa Fluor®
488-conjugated
anti-mouse IgG

Goat /F(ab’)2

1:500

Thermo-Fisher

A11017

AB_143160

Alexa Fluor®
488-conjugated
anti-rat IgG

Donkey / pAb

1:500

Jackson ImmunoResearch

715-545-152

AB_2340684

Secondary
Antibodies
Cy3®conjugated
anti-rabbit IgG

Abbreviations: Mus, mouse; Rb, rabbit; mAb, monoclonal antibody; pAb, polyclonal antibody; RRID, research resource identifier.
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Figure 2.1 – Schematic diagram showing the timeline of the EAE study design /
procedures. MOG, myelin oligodendrocyte glycoprotein; CFA, complete Freund’s

adjuvant; qPCR, quantitative polymerase chain reaction; WB, western blot; IHC,
immunohistochemistry; dpi, days post-immunization.
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Figure 2.2 – Elevated inflammation and oxidative stress during the course of EAE.
EAE was induced in C57BL/6 female mice by active immunization with MOG35-55
peptide in CFA. EAE was induced in C57BL/6 female mice by active immunization with
MOG35-55 peptide in CFA. (a) Animals were monitored daily for signs of clinical disease,
and symptoms were scored as indicated in the text. Dots represent the final clinical score
of each of the 32 EAE mice used in the study. Control animals did not exhibit neurological
symptoms (i.e. score = 0). (b) The number of lymphocytes per spinal cord section were
assessed by hematoxylin and eosin staining. (c-e) IFN-g, TNF-a, and IL-1b mRNA levels
during the course of the disease were determined by qPCR. (f) Total GSH levels were
measured using the enzymatic recycling assay and data shown was taken from one of our
previous publications (Morales Pantoja et al., 2016). Each point represents one animal.
Values are expressed relative to controls. Bars and horizontal lines show the mean ± SEM
of 3-8 animals. Asterisks denote values that are statistically different (p<0.05) from their
respective controls.
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Figure 2.3 – Altered gene expression of proteasomes, immunoproteasomes and
PA28 during the course of EAE (9 – 60 dpi). (a) Proteasome subunit b5i (Psmb8), (b)
PA28a (Psme2) and (c) proteasome subunit b5 (Psmb5) mRNA levels in the spinal cords
of control and EAE mice were determined by qPCR. Each point represents one animal.
Values are expressed relative to controls. Bars and horizontal lines show the mean ± SEM
of 3-7 animals. Asterisks denote values that are statistically different (p<0.05) from their
respective controls as assessed by Student’s t-test.
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Figure 2.4 – Reduced expression of constitutive proteasomes and increased
expression of immunoproteasomes and the 11S activator in the EAE spinal cord.
(a) Levels of subunits a1-3/5-7, b5, b5i, PA28a, PA28b and Rpt5 in control and EAE spinal
cords at 30 dpi were determined by western blot analysis. Left panel shows representative
western blots of the analyzed subunits. (b) Psma7 (a7), Psmb5 (b5), Psmb8 (b5i), Psme1
(PA28a), Psme2 (PA28b) and Psmc3 (Rpt5) mRNA levels in the spinal cords of control
and EAE mice at 30 dpi were determined by qPCR. In both panels, each point represents
one animal. Values are expressed relative to controls. Bars and horizontal lines depict the
mean ± SEM of 3-7 animals. Statistical significance was determined by Student’s t-test.
NS, not significant.
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Figure 2.5 – Representative double-label immunofluorescence images of lumbar
spinal cord sections of control and EAE mice depicting the expression of the c-20Sspecific subunit b5 in neurons (a), astrocytes (b) and oligodendrocytes (c). Spinal
cord sections (5 µm-thick) from control and EAE mice were co-stained with anti-b5
antibody and either anti-NeuN (neurons), anti-GFAP (astrocytes) or anti-CAII (mature
oligodendrocytes) antibody, and images were visualized by confocal microscopy. Red
channel is for b5 while green channel is for various cell markers. Nuclei were labeled with
TO-PRO-3. Bars at lower left of each panel represent 20 µm in length.
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Figure 2.6 – Representative double-label immunofluorescence images of lumbar
spinal cord sections of control and EAE mice depicting the expression of the i-20Sspecific subunit b5i in neurons (a), astrocytes (b) and oligodendrocytes (c). Spinal
cord sections (5 µm-thick) from control and EAE mice were co-stained with anti-b5i
antibody and either anti-NeuN (neurons), anti-GFAP (astrocytes) or anti-CAII (mature
oligodendrocytes) antibody, and images were visualized by confocal microscopy. Red
channel is for b5i while green channel is for various cell markers. Nuclei were labeled with
TO-PRO-3. Bars at lower left of each panel represent 20 µm in length.
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Figure 2.7 – Differential expression of proteasome subunits b5 (a) and b5i (b) in
neurons, astrocytes (astros) and oligodendrocytes (oligos) in EAE spinal cords.
Double immunofluorescence confocal analysis to estimate the average b5 and b5i
fluorescence intensity in neurons, astrocytes and oligodendrocytes was performed as
described in “Materials and Methods”. Each point represents one animal. Values are
expressed relative to controls. Bars and horizontal lines depict the mean ± SEM of 3-7
animals. Statistical significance was determined by Student’s t-test. NS, not significant.
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Figure 2.8 – Augmented nuclear levels of p-STAT-1 and IRF-1, but not NF-kB, in the
EAE spinal cord. Levels of p-STAT-1 (a), IRF-1 (b) and NFkB (c) in the nuclear fractions
from control and EAE spinal cords at 30 dpi were determined by western blot analysis.
Band intensities were corrected by the amount of histone H3 in the same gel lanes. Each
point represents one animal. Values are expressed relative to controls except for panel b,
where IRF-1 was undetectable in the control mice. Bars and horizontal lines depict the
mean ± SEM of 3-7 animals. Statistical significance was determined by Student’s t-test.
NS, not significant. (d) Representative western blots of the analyzed proteins.
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Figure 2.9 – Decreased Nrf1 mRNA and protein in the EAE spinal cord. (a) Nfe2l1
mRNA levels in the spinal cords of control and EAE mice were determined by qPCR. Each
point represents one animal. Values are expressed relative to controls. Bars and
horizontal lines show the mean ± SEM of 3-7 animals. Asterisks denote values that are
statistically different (p<0.05) from their respective controls. (b) Cytoplasmic and nuclear
proteins from control and EAE spinal cords at 30 dpi were analyzed by western blot using
an antibody against Nrf1. The cytoplasmic fraction shows six Nrf1-positive bands with
molecular masses ranging from 25 kDa to 100 kDa (arrows) but only the 55 kDa band
(Nrf1b) is present in the nuclear fraction. (c) Band intensities corresponding to Nrf1b in the
nuclear fraction were corrected by the amount of histone H3 in the same gel lanes. Each
point represents one animal. Values are expressed relative to controls. Bars and
horizontal lines depict the mean ± SEM of 4 animals per experimental group. Statistical
significance was determined by Student’s t-test
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Figure 2.10 – High levels of p-mTOR and reduced expression of PBX1 in EAE. (a)
The amount of p-mTOR in spinal cord homogenates from control and EAE mice at 30 dpi
was determined by western blot analysis. Band intensities were corrected by the amount
of Coomassie blue staining in the same gel lanes. (b) PBX1 levels in the nuclear fractions
from control and EAE spinal cords at 30 dpi were determined by western blot analysis.
Band intensities were corrected by the amount of histone H3 in the same gel lanes. In
both panels, each point represents one animal. Values are expressed relative to controls.
Bars and horizontal lines depict the mean ± SEM of 4-7 animals. Statistical significance
was determined by Student’s t-test. Lam B, lamin B1.
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Figure 2.11– Altered proteasome composition in the cerebella, but not the cerebra,
of EAE mice. Levels of subunits b5, b5i, a1-3/5-7, PA28a and Rpt5 in the cerebra and
cerebella of control and EAE mice at 30 dpi were determined by western blot analysis.
Band intensities were corrected by the amount of Coomassie blue staining in the same
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Bars and horizontal lines depict the mean ± SEM of 5-6 animals. Statistical significance
was determined by Student’s t-test. NS, not significant. Lower right panel shows
representative western blots of the analyzed subunits.
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Figure S2.1 - Representative double-label immunofluorescence images of lumbar
spinal cord sections from EAE mice depicting the high expression of the
immunoproteasome subunit b5i in CD45-positive infiltrating leukocytes. Spinal cord
sections (5 µm-thick) from EAE mice were co-stained with b5i antibody and CD45
antibody, and images were visualized by confocal microscopy as described in “Materials
and Methods”. Nuclei were labeled with TO-PRO-3. Bar at lower left represents 20 µm in
length.
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Figure S2.2 - Representative double-label immunofluorescence images of lumbar
spinal cord sections from EAE mice depicting the expression of the PA28b in
neurons, astrocytes and oligodendrocytes. Spinal cord sections (5 µm-thick) from EAE
mice were co-stained with anti-PA28b antibody and either anti-NeuN, anti-GFAP or antiCAII antibody, and images were visualized by confocal microscopy as described in
“Materials and Methods”. Red channel is for PA28b while green channel is for various cell
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Abstract
In this study, we investigated if subunit displacement and/or alterations in
proteasome biosynthesis are responsible for the changes in the levels of
constitutive proteasomes (c-20S), immunoproteasomes (i-20S) and the activators
PA28 and PA700 in neurons and astrocytes cultured with a cytokine mixture (IFNg / TNF-a / IL-1b). Exposure of both cell types to cytokines for 24 h increases
mRNA and protein expression of the i-20S-specific subunit b5i and PA28a/b and
leads to a decline in the amount of the c-20S-specific subunit b5. Since b5 mRNA
levels are unchanged by the cytokine treatment, it is fair to conclude that
displacement of constitutive b-subunits with inducible b5i subunits is likely the
mechanism underlying the decrease in c-20S. As expected, the increase in the
amount of the IFN-g-inducible subunits coincides with elevated expression of
phospho-STAT-1 and interferon regulatory factor-1 (IRF-1). However, inhibition of
NF-kB signaling in cytokine-treated astrocytes reduces IRF-1 expression without
affecting that of i-20S, c-20S and PA28. This suggests that STAT-1 is capable of
increasing the transcription of i20S-specific subunits and PA28a/b by itself. The
lack of a decrease in proteasome β5 mRNA expression is consistent with the fact
that Nrf1 (Nfe2l1) and Nrf2 (Nfe2l2) levels are not reduced by pro-inflammatory
cytokines. In contrast, we previously found that there is a significant Nrf1
dysregulation and reduced b5 mRNA expression in the spinal cords of mice with
experimental autoimmune encephalomyelitis (EAE). Thus, there are stressors in
EAE, other than a pro-inflammatory environment, that are not present in cytokinetreated cells.
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Introduction
Proteasomes are multi-enzyme complexes whose sole function is to
catalyze the degradation of most intracellular proteins [1]. The core of these
complexes, the 20S proteasome, is comprised of two outer a and two inner β rings
(i.e. aββa). Each a and β ring is made of seven a subunits (a1-a7) and seven β
subunits (β1-β7) [2]. While the a rings are the structural components of the
proteasome, each β ring has three proteolytic sites, which display caspase-like (β1
or Psmb6), trypsin-like (β2 or Psmb7) and chymotrypsin-like (β5 or Psmb5)
activities [3]. The expression, structure and activity of proteasomes are stringently
controlled and are constantly adjusted to fulfill cellular requirements. For example,
exposure of cells to interferon-g (IFN-g), leads to the replacement of the catalytic
β1, β2 and β5 subunits in the constitutive 20S particle (c-20S) by the inducible β1i,
β2i and β5i subunits, forming the immunoproteasome 20S particle (i-20S) [4]. IFNg promotes this displacement of subunits by two concerted processes. First, it
augments the transcription of the βi subunits [4] via binding of the signal transducer
and activator of transcription 1 (STAT-1)-dependent interferon regulatory factor-1
(IRF-1) to IFN-g regulatory elements in the promoter regions of these genes [5].
Second, it increases the expression of proteasome maturation protein, which binds
to the pro-peptides of the catalytic βi-forms with greater affinity than those of
catalytic β-forms, favoring the formation of i-20S over c-20S particles [6]. Once all
of these subunit precursors are incorporated into the proteasome, there is
cleavage of the N-terminal pro-peptides from the three pairs of catalytic β subunits
making the mature proteasome [7].
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Proteasome activity is regulated by a number of protein complexes that
attach to one or both ends of the aββa barrel. One of these regulators, PA28 (11S),
is also induced by IFN-g and attaches to the i-20S particle forming a complex
(11S/i-20S/11S) [8]. PA700 (19S), the other major activator, binds to the end of
20S core particles to form the 26S proteasome, which recognizes and hydrolyzes
abnormal and misfolded proteins conjugated with polyubiquitin chains [9]. Other
less studied regulators are the 31kDa proteasome inhibitor (PI31 or Psmf1) [10]
and the 200kDa proteasome activator (PA200 or Psme4) [11].
Responsibility for up-regulation of genes that encode the subunits of the c20S particle and the 11S and 19S activators belongs to Nrf1 (Nfe2l1) and Nrf2
(Nfe2l2) [12], which are members of the cap‘n’collar subfamily of basic-region
leucine zipper transcription factors [13]. In the absence of cellular stress, Nrf1
undergoes endoplasmic reticulum-mediated degradation, while Keap1-bound Nrf2
is degraded by the proteasome. However, upon endoplasmic reticulum stress [14]
and oxidative stress [15], the degradation of these transcription factors is reduced,
allowing them to translocate to the nucleus where they form heterodimers with
small Maf proteins. The Nrf1/Maf or Nrf2/Maf heterodimers then transactivate
proteasome genes through electrophile response elements in their promoters [16,
17]. While Nfe2l1 mRNA expression is positively regulated by the mammalian
target of rapamycin complex 1 (mTORC1) [18] and the pre-B-cell leukemia
homeobox-1 transcription factor (PBX1) [19], that of Nfe2l2 is upregulated by NFkB [20].
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We have previously shown that, at the peak of the disease, there is
increased expression of i-20S and PA28 and a concomitant decline in c-20S levels
in the cerebella and the spinal cords of mice with experimental autoimmune
encephalomyelitis (EAE) [21, 22]. In the latter study, we also found that a
combination of subunit displacement and reduced Nrf1 expression might be
responsible for c-20S impairment in EAE. Furthermore, we speculated that the
inflammatory conditions of the EAE spinal cord is likely the cause for Nrf1
impairment and the subsequent decrease in β5 subunit mRNA expression. In the
present study, we investigate the effect of a mixture of pro-inflammatory cytokines
(IFN-g, TNF-a and IL-1β), known to be elevated in EAE [22], on the protein and
mRNA expression of proteasome core particles and their activators in cultured
neurons and astrocytes. We discovered that in neurons and astrocytes exposed
to the cytokine mixture, the replacement of c-20S by i-20S occurs by subunit
displacement as Psmb5 mRNA levels are unaltered. Moreover, in contrast to EAE,
Nrf1 and Nrf2 do not appear to play a role in the cytokine-induced downregulation
of c-20S proteasomes in vitro.
Materials and Methods
Cell Culture and Drug Treatments
All incubations were performed in a humidified incubator at 37˚C under a
95% air / 5% CO2 atmosphere. Mouse neuroblastoma cells (Neuro-2A or N2a)
(ATCC® CCL-131™) were maintained in minimum essential medium (Life
Technologies, Grand Island, NY) containing 10% fetal bovine serum (FBS) (Sigma,
St. Louis, MO), 100 units of penicillin and 0.1 mg/ml streptomycin (Life
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Technologies). Differentiation of N2a cells into a neuronal phenotype was achieved
by incubation for 24 h with 0.25 mM theophylline (Sigma) and 1 mM N6-2’-Odibutyryl cyclic-AMP (Sigma) in low serum medium (0.5% FBS). These
differentiated cells develop neurites and express neuron-specific markers such as
neurofilament heavy chain (NFH) and neuron specific enolase (NSE) (Fig. 3.1a).
Cells were then incubated with or without a pro-inflammatory cytokine mixture
(CIII) consisting of 5 ng/mL IFN-γ (Sigma), 10 ng/mL IL-1β (Sigma), and 10 ng/mL
TNF-α (Sigma) [23]. After 24 h, cells were harvested and used for protein and
mRNA analysis.
Rat C6 glioma cells (ATCC® CCL-107™) were sustained in Dulbecco’s
modified Eagle’s medium / Ham’s F-12 (Sigma) containing 10% FBS, 2 mM
GlutaMAX™ (Life Technologies) and the antibiotic mixture shown above. Cells
were differentiated into astrocytes by incubating for 24 h with 0.25 mM theophylline
and 1 mM N6-2’-O-dibutyryl cyclic-AMP in low serum medium (1% FBS). These
cells display characteristic astrocyte morphology and express glia-specific markers
such as glial fibrillary acidic protein (GFAP) and excitatory amino acid transporter1 (EAAT1) (Fig. 3.1b). Astrocytes were then incubated with or without CIII in the
absence or presence of 2 µM IKK-16 (Selleckchem, Houston, TX). As before, cells
were harvested after 24 h and used for protein and mRNA analysis.
Cellular Fractionation
Preparation of the nuclear fraction was carried out using a modified version
of the nuclear extraction protocol developed by Thermo-Fisher Scientific. Briefly,
cultured cells were suspended at 4˚C in 0.15 ml of hypotonic buffer solution (20
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mM Tris-HCl pH 7.4 containing 10 mM NaCl, 3 mM MgCl2, 1 mM DTT, 1 mM PMSF
and 1x protease and phosphatase inhibitor cocktails) by pipetting up and down
several times. Suspensions were kept on ice for 15 min, mixed with 7.5 µl of 10%
w/v Nonidet P-40, and centrifuged at 3,000 g for 10 min. The supernatant (cytosolic
fraction) and the pellet (nuclear fraction) were collected, and proteins were
solubilized in sodium dodecyl sulfate (SDS)-sample buffer and analyzed by
western blotting.
Reverse Transcription and qPCR
Cells were lysed using QIAshredder columns (Qiagen, Germantown, MD)
and total RNA was isolated from the lysates via the column purification used in the
RNeasy® Mini Kit (Qiagen). DNase I-treated RNA was used to generate cDNA
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA). Briefly, 200 ng of RNA were mixed with the 2X reverse
transcription master mix, which contains the reverse transcription buffer, a dNTP
mixture, random primers, an RNase inhibitor and the MultiScribe Reverse
Transcriptase™. The samples were heated as follows: 25°C for 10 min, 37°C for
120 min, and finally 85°C for 5 min to terminate the reaction.
Gene expression levels were quantified using Power SYBR Green PCR
Master Mix (Applied Biosystems, Forster City, CA) with primers against selected
targets made by Integrated DNA Technologies (Coralville, IA) (Tables S3.1 and
S3.2). cDNAs (20 ng) were mixed with 1 µM of each primer and amplified with the
Power SYBR Green PCR MasterMix according to the manufacturer’s instructions
at 50˚C for 10 min, 95˚C for 10 min and then 40 thermal cycles of 95˚C/15 sec and
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60˚C/1 min. The relative mRNA expression was determined using the comparative
2-ΔCt method [24]. RNA levels in cultured mouse neurons were normalized to the
geometric mean of 4 reference genes (Gapdh, Hprt1, Rplp0 and Rn18s) (Table
S3.1) [25]. In cultured rat astrocytes, RNA levels were also normalized to the
geometric mean of 4 reference genes (Gapdh, Hprt1, Rplp0 and Tbp) (Table S3.2).
Western Blot Analysis
Proteins (5 μg) were separated by SDS–polyacrylamide gel electrophoresis
on 4-20% Mini-Protean TGX gels (Bio-Rad Laboratories; Hercules, CA) and were
blotted to polyvinylidene difluoride membranes. Blots were blocked with 3% (w/v)
non-fat milk in phosphate-buffered saline solution containing 0.05% (v/v) Tween
20 (PBS-T) and then incubated overnight at 4°C with the primary antibodies listed
in Table S3.3. Membranes were rinsed three times in PBS-T and incubated for 1
h with the corresponding horseradish peroxidase-conjugated secondary
antibodies (Table S3.3). Blots were developed by enhanced chemiluminescence
using the Western Lightning ECL™ kit from Perkin-Elmer (Boston, MA). Films were
scanned in a Hewlett Packard Scanjet 4050 and the images were quantified using
the NIH ImageJ 1.51 imaging analysis program. Band intensities were normalized
by the intensity of the Coomassie blue stain in the respective lanes. When
analyzing proteins from the nuclear fractions, band intensities were normalized by
the intensity of histone H3 or HDAC2 in the same lanes. All the antibodies used in
this study were validated by the suppliers and detected bands at the predicted
molecular weights on western blots.
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Statistical Analysis
Results were analyzed for statistical significance with the unpaired
Student’s t-test or two-way ANOVA test utilizing the GraphPad Prism® program
(GraphPad Software Inc.; San Diego, CA) after assessing the normality of the data
with the Shapiro-Wilk test. No outliers were identified in any of the data sets using
the GraphPad Prism® ROUT test and assigning a Q value of 1%.
Results
Reduced c-20S and Increased i-20S/PA28 Expression in CIII-treated Neurons
The amounts of proteasomes and their activators in control and CIII-treated
neurons were measured by western blot analysis (Fig. 3.2a). The mean levels of
proteasome core particles (c-20S + i-20S), assessed with an antibody that
recognizes six of the seven 20S a-subunits (a1-3/5-7), increases by 38.3 ± 22.7%
upon cytokine treatment but the difference is not significant (p = 0.1057). Similarly,
a7-subunit (Psma7) mRNA expression is unchanged in neurons incubated with the
cytokine mixture (Fig. 3.2b). In contrast, the amounts of the i-20S-specific subunit
b5i and those of PA28a and PA28b augment in the cytokine-stimulated cells by
589 ± 88% (p < 0.0001), 439 ± 101% (p < 0.0009) and 414 ± 50% (p < 0.0001),
respectively (Fig. 3.2a), and this pattern coincides with their increased gene
expression (Fig. 3.2b). The amount of c-20S-specific subunit b5 declines by 24.5
± 5.8% (p = 0.0012) in the cytokine-treated neurons (Fig. 3.2a), without changes
in its mRNA expression (Psmb5) (Fig. 3.2b). Protein and mRNA levels of the 19Sspecific subunit Rpt5 (Psmc3) are unaltered by the cytokine treatment (Fig. 3.2a,
b).
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Using the intensity values obtained by western blot analysis and purified c20S and i-20S proteasomes for calibration, we estimated the absolute amounts of
each proteasome core particle in control and CIII-treated neurons. The purity of
the c-20S particle (positive for β1, β2 and β5 but not for their inducible
counterparts) and the i-20S (positive for β1i, β2i and β5i but not for their standard
counterparts) was demonstrated by western blotting in our previous publication
[21]. We estimated that, in control neurons, the majority (~90%) of core particles
are c-20S proteasomes (12.2 pmol/mg protein) with the rest (~10%) being i-20S
proteasomes (1.40 pmol/mg protein). In contrast, only 44% of the proteasomes in
CIII-treated neurons correspond to the constitutive form (9.2 pmol/mg protein)
while 56% (11.5 pmol/mg protein) is in the form of immunoproteasomes. Based on
these numbers, the total amount of proteasomes (i.e. c-20S + i-20S) in neurons
rises by 52% upon cytokine treatment, which is close to the 38% increase
observed by western blot analysis using the 20S a1-3/5-7 antibody (Fig. 3.2a).
Increased Amounts of i-20S and PA28 in CIII-treated Neurons Correlates with
Augmented STAT-1 / IRF-1, but not with NF-kB Activation
IFN-g is known to augment the transcription of the immunoproteasomespecific subunits b1i, b2i and b5i [4] as well as PA28a/b [26]. This occurs via
binding of STAT-1-dependent IRF-1 to IFN-g regulatory elements in the promoter
regions of inducible proteasome genes [5]. Immunoproteasome-specific subunits
also have NF-kB response sequences within their promoters [7]. As shown in Fig.
3.3a and b, the amounts of phosphorylated STAT-1 (p-STAT-1) and IRF-1
increase dramatically in the nuclear fractions of CIII-stimulated neurons. In
90

contrast, nuclear levels of NF-kB (p65 subunit) are unaltered by cytokine treatment
(Fig. 3.3c). These data strongly suggest that expression of i-20S and PA28
particles in cytokine-treated neurons results from activation of the IFN-g / STAT-1
/ IRF-1 pathway instead of the TNF-a or IL-1b / NF-kB / IRF-1 pathway.
In agreement with the lack of changes in b5 mRNA expression (Fig. 3.2b),
neither Nrf1 nor Nrf2 levels are altered in neurons upon cytokine exposure (Fig.
3.3 d, e). This suggests that all the proteasome changes in the stimulated cells are
entirely due to subunit displacement, which in turn is the result of increased IFNg / STAT-1 / IRF-1 signaling. The absence of changes in Nrf1 and Nrf2 signaling
also suggests that the three pro-inflammatory cytokines do not cause significant
oxidative and endoplasmic reticulum stress in these cells.
Reduced c-20S and Increased i-20S/PA28 Expression in CIII-treated
Astrocytes
The amounts of proteasomes and their activators in control and CIII-treated
astrocytes, measured by western blot analysis, is shown in Fig. 3.4a. The levels of
proteasome core particles (c-20S + i-20S) rise by 61.8 ± 14.1% (p = 0.0033) upon
cytokine treatment. However, a7-subunit (Psma7) mRNA expression is unchanged
(Fig. 3.4b), suggesting the occurrence of translational and/or post-translational
control mechanisms. Proteasome b5i, PA28a and PA28b protein levels augment
in CIII-treated astrocytes by 237 ± 26% (p < 0.0001), 175.2 ± 38.1% (p = 0.0010)
and 209.3 ± 30.4% (p < 0.0001), respectively, following their increased gene
expression (Fig. 3.4b). The amount of the b5 subunit is reduced by 20.2 ± 7.3% (p
= 0.0142) in CIII-treated astrocytes, without changes in its mRNA expression.
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mRNA and protein levels corresponding to the 19S subunit Rpt5 are unaffected by
the cytokine treatment. Altogether, these data point to subunit displacement as the
mechanism underlying the changes in proteasome composition in CIII-stimulated
astrocytes.
As we did for neurons (see above), we also calculated the absolute amounts
of each proteasome core particle in CIII-treated and untreated astrocytes. In
control astrocytes, ~56% of core particles are c-20S proteasomes (5.3 pmol/mg
protein) and the rest (~44%) are the i-20S proteasomes (4.2 pmol/mg protein). In
contrast, only 27% of the proteasomes in CIII-treated astrocytes correspond to the
constitutive form (4.1 pmol/mg protein) while 73% (11.1 pmol/mg protein) are
immunoproteasomes. Based on these numbers, the total amount of proteasomes
(i.e. c-20S + i-20S) in astrocytes rise by 60% upon cytokine treatment, which is
close to the 61.8% increase observed by western blot analysis using the 20S a13/5-7 antibody (Fig. 3.4a).
Diminished c-20S Expression in CIII-treated Astrocytes Occurs Despite
Increased Nrf2 Signaling
Consistent with the absence of changes in b5 mRNA levels (Fig. 3.4b), the
amount of the major Nrf1 isoforms (p120 and p65) as well as Nfe2l1 mRNA levels
are unaltered in CIII-treated astrocytes (Fig. 3.5a-c). The latter may result from the
lack of changes in the expression of p-mTOR and PBX1 (Supplementary Fig. 3.1),
which are known to positively upregulate Nfe2l1 mRNA expression [18, 19]. Thus,
as in the case of cultured neurons, CIII treatment does not seem to cause
endoplasmic reticulum stress in astrocytes. In contrast to Nrf1, levels of Nrf2
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protein and mRNA in cytokine-stimulated astrocytes increase by 120.2 ± 4.7% (p
= 0.0005) and 83.7 ± 14.7% (p < 0.0001), respectively (Fig. 3.5d, e). This suggests
that (1) the pro-inflammatory cytokine mixture causes substantial oxidative stress,
which activates Nrf2 signaling, and (2) this transcription factor does not play a
significant role in the biogenesis of constitutive proteasomes in this in vitro model
of inflammation. The presence of NF-kB binding sites in the promoter region of the
Nrf2 gene [20] may explain why Nfe2l2 mRNA expression is also increased in the
stimulated astrocytes.
NF-kB Inhibition and Reduced IRF-1 Signaling have no Effect on c-20S, i-20S
or PA28 Expression in CIII-treated Astrocytes
IKK-16 is a selective IkB kinase b (IKK-b) inhibitor [27] that has been shown
to reduce the levels of NF-kB and its downstream effectors [28]. We decided to
use this drug to determine the relative contributions of (i) the IFN-g / STAT-1, (ii)
the IFN-g / STAT-1 / IRF-1 and (iii) the TNF-a or IL-1b / NF-kB / IRF-1 pathways to
the biogenesis of immunoproteasomes and the 11S activator in astrocytes. To this
end, astrocytes were pre-treated for 1 h with or without 2 µM IKK-16, a
concentration that is 50 times the IC50 for IKK-b [27]. Cells were then incubated for
another 24 h with or without the cytokine mixture. As shown in Fig. 3.6a, CIII
treatment increases the amount of nuclear NF-kB (p65) by 335 ± 76% (p < 0.0001)
and IKK-16 reduces this activation by 38.8 ± 13.2% (p = 0.0276). IRF-1 levels in
cytokine-stimulated astrocytes rise by 986 ± 195% (p = 0.0005), and IKK-16
treatment decreases this expression by 80.4 ± 8.0% (p = 0.0203). As expected, pSTAT-1 levels are greatly elevated in astrocytes incubated with CIII, while IKK-16
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has no effect. The above findings suggest that the high IRF-1 levels in astrocytes
treated with the cytokine mixture is due to NF-kB rather than STAT-1 activation.
As shown in Fig. 3.7, neither the amounts of b5i, b5 nor PA28a in CIII-treated
astrocytes change in the presence of IKK-16, suggesting that IRF-1 is not a major
contributor to the expression of inducible proteasome genes under these culture
conditions.
Discussion
IFN-g is known to up-regulate immunoproteasome-specific subunits and the
proteasome activator PA28 [4, 26]. In agreement with this concept, we discovered
that the amount of i-20S and PA28a/b, both mRNA and protein, is significantly
elevated in CIII-treated neurons (Fig. 3.2) and astrocytes (Fig. 3.4). This was
expected since (i) the promoter regions of the inducible proteasome subunits and
PA28 subunits contain gamma interferon activated site (GAS) elements that
dimers of p-STAT-1 bind to [4, 29, 30] and interferon-stimulated response
elements (ISRE) that are activated by IRF-1 [31], and (ii) the levels of both
transcription factors are elevated in the nuclear fractions prepared from CIIIstimulated neurons (Fig. 3.3) and astrocytes (Fig. 3.5). The promoter regions of
immunoproteasome-specific catalytic subunits and PA28 subunits also contain
binding sites for other transcription factors, including three regions of consensus
sequence for NF-kB binding [7]. Interestingly, nuclear NF-kB levels are unchanged
in CIII-stimulated neurons, suggesting that IFN-g is regulating immunoproteasome
expression mostly via the STAT-1/IRF-1 signaling pathway in these cells. The lack
of increased NF-kB signaling in neurons upon CIII stimulation is surprising since
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TNF-a [32] and IL-1b [33] are known to up-regulate the amount of NF-kB in the
nucleus and both are present in the cytokine mixture. One explanation might be
that, in contrast to other types of neurons, the cAMP-differentiated N2a cells used
herein express low levels of IL-1b and TNF-a receptors. In contrast to neurons,
astrocytes produce high levels of nuclear NF-kB upon exposure to the cytokine
mixture (Fig. 3.5). Importantly, inhibition of NF-kB in CIII-treated astrocytes with
IKK-16 almost brings back IRF-1 levels to control values (Fig. 3.6) without reducing
the amount of i-20S and PA28 and/or increasing the expression of c-20S (Fig. 3.7).
These findings, along with the fact that p-STAT-1 levels are unaffected by IKK-16,
suggest (i) that IRF-1 expression in stimulated astrocytes is mostly dependent on
NF-kB, despite its promoter containing binding sites for both NF-kB [34] and pSTAT-1 [35], and (ii) that in the absence of IRF-1, p-STAT-1 is enough to drive the
expression of inducible proteasome and PA28 subunits. The latter conclusion
challenges the idea that IFN-g induction of immunoproteasome-specific subunits
is solely mediated by IRF-1 [5] or IRF-1/dephospho-STAT-1 dimers [31].
Concurrent with the rise in concentration of i-20S in CIII-stimulated neurons
and astrocytes, there is a reduction in the amount of c-20S, suggesting the
displacement of constitutive proteasome subunits by inducible subunits. The
observed reduction in β5 levels after just 24 h of incubation with CIII was surprising,
since the half-lives of constitutive proteasomes have been reported to range from
40-200 h [6, 36]. In one of these studies, the half-lives of c-20S and i-20S particles
in human lymphoblast T2 cells were found to be 133 h and 27 h, respectively, and
were independent of IFN-g [6]. Interestingly, figure 6a in that article shows that the
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amount of mature β5 is greatly reduced after just a 24 h-exposure to IFN-g, but no
explanation was provided for this observation. More recently, it was found that
suppression of STAT-3 phosphorylation in human prostate epithelial DU-145 cells
coordinately decreases the mRNA and protein levels of all the c-20S β subunits in
less than 18 h – similar findings were obtained in HeLa, human lung epithelial A549 and human mammary epithelial MDA-MB-231 cells [37]. These studies
suggest that proteasome turnover may be much faster than that determined by
pulse-chase experiments. Indeed, incubation of neuron-like PC12 cells with the
lysosomal/autophagy inhibitor chloroquine doubles the amount of β5 subunits in
just 24 h, indicating high rates of constitutive proteasome synthesis and
degradation (Supplementary Fig. 3.2). It is important to note that the possibility of
constitutive subunits being exchanged by inducible subunits in the mature
proteasome particle has been previously ruled out because no free processed
forms of constitutive and inducible subunits has been found, while their free
precursors are detectable [38].
Little is known about what regulates the production of the proteasome asubunits, although it has been postulated that they are always produced in excess
and that the rate limiting step in proteasome biosynthesis is the amount of β
subunits [39, 40]. In this study, we found that the increase in the amount of
proteasome in the CIII-treated neurons and astrocytes, calculated based on the
content of β5 and β5i subunits, is similar to that of the total 20S pool, as determined
by western blotting using the antibody against the a1-3/5-7 chains. This suggests
that a chains are mostly part of mature, functional proteasomes. However, in other
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systems this does not seem to be the case. For example, we found in the cerebella
of EAE mice, the molar amounts of hemi-proteasomes, determined by quantifying
the a-subunits, is almost twice than that calculated using values of mature β
subunits [21]. Also, in the lumbar spinal cords of SOD1G93A transgenic mice, an
animal model of amyotrophic lateral sclerosis, the reduction in β5 is not
accompanied by an increase in amount of β5i subunits and yet the levels of
structural 20S a chains are normal [41]. Similarly, the upregulation of inducible
catalytic subunits in the cortices and striata of HD94 mice, an animal model of
Huntington's disease, is not followed by an increase in a chain levels despite
normal amounts of standard catalytic subunits [42].
PA28 expression augments in response not only to inflammation but also
to oxidative stress, inhibition of proteasomal function, generation of misfolded
proteins and impairment of mitochondrial function [43, 44]. This suggests that this
activator plays roles other than increasing the generation of peptides for antigen
presentation. Indeed, PA28 has been found to raise the rate of oxidized protein
degradation by core 20S particles, and enhancement of proteasome function by
PA28 overexpression has been shown to protect cells against oxidative stress [43,
45, 46]. Therefore, the increase in the levels of proteasomal activator PA28 in CIIIstimulated neurons and astrocytes likely makes these cells more resistant to
proteotoxic damage. In cell-free systems, PA28 interacts with and increases the
proteolytic activities of both c-20S and i-20S core proteasomes [47]. However, a
recent mass spectrometric study on cross-linked proteasome complexes in live
cells revealed an unexpected pattern regarding the interactions between
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proteasome core particles and the various activators [48]. In that study, the authors
show that PA28 associates preferentially with the i-20S particle in both untreated
and IFN-g-treated cells, while PI31 and PA200 are mostly bound to the c-20S
proteasome. The 19S cap on the other hand does not have any preference for
interacting with c-20S and i-20S proteasome subtypes. Based on this selectivity of
activators for core proteasome particles, it is fair to conclude that 11S:i-20S:11S,
11S:i-20S:19S and 19S:i-20S:19S complexes are likely the major proteasome
structures in the cytokine-treated cells.
In our previous study, we presented evidence suggesting that both subunit
displacement and reduced levels of Nrf1 might be responsible for the reduced c20S levels in the spinal cords of EAE mice. We also speculated that perhaps
inflammatory conditions were behind the impaired Nrf1 signaling in the diseased
animals [22]. In this study, we found that neither Nrf1 nor Nrf2 appear to be
important in the regulation of constitutive proteasomes in neurons and astrocytes
upon a 24 h - exposure to pro-inflammatory cytokines. The lack of changes in
proteasome β5 mRNA expression in both cell types reflects the fact that Nrf1 levels
are unaltered by pro-inflammatory cytokines. Furthermore, neither mTOR nor
PBX1 signaling, the two major pathways that cells use to upregulate Nfe2l1 mRNA
expression, is affected by the cytokine mixture in astrocytes. This is in contrast to
EAE where we found a significant reduction in PBX1 levels in the spinal cord [22],
which may lead to Nrf1 dysregulation and additionally decrease proteasome
expression. Thus, there are conditions or stressors in the CNS tissue of EAE mice,
other than a pro-inflammatory environment, that cannot be reproduced in cytokine-
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treated cells. The obvious next step will be to investigate the abnormal processes
that cause PBX1 impairment in EAE.
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Figure 3.1 – N2a and C6 cells display specific cellular markers following
differentiation. (a) Representative immunofluorescence images of undifferentiated and
differentiated N2a cells depicting the expression of neuron-specific NFH (green) and NSE
(red)

proteins.

Nuclei

were

labeled

with

DAPI

(blue).

(b)

Representative

immunofluorescence images of undifferentiated and differentiated C6 glioma cells
showing the expression of astrocyte-specific GFAP (green) and EAAT-1 (red). Nuclei were
labeled with DAPI (blue). A description of the primary and secondary antibodies used in
these experiments is provided in Table S3.4.
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Figure 3.2 – Reduced expression of constitutive proteasomes and increased
expression of immunoproteasomes and the 11S activator in the CIII-treated
neurons. (a) Levels of subunits a1-3/5-7, b5, b5i, PA28a, PA28b and Rpt5 in control and
CIII-treated neurons were determined by western blot analysis as described in “Materials
and Methods”. Band intensities were normalized by the intensity of the Coomassie blue
stain in the respective lanes. Values are expressed relative to control and represent the
mean ± SEM of 7-12 experiments. Left panel shows representative western blots of the
analyzed subunits. (b) Psma7 (a7), Psmb5 (b5), Psmb8 (b5i), Psme1 (PA28a), Psme2
(PA28b) and Psmc3 (Rpt5) mRNA levels were determined by qPCR using the primers
shown in Table S3.1, and are corrected by the geometric mean of 4 reference genes as
described in “Materials and Methods”. Values are expressed relative to control and
represent the mean ± SEM of 11 experiments. In all cases, statistical significance was
determined by Student’s t-test. NS, not significant.
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Figure 3.3 – Augmented nuclear levels of p-STAT-1 and IRF-1, but not NF-kB, Nrf1
and Nrf2, in the CIII-treated neurons. Levels of p-STAT-1 (a), IRF-1 (b) and NF-kB (c),
Nrf1 (d) and Nrf2 (e) in the nuclear fractions from control and CIII-treated neurons were
determined by western blot analysis. Band intensities were corrected by the amount of
histone H3 in the same gel lanes. Values are expressed relative to control and represent
the mean ± SEM of 5-7 experiments. Statistical significance was determined by Student’s
t-test. NS, not significant. (f) Representative western blots of the analyzed transcription
factors.
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Figure 3.4 – Reduced expression of constitutive proteasomes and increased
expression of immunoproteasomes and the 11S activator in the CIII-treated
astrocytes. (a) Levels of subunits a1-3/5-7, b5, b5i, PA28a, PA28b and Rpt5 in control
and CIII-treated astrocytes were determined by western blot analysis as described in
“Materials and Methods”. Band intensities were normalized by the intensity of the
Coomassie blue stain in the respective lanes. Values are expressed relative to control and
represent the mean ± SEM of 5-9 experiments. Left panel shows representative western
blots of the analyzed subunits. (b) Psma7 (a7), Psmb5 (b5), Psmb8 (b5i), Psme1 (PA28a),
Psme2 (PA28b) and Psmc3 (Rpt5) mRNA levels were determined by qPCR using the
primers shown in Table S3.2, and are corrected by the geometric mean of 4 reference
genes as described in “Materials and Methods”. Values are expressed relative to control
and represent the mean ± SEM of 7-9 experiments. In both panels, statistical significance
was determined by Student’s t-test. NS, not significant.
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Figure 3.5 – Nrf2, but not Nrf1, signaling is augmented in CIII-treated astrocytes.
Levels of Nrf1 (p120) (a), Nrf1 (p65) (b) and Nrf2 (d) in the nuclear fractions from control
and CIII-treated astrocytes were determined by western blot analysis. Band intensities
were corrected by the amount of HDAC2 in the same gel lanes. Nfe2l1 (Nrf1) (c) and
Nfe2l2 (Nrf2) mRNA levels (e) were measured by qPCR using the primers shown in Table
S3.2 and are corrected by the geometric mean of 4 reference genes as described in
“Materials and Methods”. In all cases, values are expressed relative to control and
represent the mean ± SEM of 3-7 experiments. Statistical significance was determined by
Student’s t-test. NS, not significant. (f) Representative western blots of the analyzed
transcription factors.
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Figure 3.6 – NF-kB inhibition in CIII-treated astrocytes reduces IRF-1 but not pSTAT-1 levels. Astrocytes were incubated with or without CIII in the absence or presence
of 2 µM IKK-16 as described in “Materials and Methods”. Levels of NF-kB (a) and IRF-1
(b) in the nuclear fractions were determined by western blot analysis. Band intensities
were corrected by the amount of histone H3 in the same gel lanes. The amount of p-STAT1 (c) was determined by western blotting of the cell homogenates. Band intensities were
normalized by the intensity of the Coomassie blue stain in the respective lanes. In all
cases, values are expressed relative to the untreated control and represent the mean ±
SEM of 3-6 experiments. Statistical significance was determined by two-way ANOVA.
Asterisks denote values that are significantly different (p < 0.05) from untreated cells.
Pound symbols indicate values that are significantly different (p < 0.05) from IKK-16treated cells. ND, not detected. (d, e) Representative western blots of the analyzed
transcription factors.
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Figure 3.7 – NF-kB inhibition in CIII-treated astrocytes has no effect on proteasome,
immunoproteasome or PA28 levels. Astrocytes were incubated with or without CIII in
the absence or presence of 2 µM IKK-16 as described in “Materials and Methods”. Levels
of i-20S-specific subunit b5i (a), c-20S-specific subunit b5 (b), and PA28a (c) were
determined by western blotting of the cell homogenates. Band intensities were normalized
by the intensity of the Coomassie blue stain in the respective lanes. In all cases, values
are expressed relative to untreated control and represent the mean ± SEM of 6-9
experiments. Statistical significance was determined by two-way ANOVA. Asterisks
denote values that are significantly different (p < 0.05) from untreated cells. (e)
Representative western blots of the analyzed proteins.
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Figure S3.1- List of mouse PCR primers used in the study
Proteasome subunits
Psmb5 / b5
Psmb8 / b5i
Psme1 / PA28a
Psme2 / PA28b
Psmc3 / Rpt5
Psma7 / a7
House-keeping genes
Gapdh / GAPDH
Hprt1 / HPRT1
Rplp0 / RPLP0
Rn18s / 18S rRNA

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5’-GATCTGTGGCTGGGATAAGAG-3’
5’-TCCATAACGCCGTAAGCATAC-3’
5’-GCTGCTTTCCAAACATGATGC-3’
5’-CCGAGTCCCATTGTCATCTAC-3’
5’-TCCATCCCGAAGCCCAA-3’
5’-CCTTTAAGAACGCATCCAACTC-3’
5’-TCATATCCCTGAGTCAGCTCT-3’
5’-TGCTTGTCTGTTTCCATCTCG-3’
5’-GATCATACCCGCCTCCAC-3’
5’-ATCATGCAGATCCACTCACG-3’
5’-ACAATGTCCTTTCCTCGAACA-3’
5’-GCCATCACCGTCTTCTCG-3’

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5’-TGTGATGGGTGTGAACCACGAGAA-3’
5’-GAGCCCTTCCACAATGCCAAAGTT-3’
5’-TGGGCTTACCTCACTGCTTT-3’
5’-CTAATCACGACGCTGGGACT-3’
5’-TCCAGGCTTTGGGCATCA-3’
5’-CTTTATCAGCTGCACATCACTCAGA-3’
5’-GCAATTATTCCCCATGAACG-3’
5’-GGCCTCACTAAACCATCCAA-3’
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Figure S3.2 - List of rat PCR primers used in the study
Proteasome subunits
Psmb5 / b5
Psmb8 / b5i
Psme1 / PA28a
Psme2 / PA28b
Psmc3 / Rpt5
Psma7 / a7
Transcription factors
Nfe2l1 / Nrf1
House-keeping genes
Gapdh / GAPDH
Hprt1 / HPRT1
Rplp0 / RPLP0
Tbp / TBP

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5’-CTCCAAACTGCTTGCCAAC-3’
5’-CCTGTTCCCCTCACTGTCTA-3’
5’-CGCAGGAAGTTACATTGCTAC-3’
5’-CCATTCCGCAGATAGTATAGCC-3’
5’-GTCCATCCTGAAGCCCAAG-3’
5’-GCATCCAACTCTGAGATCTTCT-3’
5’-CCTCTACAGACACCAGATATGC-3’
5’-CCTCGACTTCCTAGAACCCT-3’
5’-GCCTAGACCGCAAGATTGAG-3’
5’-GCCAGCTCTTCATAGTTCACA-3’
5’-CAGGAGGCGGTCAAGAAG-3’
5’-CCGTTCTTTCATCTTGTAGCTTG-3’

Forward
Reverse

5’-CTCCGTCTCCTTTAATCAGTCAC-3’
5’-CACCATCCTGAACCTAGAACG-3’

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5’-AACCCATCACCATCTTCCAG-3’
5’-CCAGTAGACTCCACGACATAC-3’
5’-GCTTTTCCACTTTCGCTGATG-3’
5’-GGTGAAAAGGACCTCTCGAAG-3’
5’-TGTCTGCTCCCACAATGAAG-3’
5’-CAATCCCTGACGCACCG-3’
5’-GGAGAACAATTCTGGGTTTGATC-3’
5’-TGTGAAGTTCCCCATAAGGC-3’
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Figure S3.3 - List of primary and secondary antibodies used for western blot analysis.

Primary Antibodies
20S a1-3/5-7
20S b5
20S b5i
PA28a
PA28b
Rpt5
Nrf1
Nrf2
HDAC2
Histone-3
NF-kB (p65)
IRF-1
p-STAT-1
PBX1

Species/Clonality
Mus / mAb
Rb / pAb
Rb / mAb
Rb / mAb
Rb / pAb
Rb / mAb
Rb / pAb
Rb / pAb
Rb / mAb
Rb / mAb
Rb / mAb
Rb / mAb
Rb/mAB
Rb / pAb

Dilutions
1:500
1:2000
1:2000
1:1000
1:1000
1:2000
1:1000
1:4000
1:2000
1:10000
1:2000 - 1:5000
1:2000
1:2000
1:2000

Supplier
Enzo Life Science
Enzo Life Science
Cell Signaling Technology
Abcam
Abcam
Abcam
Proteintech
GeneTex
Millipore
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Proteintech

Cat#
BML-PW8195
BML-PW8895
13635
ab155091
ab91548
ab171974
12936-1-AP
103332
04-229
4499
8242
8478
8826
18204

RRID
AB_2052368
AB_2052392
AB_2744693
AB_2801483
AB_2050212
AB_2801479
AB_2267298
AB_1950993
AB_11211222
AB_10544537
AB_10859369
AB_10949108
AB_2773718
AB_10949108

Secondary Antibodies
Peroxidaseconjugated
anti-rabbit IgG
Peroxidaseconjugated
anti-mouse IgG

Species/Clonality

Dilutions

Supplier

Cat#

RRID

Goat / pAb

1:5000

Jackson ImmunoResearch

111-035144

AB_2307391

Goat /pAb

1:5000

Jackson ImmunoResearch

115-035-003

AB_10015289

Abbreviations: Mus, mouse; Rb, rabbit; mAb, monoclonal antibody; pAb, polyclonal antibody; RRID, research resource identifier.
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Figure S3.4 - List of primary and secondary antibodies used for ICC analysis.

Primary
Antibodies
NFH
NSE
GFAP
EAAT-1
Secondary
Antibodies
Cy3®conjugated
anti-rabbit IgG
Alexa Fluor®
488-conjugated
anti-mouse IgG
Alexa Fluor®
488-conjugated
anti-rabbit IgG

Species/Clonality
Mus / mAb
Rb / pAb
Rb / pAb
Rb / mAb

Dilutions
1:200
1:30
1:200
1:200

Supplier
Millipore
Sigma
Dako
Cell Signaling

Cat#
MAB5256
N0649
Z0334
5685

RRID
AB_ 11210992
AB_ 260746
AB_10013382
AB_10694915

Species/Clonality

Dilutions

Supplier

Cat#

RRID

Donkey / pAb

1:500

Jackson ImmunoResearch

711-165-152

AB_2307443

Goat /F(ab’)2

1:500

Thermo-Fisher

A11017

AB_143160

Goat / pAb

1:500

Thermo-Fisher

A27034

AB_12536097

Abbreviations: Mus, mouse; Rb, rabbit; mAb, monoclonal antibody; pAb, polyclonal antibody; RRID, research resource identifier.
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Figure S3.1– Cytokine-treatment does not alter the levels of p-mTOR and PBX1 in
astrocytes. Levels of p-mTOR (a) and PBX1 (b) were determined in control and CIIItreated astrocytes by western blot analysis. Band intensities were normalized by the
intensity of the Coomassie blue stain in the respective lanes. Values are expressed
relative to the untreated control and represent the mean ± SEM of 3-6 experiments.
Statistical significance was determined by Student’s t-test. NS, not significant. (c)
Representative western blots of the analyzed proteins.
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Figure S3.2 – The autophagy inhibitor chloroquine increases proteasome b5 levels
in neuron-like PC12 cells. PC12 cells were differentiated into the neuronal phenotype
with nerve growth factor and were incubated with or without 50 µM chloroquine (CQ) for
24 h. Levels of the c-20S-specific subunit b5 (a) were determined by western blotting of
the cell homogenates. Band intensities were normalized by the intensity of the Coomassie
blue stain in the respective lanes. Values are expressed relative to the untreated control
and represent the mean ± SEM of 3 experiments. Statistical significance was determined
by Student’s t-test. (b) Representative western blot of the analyzed protein.
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Abstract
Dysregulation of the cellular antioxidant response has been implicated in
inflammatory disorders like multiple sclerosis (MS) and its animal model,
experimental autoimmune encephalomyelitis (EAE). This study investigates the
role of pro-inflammatory cytokines, highly expressed in MS and EAE, on nuclear
factor (erythroid-derived 2)-like 2 (Nrf2) signaling in astrocytes. We found that
varied populations of reactive astrocytes are present in mouse spinal cords, with
neurotoxic A1-reactive astrocytes appearing more in EAE than in controls.
Differentiated C6 glioma cells exposed to a combination of interferon-g, interleukin1b and tumor necrosis factor-a for 24h produce two populations of astrocytic cells
with heterogeneous reactivity. Cells are distinguished by the levels of complement
C3 mRNA (C3) and nuclear factor kappa B (NF-kB). Astrocytes with low C3 and
NF-kB content, or pan-reactive cells, have reduced Nrf2 protein and mRNA levels.
In contrast, cells with elevated C3 and NF-kB expression, or A1-reactive cells,
display an increase in the amount of Nrf2 protein and mRNA. Expression of target
genes is diminished in pan-reactive cells but elevated in A1-reactive cells,
indicating that the changes in Nrf2 have functional consequences. Inhibition of NFkB signaling in A1-reactive astrocytes with the IkB kinase b inhibitor IKK-16 leads
to a reduction of both Nrf2 and C3, mimicking the pan-reactive phenotype. In sum,
our results suggest that both astrocytic response to inflammation and Nrf2
expression are connected to NF-kB signaling.

119

Introduction
The connection between neuroinflammation and oxidative stress is a key
pathological characteristic found in many neurodegenerative diseases including
Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis (MS). During
disease or injury, the release of inflammatory factors promotes the production of
oxidants and free radicals, or vice-versa depending on the disorder (Fischer and
Maier, 2015). In experimental autoimmune encephalomyelitis (EAE), an animal
model of MS, long-lasting neuroinflammation leads to continuous oxidative stress
and cellular damage (Mossakowski et al., 2015). Activated microglia in vitro have
been shown to induce oxidative stress and cellular injury as well, following the
release of pro-inflammatory cytokines (Penta et al., 2013).
The antioxidant response system responsible for combating oxidative
stress in most cells is regulated via the nuclear factor (erythroid-derived 2)-like
transcription factors (Nrfs) that belong to the cap’n’ collar basic leucine zipper
(CNC-bZIP) family. A common function of these factors is their ability to bind to
enhancer sequences within the promoters of antioxidant and phase II xenobiotic
genes referred to as electrophilic response elements (EpREs) (Itoh et al., 1997).
Although all CNC-bZIP transcription factors can bind to EpREs, Nrf2 (Nfe2l2) is
the most studied of these and controls the activation of genes related to antioxidant
response, autophagy and cytoprotection (Chorley et al., 2012). Genetic knockouts
of Nrf2 have severe consequences including reduced levels of essential
antioxidants and neuronal death in neurodegenerative disease models (Tebay et
al., 2015). Because of the breadth of Nrf2’s transcriptional task, its activation is
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tightly regulated both translationally (Li et al., 2010) and post-translationally (Itoh
et al., 1999; Bryan et al., 2013)
Neurodegenerative diseases are known to have different antioxidant
responses down to the cellular level (Baxter and Hardingham, 2016; Liddell and
Liddell, 2017). Neurons have little endogenous Nrf2 due to rapid degradation of
Nrf2 protein, and thus a minimal capacity to produce antioxidants. In contrast,
astrocytes have a lower Nrf2 degradation rate (i.e. higher Nrf2 levels), allowing
neurons to rely heavily on astrocytes for their antioxidant responses (Baxter and
Hardingham, 2016; Jimenez-Blasco et al., 2015). Active neurons produce reactive
oxygen species during synaptic transmission that cannot be completely cleared by
their own antioxidant defense. Astrocytes are able to sense the enhanced
glutamate and calcium secreted by nearby neurons and supplement the neuronal
response by activating their own and transferring glutathione precursors to the
neurons (Habas et al., 2013; Jimenez-Blasco et al., 2015). Additionally, astrocytes
have been shown to promote neuroprotection when Nrf2 is activated or
overexpressed in various models of neurological conditions (Bell et al., 2011;
Draheim et al., 2016; Sigfridsson et al., 2018; Vargas and Johnson, 2009).
However, a previous study has revealed that astrocytes stimulated by conditioned
medium from reactive microglia experience a depletion of Nrf2 protein (Correa et
al., 2011). Furthermore, C6 glioma cells and primary astrocytes treated with
lipopolysaccharide (LPS) and interferon-gamma (IFN-g) have reduced Nrf2
activation that is rescued using the electrophilic drug dimethyl fumarate (Lin et al.,
2011).
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Recent work has revealed that astrocyte reactivity is more complex than
previously thought, and astrocytic responses can be heterogeneous depending
upon the stimuli (Liddelow and Barres, 2017). Following certain stressors, like
neuroinflammation or hypoxia, distinct subsets of genes become upregulated,
allowing the designation of new reactive phenotypes within the astrocyte
population (Zamanian et al., 2012). Neurotoxic A1 astrocytes react to the
inflammatory signaling of active microglia, while neurotrophic A2 astrocytes
respond to hypoxic stimuli (Liddelow et al., 2017). Additionally, Liddelow et al.
(2017) found pan-reactive astrocytes that display elevated glial fibrillary acidic
protein (GFAP) without concurrent increases in either the A1 or A2 gene subsets.
This led to two different theories: 1) astrocyte reactivity may lie within a continuum
between A1 and A2, or 2) that there are many more phenotypes than just A1 and
A2 (Liddelow and Barres, 2017). Though the reason for these variations in
astrocyte reactivity has yet to be determined, A1 astrocytes have been discovered
in many neurodegenerative diseases – including MS – and in animal models like
EAE (Brambilla et al., 2014; Liddelow et al., 2017; Ponath et al., 2018).
The idea that subpopulations of astrocytes react distinctly during
inflammation led us to hypothesize that perhaps Nrf2 expression is variable and
connected to the mechanisms regulating these cellular responses. The current
study investigates whether there is a link between the role that Nrf2 plays in acute
neuroinflammation and astrocytic reactivity in EAE and in cultured astrocytes. We
report that there are two distinct subtypes of astrocytic responses in vivo and in
vitro: pan-reactive and A1-reactive. Whereas A1-reactive astrocytes in vitro
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respond to inflammatory stress with an increase in the expression of Nrf2 and its
targets, pan-reactive cells have a reduction in Nrf2 signaling that coincides with a
decrease in target gene expression. Nrf2 levels correlate positively with NF-kB
expression in the two cell types. Furthermore, inhibition of NF-kB in A1-reactive
astrocytes diminishes Nrf2 expression. Finally, we show that down-regulation of
NF-kB in A1-reactive astrocytes decreases C3 mRNA expression, causing these
cells to behave more like pan-reactive cells. Altogether, our results suggest that
both the astrocytic response to inflammation and Nrf2 expression are connected
to NF-kB signaling.
Materials and Methods
Materials
Actinomycin D (Act D), cycloheximide (CHX), Dulbecco’s modified
Eagle’s/F-12 media (DMEM/F-12), interferon-g (IFN-g), interleukin-1β (IL-1b), fetal
bovine serum (FBS), N6-2’-O-dibutyryl cyclic-AMP (Bt2AMP), theophylline and
tumor necrosis factor-a (TNF- a) were purchased from Sigma Aldrich (St. Louis,
MO). GlutaMAX™, penicillin/streptomycin, and trypsin EDTA were obtained from
Thermo Fisher Scientific (Waltham, MA). IKK-16 and MG-132 were purchased
from Selleckchem (Houston, TX) while epoxomicin was purchased from Enzo Life
Sciences (Plymouth Meeting, PA).
Induction of experimental autoimmune encephalomyelitis (EAE)
Housing and handling of the animals, as well as the euthanasia procedure,
were in strict accordance with the NIH Guide for the Care and Use of Laboratory
Animals and approved by the Institutional Animal Care and Use Committee
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(protocol 16-200424-HSC). To induce EAE, the following mixture was injected
subcutaneously into the lower back area of eight-week-old female C57BL/6 mice
(Envigo; Indianapolis, IN): 200 µl of MOG35-55 peptide (200 µg) (21st Century
Biochemicals; Marlborough, MA) in saline mixed with complete Freund's adjuvant
(CFA) supplemented with 4 mg/ml of heat killed Mycobacterium tuberculosis
H37Ra (Chondrex Inc; Redmond, WA). Control animals were given CFA without
MOG peptide. Two and 48 h after EAE induction, all animals received an
intraperitoneal injection of 0.3 µg of pertussis toxin (List Biological Laboratories;
Campbell, CA) in 100 µl of saline. Seven days after disease induction, mice
received a second immunization with MOG35-55 peptide in CFA on the other flank.
Animals were weighed and examined daily for the presence of neurological signs.
Animals were euthanized 21 days after disease induction, and the spinal cords
were removed for immunohistochemistry.
Immunohistochemistry
To determine astrocytic reactivity in the spinal cords of control and EAE
mice, we performed double-label immunofluorescence analysis using antibodies
against GFAP and complement C3 (Supplementary Table 1). Briefly, 5 µm-thick
sections mounted to slides were deparaffinized and hydrated in down-grade
alcohol series. Antigen retrieval was carried out in 10 mM Tris-HCl buffer pH 7.5,
containing 1 mM EDTA and 0.05% Tween 20, using a heat-retrieval method.
Spinal cord sections were blocked for 30-40 min in PBS supplemented with 3%
BSA and 0.1% Triton X-100, and then incubated overnight at 4°C with primary
antibodies in phosphate buffer saline (PBS) containing 2% BSA and 0.1% Tween-
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20. GFAP and complement C3 were co-visualized with Dylight 488 donkey antimouse and Dylight 549 donkey anti-rabbit secondary antibodies, respectively
(Jackson Immunoresearch Laboratories, Inc., West Grove, PA). Nuclei were
counterstained using DRAQ5 (Thermo Fisher). Images were taken on a Leica TCS
SP5 confocal microscope system (Leica Microsystems Inc, Buffalo Grove, IL) and
GFAP+/complement C3+ astrocytes were counted using the Leica Application
Suite X. Cells were counted using images taken from entire spinal cord sections
of control (n = 3) and EAE (n = 3) mice, and the average number of cells per section
within each condition was calculated.
Cell Culture
All incubations were performed in a humidified incubator at 37˚C under a
95% air / 5% CO2 atmosphere. Rat C6 glioma cells (CCL-107) were obtained from
American Type Culture Collection (Manassas, VA, USA) and maintained as a
monolayer in DMEM/F-12 supplemented with 10% FBS, 2 mM GlutaMAX, 100
units of penicillin and 0.1 mg/ml streptomycin (Life Technologies, Carlsbad, CA).
Cells were differentiated into astrocytes by incubating for 24 h with 0.25 mM
theophylline and 1 mM N6-2’-O-dibutyryl cyclic-AMP in low serum medium (1%
FBS) as described previously (Zheng and Bizzozero, 2010: Shanley et al. 2019b).
This protocol produces morphological characteristics and the expression of cell
type specific markers, such as GFAP and excitatory amino acid transporter-1
(EAAT-1), that are reminiscent of astrocytes (Shanley et al., 2019b). Astrocytes
were then treated for 24 h with a pro-inflammatory cytokine cocktail (CIII; 5 ng/ml
IFN- g, 10 ng/ml IL-1b, and 10 ng/ml TNF-a) as established by Lin et al. (2011) and
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used in our previous study (Shanley et al., 2019b). Several drugs were added to
the cells before or after incubation with the cytokine mixture as described below.
Following collection, cells were either processed for RNA isolation or for protein
quantification according to methods below. Isolated total RNA and protein
homogenates were then stored at -80⁰C until use.
Subcellular Fractionation
Preparation of the nuclear fraction was carried out using a modified version
of the nuclear extraction protocol developed by Thermo-Fisher. To this end,
cultured cells were suspended at 4˚C in 0.15 ml of hypotonic buffer solution (20
mM Tris-HCl pH 7.4 containing 10 mM NaCl, 3 mM MgCl2, 1 mM dithiothreitol, 1
mM phenylmethylsulfonyl fluoride and 1x protease and phosphatase inhibitor
cocktails) by pipetting up and down several times. Suspensions were kept on ice
for 15 min, mixed with 7.5 µl of 10% w/v Nonidet P-40, and centrifuged at 3,000 g
for 10 min. The supernatant (cytosolic fraction) and the pellet (nuclear fraction)
were collected, and proteins were solubilized in sodium dodecyl sulfate (SDS)sample buffer and analyzed by western blotting. Levels of histone deacetylase 2
(HDAC2) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were
measured by western blotting to determine the purity of the isolated fractions.
Reverse-transcription and qPCR
Total RNA was isolated from lysed cells via the RNeasy Mini Kit (Qiagen;
Germantown, MD) using column purification, and RNA concentration was
quantified fluorometrically using a Qubit 2.0 Fluorometer (Invitrogen; Carlsbad,
CA). cDNA was reverse-transcribed from the purified RNA using the High-Capacity
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cDNA Reverse Transcription Kit (Applied Biosystems; Foster City, CA). Briefly,
RNA was incubated with 1U of DNase I at 37°C for 15 min. The enzyme was then
inactivated using 5 mM EDTA and heating at 75°C for 10 min. The DNase I-treated
RNA (200 ng) was mixed with the 2X reverse transcription master mix, which
contains the reverse transcription buffer, a dNTP mixture, random primers, an
RNase inhibitor and the MultiScribe Reverse Transcriptase™. The samples were
heated as follows: 25°C for 10 min, 37°C for 120 min, and finally 85°C for 5 min to
terminate the reaction. A control that was not reverse transcribed was made
following the same protocol with pooled RNA from all samples and master mix
without reverse transcriptase. Gene expression levels were quantified using Power
SYBR Green PCR Master Mix (Applied Biosystems, Forster City, CA) with primers
against selected targets made by Integrated DNA Technologies (Coralville, IA)
(Supplementary Table 2). cDNAs were mixed with 1 µM of each primer and Power
SYBR Green PCR Master Mix. Samples were amplified using the following
conditions: 50˚C for 10 min, 95˚C for 10 min and then 40 thermal cycles of 95˚C
for 15 s and 60˚C for 1 min. The relative mRNA expression was determined using
the comparative 2-ΔCt method (Livak & Schmittgen, 2001) and values were
normalized to the geometric mean of four reference genes (Gapdh, Hprt1, Rplp0,
and Tbp).
Western blot analysis
Cells were homogenized in 20 mM sodium phosphate, pH 7.5, containing 5
mM EDTA, 0.1 mM neocuproine, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride, 1x protease inhibitor cocktail and 1x phosphatase inhibitor cocktail.
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Protein concentration was quantified using the Bio-Rad DC protein assay (Bio-Rad
Laboratories; Hercules, CA, USA) with bovine serum albumin as a standard.
Proteins were separated by SDS-polyacrylamide gel electrophoresis on 4-20%
gradient gels (Bio-Rad Laboratories) and blotted to polyvinylidene difluoride
membranes. Blots were then incubated overnight at 4°C with the primary
antibodies listed in Supplementary Table 1. Membranes were rinsed three times
in PBS containing 0.05% Tween-20 and were incubated for 1 h with horseradish
peroxidase-conjugated goat anti-mouse antibody (1:4000; Sigma) or goat antirabbit

antibody

(1:4000;

Sigma).

Blots

were

developed

by

enhanced

chemiluminescence using the Western Lightning ECL™ kit from Perkin-Elmer
(Boston, MA). Films were scanned in a Hewlett Packard Scanjet 4890 and the
images were quantified using the NIH Image 1.63 imaging analysis program. Band
intensities were normalized by the amount of Coomassie stain in the
corresponding lanes.
Determination of Nrf2 half-life
Following the 24 h CIII treatment, cells were incubated with 20 µM CHX to
inhibit protein synthesis. Cells were collected at 5 min intervals after the addition
of the inhibitor up to 30 min. Proteins were rapidly dissolved in SDS-sample buffer
and analyzed by western blotting. Nrf2 intensities at each time point were
determined as described above and normalized against those of GAPDH in the
corresponding lanes. Values were expressed as percentage of those at 0 min and
were log transformed. Nrf2 half-life was calculated using a linear regression
"

analysis of each time-course and the formula: ! # = % ' ()!*+,-. −
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Measurement of Nrf2 rate synthesis
The rate of Nrf2 synthesis in control and CIII-treated cells were measured
by blocking its degradation with either 1 µM epoxomicin or 10 µM MG-132. Briefly,
cells were collected at 0, 30 and 60 min after the addition of the proteasome
inhibitors and the amount of Nrf2 protein was determined by western blot analysis.
Determination of Nfe2l2 mRNA half-life
To determine the rate of Nfe2l2 mRNA degradation, control and CIIIstimulated cells were treated with 2 µg/mL Act D to block transcription and were
collected at 0, 1, 2, 4 and 6 h after the addition of the inhibitor. RNA was isolated
from the cells and RT-qPCR was performed as described above. Relative Nfe2l2
mRNA expression was determined using the comparative 2-ΔCt method using the
geometric mean of only 3 housekeeping genes (Gapdh, Hprt1, and Rplp0) since
Act D was found to affect the expression of Tbp. The half-life of Nfe2l2 mRNA was
calculated using the same linear regression analysis as shown above.
NF-kB inhibition
Activation of NF-kB was inhibited through the use of IKK-16, a known IkB
kinase inhibitor. Astrocytes were pre-treated with 2 µM IKK-16 (stock prepared in
dimethyl sulfoxide or DMSO). After 1 h, the cytokine mixture was added to some
of the cultures and incubation continued for an additional 24 h. Cells treated with
just DMSO represented the vehicle controls. After incubation, cells were collected
for RNA and western blot analysis as described above.
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Statistical Analysis
Results were analyzed for statistical significance with the unpaired
Student’s t-test or two-way ANOVA test utilizing the GraphPad Prism® program
(GraphPad Software Inc.; San Diego, CA) after assessing the normality of the data
with the Shapiro-Wilk test. Data points outside of two standard deviations were
considered outliers and removed from the study.
Results
A small but significant number of astrocytes in the spinal cords of EAE mice
display A1-like reactivity
A1-reactive astrocytes have been found in the brains of MS patients,
particularly around demyelinating lesions (Liddelow et al., 2017). To determine
whether A1-reactive astrocytes are also present in EAE, spinal cord sections were
simultaneously immunostained with antibodies against GFAP (a classical
astrocyte marker) and complement C3 (a marker of A1-reactive cells).
Immunofluorescence confocal microscopy analysis revealed that there is a general
increase in both GFAP and complement C3 staining in the EAE spinal cord
compared to the CFA-injected controls (Fig. 4.1a). While the majority of astrocytes
in the EAE and control spinal cords are GFAP+/C3-, there are double-stained
astrocytes noticeably localized around the lesions, which in this model are near
the meninges of the ventral areas (Fig. 4.1b). In contrast, control spinal cords have
about a quarter of the number of GFAP+/C3+ astrocytes than the EAE spinal cords
(p = 0.0008) (Fig. 4.1c). These data suggest that astrocyte reactivity in the spinal
cords of EAE mice is diverse and that, although they represent a small population
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of the cells, there are indeed A1-reactive astrocytes present in EAE. It is interesting
to note that C3 is also found in EAE neurons which, along with higher overall C3,
is consistent with a previous study showing C3 deposition in the spinal cord of
Biozzi ABH mice with chronic/relapsing EAE (Ramaglia et al., 2015).
Pro-inflammatory cytokines induce heterogeneous responses in cultured
astrocytes
To tease out the cellular mechanisms underlying astrocyte reactivity under
neuroinflammatory conditions, we incubated an astrocyte cell line with a
combination of three pro-inflammatory cytokines (IFN-g, IL-1b, and TNF-a),
designated CIII. These are also the three major pro-inflammatory cytokines we
found to be greatly elevated in EAE (Shanley et al., 2019a). Using RT-qPCR, we
first measured the expression of two genes that have been previously
characterized as an A1 reactivity marker – complement 3 (C3) – and as an A2
reactivity marker – pentraxin 3 (Ptx3) (Liddelow et al., 2017). We found that, while
C3 mRNA is always upregulated upon exposure of astrocytes to CIII, there were
whole experiments where the expression of this A1 marker was not as pronounced
(Fig. 4.2a). Therefore, we considered the cells with very high C3 mRNA levels
(~100 fold) and high NF-kB levels (see below) as A1-reactive – those with smaller
elevation of C3 mRNA levels (~20 fold) and no changes in the expression of NFkB were considered pan-reactive astrocytes. We also found a significant increase
in Ptx3 mRNA expression in the seemingly more reactive population of astrocytes
(Fig. 4.2b) but, because the magnitude of increase was much lower than that of
C3, we did not consider these cells A2-reactive. The rise in Ptx3 could be due to
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the presence of IL-1b and TNF-a in the cytokine mixture, which are known to
increase Ptx3 expression (Mantovani et al., 2008).
To further characterize the proinflammatory signaling in these cells, the p65
RelA component of NF-kB was measured by western blot. Previous studies have
shown that the A1 astrocyte phenotype can be prevented via the inhibition of NFkB signaling, which is typically upregulated during inflammation (Li et al., 2018;
Lian et al., 2015). As shown in Fig. 4.2c and d, the average levels of NF-kB in the
less reactive, pan-astrocyte population is ~ 17% lower than that in control cells,
although this change is only borderline significant (p = 0.0715). In contrast, NF-kB
p65 levels in A1-reactive astrocytes increase by 34.9 ± 12.1% (p= 0.0073) relative
to the controls. These data suggest that even in tightly controlled in vitro models
of neuroinflammation, astrocytes can respond heterogeneously both in terms of
NF-kB signaling and C3/Ptx3 expression.
Upon cytokine treatment, Nrf2 expression / activity increase in A1-reactive but
not pan-reactive astrocytes
Because there is substantial crosstalk between NF-kB and Nrf2 signaling
(Wardyn et al., 2015), we investigated the expression of the latter in pan- and A1reactive astrocytes. As shown in Fig. 4.3a and b, A1-reactive astrocytes have
significantly elevated Nrf2 levels compared to controls (72.7 ± 30.4%, p = 0.0236),
while pan-reactive C6 cells display a reduction in Nrf2 protein expression (26.4 ±
9.2%, p = 0.0078). The variations in Nrf2 expression in A1- and pan-reactive cells
seem to allude to a connection between the magnitude of astrocyte reactivity and
its antioxidant response.
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In both pan- and A1-reactive astrocytes, as well as in control cells, the
majority of Nrf2 is present in the nuclear fraction – this represents the active form
of the transcription factor (Fig. 4.3c). We also investigated the functional
consequences of these Nrf2 by measuring the expression of two Nrf2 target genes:
the catalytic subunit of g-glutamylcysteine ligase (Gclc) and NAD(P)H quinone
dehydrogenase 1 (Nqo1). Gclc and Nqo1 were also selected as they are
downregulated in EAE (Morales Pantoja et al., 2016). Nqo1 mRNA levels are
augmented in the CIII-treated A1-reactive astrocytes by 212.7 ± 45.3% (p <
0.0001) compared to control, whereas Gclc does not change (Fig. 4.4a).
Conversely, pan-reactive C6 cells have a decline in both Gclc and Nqo1 mRNA
levels by 51.8 ± 10.8% (p = 0.0031) and 53.6 ± 12.7% (p = 0.0056), respectively,
compared to controls (Fig. 4.4b). Thus, variations in Nrf2 levels have functional
consequences as demonstrated by the altered expression of its target genes.
Translational and post-translational regulation of Nrf2 are unaffected in CIIItreated pan-reactive astrocytes
To evaluate whether the diminished Nrf2 protein in pan-reactive astrocytes
is due to increased protein degradation, we determined the half-life of Nrf2 in the
absence or presence of cytokines. To this end, astrocytes were exposed to the
protein synthesis inhibitor cycloheximide (CHX) and Nrf2 levels were then
measured at 5-minute intervals for up to 1 h by western blot analysis. Time
intervals and length of the experiment were chosen based on a previous study that
shows a half-life of ~ 30 min for this protein (Nguyen et al., 2009). As depicted in
Fig. 4.5, the calculated half-life of Nrf2 in the control and pan-reactive astrocytes
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are almost identical (20.6 min vs 20.4 min), indicating that increased degradation
of Nrf2 is not responsible for the decline in Nrf2 protein expression in these cells.
This conclusion is supported by the observations that (i) both Keap-1 and Cul3
levels are not altered by the cytokine treatment and (ii) the amount of active
phospho-GSK-3β (Y216) is unchanged in CIII-treated cells (data not shown).
An internal ribosome entry site is present in the 5’ untranslated region of
Nfe2l2 mRNA, indicating that its encoded protein can undergo cap-independent
translation (Li et al., 2010). To explore whether reduced Nrf2 levels in pan-reactive
astrocytes result from decreased translation, cells were incubated separately with
two proteasome inhibitors (MG-132 and epoxomicin) to block Nrf2 degradation.
We found that, over the course of 1 h of incubation, neither MG-132 (Fig. 4.6a) nor
epoxomicin (Fig. 4.6b) changes the rate of Nrf2 appearance in pan-reactive
astrocytes compared to unstimulated cells. These data indicate that a reduction in
the rate of Nrf2 synthesis is also not the cause for decreased Nrf2 protein levels in
the less reactive astrocyte population.
Changes in Nrf2 protein levels in CIII-treated astrocytes correspond to
variations in their gene expression
We next investigated whether altered gene expression may be underlying
the changes in Nrf2 protein levels in cytokine-stimulated astrocytes. Nfe2l2 mRNA
levels were measured in pan-reactive and A1-reactive astrocytes by RT-qPCR.
Interestingly, there is a significant decrease (33.7 ± 13.3%; p = 0.0442) of Nfe2l2
expression in pan-reactive astrocytes compared to controls. In contrast, Nfe2l2
mRNA expression augments by 69.4 ± 20.8% (p = 0.0033) in A1-reactive
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astrocytes relative to control cells (Fig. 4.7a). Because Nrf2 protein levels in both
cell types (Fig. 4.3) seems to follow the respective mRNA expression (Fig. 4.7a),
it is likely that Nrf2 is being regulated at the transcriptional level during
neuroinflammatory signaling.
To determine if the Nfe2l2 mRNA stability is increased in A1-reactive
astrocytes, cells were exposed to the transcription inhibitor actinomycin D (ActD).
Levels of Nfe2l2 mRNA were then measured at different times for up to 6 h by RTqPCR. Time intervals were selected based on a previous report that determined a
half-life of ~ 3 h for this transcript (Yang et al., 2011). As shown in Fig. 4.7, the
Nfe2l2 mRNA half-life in A1-reactive cells is significantly reduced compared to
controls (2.63 ± 0.14 h vs 3.54 ± 0.04 h, p < 0.0008). These data indicate that
increased Nfe2l2 mRNA levels in A1-reactive cells is caused by increased
transcription rather than by reduced mRNA degradation. The reason for the faster
removal of Nfe2l2 transcripts in A1-reactive astrocytes is unknown.
Reduction of nuclear NF-kB in A1-reactive astrocytes results in concurrent
decrease of Nrf2 and C3 expression
The above experiments suggest a strong link between NF-kB activation and
Nrf2 levels. We decided to use IKK-16, a selective IkB kinase b (IKK-b) inhibitor
(Waelchli et al., 2006), to determine if NF-kB is indeed responsible for Nrf2
regulation in this model of inflammation. IKK-16 has been previously shown to
reduce the levels of NF-kB and its downstream effectors (Ahmmed et al., 2019).
To this end, astrocytes were pre-incubated for 1 h with or without 2 µM IKK-16, a
concentration that is 50 times the IC50 for IKK-b (Waelchli et al., 2006). Cells were
135

then incubated for an additional 24 h with or without the cytokine mixture. As shown
in Fig. 4.8a and c, CIII treatment increases the amount of nuclear NF-kB (p65) by
335 ± 76% (p < 0.0001) and IKK-16 reduces this activation by 38.8 ± 13.2% (p =
0.0276).
We next measured Nrf2 protein to determine whether decreasing NF-kB
levels would also impact the antioxidant response. As presented in Fig. 4.8b and
c, Nrf2 levels in A1-reactive cells rise by 406 ± 48% (p < 0.0001) compared to
vehicle-treated cells while addition of the IKK-16 decreases this stimulation by 73.7
± 3.4 % (p < 0.0001). These data clearly suggest that NF-kB is an important
positive regulator of Nrf2 signaling in these cytokine-treated astrocytes.
Furthermore, RT-qPCR revealed that IKK-16 also diminishes the levels of Nfe2l2
mRNA compared to A1-reactive cells by 20.7 ± 10.0% (p = 0.0133), suggesting
that NF-kB reduction affects Nrf2 at the transcriptional level in A1-reactive cells.
Finally, we investigated whether NF-kB inhibition has an effect on the
expression of C3 and Ptx3 mRNA levels in A1-reactive astrocytes. As show in Fig.
4.9, IKK-16 treatment reduces the transcriptional expression of C3 and Ptx3 by
59.1 ± 7.0% (p < 0.0001) and 83.9 ± 5.9 % (p < 0.0001), respectively. This
suggests not only that NF-kB signaling is critical for the expression of these
reactivity markers but also the NF-kB inhibition makes these A1-type cells behave
more like pan-reactive astrocytes.
Discussion
The role of diverse astrocyte populations during disease or after CNS injury
has become a topic of great interest. Our study shows that the assortment of
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astrocyte responses is not limited to post-mortem tissue or in vivo models of
disease, but rather can also be found in an astrocyte-like cell line exposed to
inflammatory stress. Following exposure to a combination of pro-inflammatory
cytokines, specifically those that are upregulated in EAE (Shanley et al., 2019a),
differentiated C6 cells assume either a pan-reactive or an A1-reactive phenotype.
The reason(s) for this differential reactivity is unknown, but it does not involve
changes in culture conditions (e.g., temperature, oxygen concentration, medium
composition), cell passage number or degree of confluency. The two phenotypes
were characterized using expression of C3 mRNA and NF-kB (p65), wherein A1reactive cells have significantly higher levels of both compared to pan-reactive
cells (Fig. 4.2). This somewhat matches our findings in the spinal cords of EAE
mice, where there are more GFAP+/C3+ astrocytes adjacent to peripheral areas of
high immune cell infiltration and pro-inflammatory cytokine production (Fig. 4.1).
The term pan-reactive was coined by Liddelow and Barres (2017) to describe
astrocytes that are neither A1 nor A2 – clearly the astrocyte population that we
designated as pan-reactive does not overexpress the A2-reactive marker Ptx3. We
also demonstrated that changes in Nrf2 between both reactivities results from
transcriptional level variations – pan-reactive astrocytes have lower mRNA and
protein expression while A1-reactive cells display elevated mRNA and protein
expression (Fig. 4.3 and 4.8). Changes in Nrf2 transcription are most likely due to
differential NF-kB expression in the two cell types. Indeed, the pharmacological
reduction of NF-kB protein levels causes a corresponding decrease in the amount
of Nrf2 protein (Fig. 4.8). In this aspect, pan-reactive astrocytes resemble neuron-
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like N2a cells, whose NF-kB and Nrf2 signaling is unaffected or even reduced in
the presence of pro-inflammatory cytokines (Shanley et al., 2019b). Finally, we
show that down-regulation of NF-kB in A1-reactive astrocytes also causes a
decrease in C3 mRNA expression, causing these cells to behave more like panreactive cells whose NF-kB signaling is unresponsive to the cytokine mixture.
Because inflammation is the primary trigger for A1 astrocyte reactivity, the
NF-kB signaling pathway has been associated with the toxic function of these cells
during disease or injury. One target of this pathway in astrocytes seems to be C3,
since enhancing NF-kB levels in cultured astrocytes has been shown to increase
C3 levels as well as cause neuronal dysfunction and damage (Lian et al., 2015).
Furthermore, in a mouse model of Alzheimer’s disease, amyloid beta production
by neurons contributes to augmented NF-kB and C3 in astrocytes (Lian et al.,
2016). This response – which results in greater neuroinflammation by interfering
with microglial functions – is prevented through inhibition of the C3a receptor (Lian
et al., 2015, 2016), thereby implicating A1-reactive astrocytes as a potential origin
of neurodegenerative signaling in diseases like Alzheimer’s disease. Moreover,
therapeutic use of mesenchymal stem cells and their exosomes following spinal
cord injury is able to prevent A1 reactivity in astrocytes by diminishing inflammatory
cytokine levels and hindering the nuclear entry of NF-kB (Wang et al., 2018). The
above studies all point to the neurotoxic role that NF-kB signaling in A1 astrocytes
plays during neuroinflammation and neurodegeneration. However, not all data
support that heightened astroglial NF-kB is detrimental. For example, blockage of
astrocytic NF-kB signaling in the eyes of a Drosophila model for Machado-Joseph
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disease contributes to toxic accumulation of proteins and death of neurons (Li et
al., 2018). Furthermore, our study shows that C6 astrocyte-like cells exposed to
inflammatory cytokines also upregulate Nrf2 via NF-kB signaling, which could have
some beneficial effect during acute neuroinflammation (Chen et al., 2009).
Under physiological conditions, Nrf2 levels are regulated at the posttranslational level by Keap1, which directs the transcription factor for proteasomal
degradation (Itoh et al. 1999), and by GSK-3b, which increases the removal of Nrf2
by various mechanisms (Jain and Jaiswal 2007, Bryan et al. 2013). Interestingly,
the reduction in the amount of Nrf2 in pan-reactive astrocytes is not caused by an
increase in its rate of degradation (Fig. 4.5) – a conclusion supported by the lack
of changes in the levels of Keap1 and p-GSK-3b. Because there are no changes
in the rate of Nrf2 translation upon cytokine treatment and the decrease in Nrf2
protein levels matches that of Nfe2l2 mRNA, it is fair to conclude that Nrf2 in the
pan-reactive cells is controlled mostly at the transcriptional level. This also seems
to be the case for the Nrf2 upregulation in A1-reactive astrocytes. Supporting this
conclusion is the discovery of several conserved regions for NF-kB in the Nfe2l2
promoter and that the amount of Nrf2 in human acute myeloid leukemia cells can
be reduced by treatment with NF-kB inhibitors (Nair et al., 2008; Rushworth et al.,
2012).
It is well known that cancer cells normally have elevated Nrf2 levels, most
likely driven by NF-kB, which protects them from drug-induced death. Although it
could be argued that the regulation of Nrf2 by NF-kB is specific to cancer cells,
treatment of monocytes with LPS increases Nfe2l2 gene expression, which is
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blocked by an IkBa phosphorylation inhibitor (Rushworth et al., 2012). Thus, NFkB-mediated control of Nrf2 expression does not seem to take place only in tumor
cells. Indeed, we have found that while Nfe2l2 mRNA levels are elevated in the
spinal cords of EAE mice during the inflammatory phase of the disease (i.e. 14-30
days after MOG immunization), they decline to normal values in the
neurodegenerative phase (i.e. 60-90 days after MOG immunization) (Morales
Pantoja et al., 2016). Similarly, expression of NF-kB p65 increases dramatically in
the spinal cord during the early and peak stages of EAE but diminishes later in the
disease (Hwang et al., 2011), suggesting that the relationship between NF-kB and
Nrf2 signaling is also present in vivo. While pathological changes in the acute
phase of EAE are mainly driven by inflammation from resident microglia and
infiltrating immune cells, the damage in the chronic (degenerative) phase appears
to result from high levels of oxidative stress (Morales Pantoja et al., 2016; Shanley
et al., 2019a). Since Nrf2 signaling in the spinal cords of animals with chronic EAE
is unchanged, despite augmented oxidative stress (Morales Pantoja et al., 2016),
it is fair to conclude that NF-kB is the major determinant of Nrf2 levels in this model
of CNS demyelination.
Astrocyte reactivity is an important contributor to the pathology of MS and
its various animal models. It has been previously shown that nervous system
demyelination is often preceded by astrocyte-mediated damage – high GFAP
levels were recently correlated with MS disease severity and time-course in
patients with primary progressive MS (Abdelhak et al., 2019; Sharma et al., 2010).
The pathophysiological role of reactive astrocytes and increased NF-kB signaling
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in EAE was also demonstrated by the finding that genetic ablation of this
transcription factor in astrocytes specifically leads to less pro-inflammatory gene
expression during the acute phase of the disease and reduced neurological
symptoms (Brambilla et al., 2009). Additionally, neurons and oligodendrocytes
within the same microenvironment as the inhibited astrocytes show improved
survival, indicating that elevated expression of NF-kB during this disease is
harmful (Brambilla et al., 2009, 2014). Although the precise role of A1-reactive and
pan-reactive astrocytes in EAE is presently unknown, we have shown that there
are at least two distinct populations of these cells in the spinal cord of diseased
animals. We have also demonstrated that this mixed reactivity extends to
differentiated C6 cells, as determined by varying levels of complement C3 and NFkB expression. In this in vitro system, NF-kB expression drives astrocytic reactivity
as well as antioxidant response, similarly to what is seen in EAE. Overall, this study
furthers our understanding of the role that this diverse population of glial cells plays
in complex diseases like MS.
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Figure 4.1— A small but significant number of C3+ astrocytes are present in the EAE
spinal cord. (a, b) Representative images of double-labeled immunofluorescent lumbar
spinal cord sections from control and EAE mice. Sections (5 µm-thick) of lumbar spinal
cords were stained with mouse anti-GFAP and rabbit anti-C3 and images were taken
using confocal microscopy as described in “Materials and Methods”. Nuclei were detected
with DRAQ5 stain. The red channel is representative of C3 staining, the green channel is
representative of GFAP and the blue channel is representative of DRAQ5. Bars at lower
left represent 50 µm in length. (c) Average numbers of double-labelled astrocytes were
counted in EAE and control spinal cords as described in “Materials and Methods”. Values
are expressed as the mean ± SEM of 3 animals per condition and statistical significance
was calculated using an unpaired Student’s t-test.
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Figure 4.2 – Differential expression of C3, Ptx3 and NF-kB (p65) reactivity markers
in cultured astrocytes. Levels C3 (a) and Ptx3 mRNA (b) were assessed by qRT-PCR
using primers listed in Supplementary Table 2. Values were corrected using the geometric
mean of four housekeeping genes as described in “Materials and Methods”. Values are
expressed as relative to controls and represent the mean ± SEM of 4-11 experiments per
group. NS, not significant. (c) Amounts of NF-kB p65 in pan- and A1-reactive astrocytes
were measured as band intensity corrected by the amount of Coomassie blue stain in the
respective gel lanes. Values are expressed as relative to controls and represent the mean
± SEM of 10-15 experiments per group. Statistical significance was determined using an
unpaired Student’s t-test. (d) Representative western blot of NF-kB (p65).
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Figure 4.3 – Altered levels of Nrf2 protein are found in pan- and A1-reactive
astrocytes. (a) Representative Coomassie stain and western blots of Nrf2 in each
reactive cell type alongside its control. (b) Nrf2 protein levels were determined by western
blot with band intensities corrected by Coomassie stain in the corresponding gel lanes.
Values are expressed as relative to control and reflect the mean ± SEM of 14-16
experiments per group. Statistical significance was determined using an unpaired
Student’s t-test. (c) Representative western blots of Nrf2, HDAC2 and GAPDH in the
cytoplasmic (Cyto) and nuclear (Nuc) fractions of pan- and A1-reactive astrocytes showing
that in all cases the majority of Nrf2 is in the nucleus.
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Figure 4.4 – Differential expression of antioxidant genes in pan- and A1-reactive
astrocytes. (a) Gclc and Nqo1 mRNA levels in control and A1-reactive astrocytes. (b)
Gclc and Nqo1 mRNA levels in control and pan-reactive astrocytes. mRNA levels were
determined by qRT-PCR using primers listed in Supplementary Table 2. Values were
corrected using the geometric mean of four housekeeping genes as described in
“Materials and Methods” and are expressed as relative to controls. Each bar reflects the
mean ± SEM of 4-11 experiments per group. Statistical significance was determined using
an unpaired Student’s t-test. NS, not significant.
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Figure 4.5 – The degradation rate of Nrf2 protein in pan-reactive and control
astrocytes are identical. (a) Representative western blots of Nrf2 and GAPDH
expression in control and pan-reactive astrocytes following exposure to 20 µM
cycloheximide (CHX). (b) Nrf2 amounts at each time point were calculated using the band
intensity corrected by GAPDH in each gel lane and are expressed as percentage of Nrf2
level at time 0 for both controls and pan-reactive cells. Percentages were log transformed
for visualization on the graph. (c) The half-life of Nrf2 was calculated for each experiment
using the formula shown in “Materials and Methods”. Values are expressed as mean ±
SEM of 4 experiments per group. Statistical significance was determined using the
unpaired Student’s t-test. NS, not significant.
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Figure 4.6 – The rate of Nrf2 synthesis in pan-reactive and control astrocytes are
similar. Nrf2 and GAPDH protein levels in control and pan-reactive astrocytes following
exposure to 10 µM MG-132 (a) or 1 µM epoxomicin (b) were determined by western blot
analysis. In both cases, the intensity of the Nrf2 band was corrected by that of GAPDH in
each gel lane. Values are expressed as arbitrary units and represent the mean ± SEM of
5-6 experiments per time-point within each group. Statistical significance was determined
using unpaired Student’s t-tests at each time-point.
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Figure 4.7 – Altered Nfe2l2 mRNA levels in pan- and A1-reactive astrocytes. (a)
mRNA levels of Nfe2l2 were measured by qRT-PCR using primers listed in
Supplementary Table 2. Values were corrected using the geometric mean of three
housekeeping genes as explained in “Materials and Methods” and are expressed as
relative to control. Each value represents the mean ± SEM of 4-11 experiments per group.
(b) Nfe2l2 mRNA degradation in A1-reactive cells was determined by qRT-PCR after
addition of 2 µg/ml ActD. Values are expressed as percentage of Nfe2l2 mRNA levels at
time 0 for both controls and A1-reactive cells. Percentages were log transformed for
visualization on the graph. (c) The half-life of Nfe2l2 in control and A1-reactive cells was
calculated for each experiment using the formula shown in “Materials and Methods”.
Values are expressed as mean ± SEM of 4 experiments per group. Statistical significance
was determined using an unpaired Student’s t-test.
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Figure 4.8 – Nrf2 mRNA and protein in A1-reactive astrocytes are reduced following
inhibition of NF-kB. Astrocytes were incubated with or without CIII in the absence or
presence of 2 µM IKK-16 as described in “Materials and Methods”. (a) Levels of NF-kB in
the nuclear fractions were determined by western blot analysis. Band intensities were
corrected by the amount of histone H3 in the same gel lanes. (b) The amount Nfr2 in cell
homogenates was also determined by western blotting. Nrf2 band intensities were
normalized by the intensity of the Coomassie blue stain in the respective lanes. NF-kB
and Nrf2 levels are expressed relative to the untreated control and represent the mean ±
SEM of 6 experiments per group. Statistical significance was determined by two-way
ANOVA. Asterisks denote values that are significantly different (p < 0.05) from untreated
cells. Pound symbols indicate values that are significantly different (p < 0.05) from
cytokine-treated cells. (c) Representative western blots of the analyzed transcription
factors. (d) Relative Nfe2l2 mRNA levels were measured by qRT-PCR as described in
“Materials and Methods” with values expressed as relative to controls. Values represent
the mean ± SEM of 8 experiments per group and statistical significance was determined
by two-way ANOVA. Asterisks denote values that are significantly different (p < 0.05) from
untreated cells. Pound symbols indicate values that are significantly different (p < 0.05)
from cytokine-treated cells.
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Figure 4.9 – C3 and Ptx3 mRNA in A1-reactive astrocytes is decreased following
inhibition of NF-kB. Astrocytes were incubated with or without CIII in the absence or
presence of 2 µM IKK-16. Relative C3 (a) and Ptx3 mRNA levels (b) were measured by
qRT-PCR as described in “Materials and Methods”. Values are expressed as relative to
controls and represent the mean ± SEM of 5-6 experiments per group. Statistical
significance was determined by two-way ANOVA. Asterisks denote values that are
significantly different (p < 0.05) from untreated cells. Pound symbols indicate values that
are significantly different (p < 0.05) from cytokine-treated cells.
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Table S4.1 – List of primary antibodies used in the study

Antigen
Complement C3
EAAT1
GAPDH
GFAP
GFAP
HDAC2
Histone H3
NF-κB p65
Nrf2

Species
Rabbit
Rabbit
Mouse
Mouse
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit

Clonality
Monoclonal
Monoclonal
Monoclonal
Monoclonal
Polyclonal
Monoclonal
Monoclonal
Monoclonal
Polyclonal

Dilution
1:1000
1:50
1:10000
1:800-1:1000
1:500
1:2000
1:2000
1:5000-1:2000
1:2000
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Supplier (Cat #)
Abcam (ab200999)
Cell Signaling (D20D5)
Santa Cruz (SC-32233)
Sigma (G3893)
Dako (Z0334)
Millipore (04-229)
Cell Signaling (4499T)
Cell Signaling (8242S)
GeneTex (GTX103322)

Table S4.2 – List of PCR primers used in the study
Astrocyte reactivity markers
C3 / Complement 3
Forward
Reverse
Ptx3 / Pentraxin 3
Forward
Reverse

5’-GAATGAACGACTAGACAAGGCT-3’
5’-CATCAAAATCATCCGACAGCTC-3’
5’-CGGTGCTGGAGGAACTG-3’
5’-GCACGCTTCCAAAAATCTTCT-3’

Enzymes involved in GSH production – Nrf2 Targets
Gclc / GCLc
Forward 5’-CCACTGTCCAAGGTTGACGA-3’
Reverse 5’-CTTGCTACACCCATCCACCA-3’
Nqo1 / NQO1
Forward 5’-GCCAGAGAATGACGTTCATGT-3’
Reverse 5’-ACGTATGCCACCATGTATGAC-3’
Transcription factors regulating the antioxidant response
Nfe212 / Nrf2
Forward 5’-CCATTTGTAGATGACCATGAGTCGC-3’
Reverse 5’-GAGCTATCGAGTGACTGAGCC-3’
House-keeping proteins
Gapdh / GAPDH
Forward
Reverse
Hprt1 / HPRT1
Forward
Reverse
Rplp0 / RPLP0
Forward
Reverse
Tbp / TBP
Forward
Reverse

5’-AACCCATCACCATCTTCCAG-3’
5’-CCAGTAGACTCCACGACATAC-3’
5’-GCTTTTCCACTTTCGCTGATG-3’
5’-GGTGAAAAGGACCTCTCGAAG-3’
5’-TGTCTGCTCCCACAATGAAG-3’
5’-CAATCCCTGACGCACCG-3’
5’-GGAGAACAATTCTGGGTTTGATC-3’
5’-TGTGAAGTTCCCCATAAGGC-3’
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Chapter 5 – General Discussion
General Conclusions
Although the cause of MS remains elusive, the mechanisms underlying MS
pathology are becoming clearer – for instance, tissue injury in MS tends to result
from a combination of DNA/protein damage, inflammation and oxidative stress
(Fischer et al., 2013). The same can be said of EAE, as we found heightened
inflammation and oxidative stress at the peak of disease in our model – evidenced
by the elevated inflammatory cytokine expression and lessened glutathione levels
(Fig. 2.1). We have previously shown that this combination of stressors varies at
different stages of EAE, with inflammation primarily occurring in the acute phase
(Dasgupta et al., 2013). Oxidative stress also tends to start during the acute phase
and continues into the chronic phase, as demonstrated by the gradual reduction
of glutathione starting at 21 days post-immunization (dpi) and continuing into 60
dpi (Morales Pantoja et al., 2016). In a previous study, our lab discovered that
proteasome activity in the EAE cerebellum increases during the acute phase of the
disease, but then decreases as the disease progresses (Zheng and Bizzozero,
2010b). This is consistent with the reduced proteasomal activity we found in both
white and gray matter from chronic MS patients (Zheng and Bizzozero, 2011). With
all of this in mind, the primary objectives of this dissertation were 1) to determine
how proteasome expression in EAE is regulated by upstream effectors, and 2) to
examine how neuroinflammation influences these effectors in vitro and what would
be the cellular and physiological consequences.
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The data presented in chapter 2 show that changes in proteasome subunit
expression in the spinal cords of EAE mice at the peak of the disease are most
likely due to a combination of altered Nrf1 signaling and replacement of constitutive
subunits by inducible subunits (Fig. 5.1). At this disease stage, elevated proinflammatory cytokines and leukocyte infiltration as well as low glutathione levels
are present in the spinal cords. We also observed low c-20S proteasome levels in
opposition to high levels of the immunoproteasome and 11S in EAE neurons and
astrocytes. The reduction in Nrf1 levels and the resulting abrogation of c-20S
subunit synthesis are probably the result of decreased PBX1 expression. On the
other hand, elevated p-STAT-1 and IRF-1 levels – likely originating from increased
IFN-g signaling – augment the expression of both i-20S-specific and 11S regulator
subunits.
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Figure 5.1 – Chapter 2 Summary: the number of immunoproteasomes is increased
in neurons and astrocytes from EAE spinal cords and is probably due to a rise in pSTAT1 and IRF-1 levels. Immunoproteasome increase is accompanied by a decrease in
constitutive proteasomes levels, which correlates with low Nrf1 expression and is likely
caused by reduced PBX1 signaling. The displacement of constitutive subunits by their
inducible counterparts may also be responsible for alterations in proteasome composition.
Chapter 2 provides insights into the dynamics of proteasome expression in EAE and is
the first to explore Nrf1 signaling in an inflammatory demyelinating disorder.

Chapter 3 dove deeper into proteasome expression and regulation in
cultured astrocytes and neurons exposed to pro-inflammatory cytokines. The
experiments therein reveal that subunit displacement is the most probable
mechanism underlying the cytokine-induced shift from c-20S to i-20S proteasome
in both neurons (Fig. 5.2a) and astrocytes (Fig. 5.2b). The increase in the amount
of the IFN-g-inducible proteasome subunits in neurons and astrocytes coincides
with high expression of p-STAT-1 and IRF-1. However, inhibition of NF-kB
signaling in cytokine-treated astrocytes – neurons were not studied – reduces IRF1 expression without affecting that of i-20S, c-20S or 11S. This suggests that
STAT-1 is capable of increasing the transcription of i20S-specific subunits and 11S
subunits by itself. It is also interesting that the cytokine mixture does not increase
Nrf1 mRNA and protein levels, in contrast to EAE, which explains why Psmb5
mRNA expression is unchanged. This chapter also presents evidence that Nrf2
signaling does not play a role in the expression of constitutive proteasome subunits
in this in vitro model of inflammation.
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Figure 5.2 – Chapter 3 Summary: immunoproteasomes increase while constitutive
proteasomes decrease in cultured a) neurons and b) astrocytes exposed to proinflammatory cytokines. In both cell types, this switch is due primarily to subunit
displacement, since Psmb5 mRNA levels are unaltered. The latter is likely due to the lack
of changes in Nrf1 expression. Increased expression of proteasome immuno-subunits and
PA28a/b in both cell types is probably caused by IFN-g-induced activation of the STAT-1
/ IRF-1 pathway. However, at least in astrocytes, p-STAT-1 alone is capable of activating
the transcription of genes encoding for the i-20S-specific subunit b5i and PA28a/b (11S).
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Chapter 4 teased out the relationship between NF-kB and Nrf2 signaling
upon inflammation in astrocytes. IHC analysis of EAE spinal cord shows that a
small but significant amount of GFAP+ astrocytes also express complement C3
and are therefore considered A1-reactive. We also found that astrocytes of varied
reactivity develop in vitro upon cytokine exposure, namely A1-reactive (Fig. 5.3a)
and pan-reactive (Fig. 5.3b) phenotypes. A1-reactive astrocytes express high
levels of both C3 and NF-kB while pan-reactive astrocytes have smaller increases
in C3 and unaffected NF-kB levels. Nrf2 mRNA and protein expression are also
high in A1-reactive astrocytes and low in pan-reactive, possibly indicating a direct
transcriptional regulation of Nrf2 by NF-kB in response to varying astrocytic
reactivity. This is confirmed by a corresponding decline in Nrf2 when NF-kB
activation was diminished pharmacologically. Furthermore, NF-kB inhibition in A1reactive astrocytes results in reduced expression of C3 and Ptx3 mRNA, making
the reactivity of these cells more pan-like.
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Figure 5.3 – Chapter 4 Summary: A1-reactive astrocytes are part of the astrocyte
population in the spinal cords of EAE mice. We also show that a) A1-reactive and b)
pan-reactive astrocytes exist in culture following exposure to pro-inflammatory cytokines.
The distinct phenotypes seem to depend upon NF-kB signaling and its upregulation of
complement C3 and crosstalk with Nrf2. Chapter 4 demonstrates that heterogeneous
astrocyte reactivity exists both in vivo and in vitro and connects astrocyte reactivity to NFkB / Nrf2 crosstalk.

The findings of this dissertation provide additional clues as to why
proteasome expression and activity fluctuate in diseases like MS and EAE,
particularly those fluctuations pertaining to the inflammatory phases of the disease.
These studies also offer a window into cell-specific upstream signaling and
proteasome function during neuroinflammation as well as how cellular functions
can vary under such conditions. Perhaps understanding how signaling in reactive
astrocytes and in neurons affects proteasome function could explain how these
cells interact in inflammatory, demyelinating diseases like MS.
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Aim 1: Cellular differences in proteasome composition may be contributing
to the pathology of acute EAE
As mentioned above, data presented in chapter 2 reveal that the switch from
c-20S proteasomes to i-20S proteasomes in acute EAE could be attributed to two
mechanisms: 1) subunit displacement, and 2) dysregulated PBX1 / Nrf1 signaling.
The i-20S core proteasome, in combination with the 11S regulator, seems to be
more efficient than the c-20S particle at producing peptides for major
histocompatibility complex (MHC) presentation during immune responses
(Johnston-Carey et al., 2015; Tanaka and Kasahara, 1998) and it also participates
in the removal of damaged proteins (Zheng et al., 2012). The latter suggests that
cells with high content of i-20S and 11S have an increased ability to prevent
proteotoxic damage. In our model of EAE, oligodendrocytes are the most sensitive
to cell death (Hu et al., 2019) and are also the cells where immunoproteasome
expression is unchanged. In contrast, the expression of i-20S in EAE increases in
both neurons and astrocytes. Therefore, it is tempting to speculate that augmented
immunoproteasome levels in neurons and astrocytes help prevent the demise of
these cells at the peak of the disease. In contrast, the lack of changes in
proteasome expression in EAE oligodendrocytes may cause these cells to be more
sensitive to proteotoxic damage and die at a higher rate.
The other side of proteasome regulation illuminated by the studies in this
chapter is the role played by Nrf1 in the control of c-20S proteasome expression.
Though we show that the downregulated PBX1 / Nrf1 axis could be one reason for
the low c-20S expression, we did not address whether impaired Nrf1 signaling
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could lead to other pathological consequences. Nrf1 regulates more than just
proteasomal gene expression, as it is heavily involved in the ER stress response
and the unfolded protein response (UPR). Genetic knockout of Nrf1 in mouse liver
leads to dysregulation of ER stress sensing genes, through binding of an enhancer
in the activating transcription factor 6 (Atf6) locus, and the UPR-mediated
apoptosis pathway, through an upregulation of DNA damage inducible transcript 3
or CHOP (Baird et al., 2017). Interestingly, augmented CHOP has been found in
the hippocampi of EAE mice – this could reflect the downregulation of Nrf1
expression in this disease that we have described here for the first time. In addition,
reduced Atf6a is known to cause more severe EAE symptoms (Kamarehei et al.,
2019; Stone et al., 2018).
It is important to note that deficient Nrf1 signaling could also increase the
expression of i-20S-specific subunits in EAE. It has been shown that microglia in
which Nrf1 p120 is knocked down not only has augmented IL-1b and TNF-a
expression, but also that of p-STAT-1 (Wang et al., 2018). This suggests that the
diminished Nrf1 levels in our MS model could also contribute to further activation
of p-STAT-1 and its downstream signaling to increase the synthesis of immunosubunits.
One caveat of our in vivo studies is that we have focused primarily on the
pathological processes underlying acute damage, the reason being that we wanted
to discover what consequences the blend of inflammation and oxidative stress
have on our targets of interest. However, because the expression of constitutive
proteasome worsens over the course of EAE, it will be important to study if Nrf1
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also participates in proteasome failure in the chronic animals. Notably, Nfe2l1
mRNA expression in EAE seems to go back to control values at 60 dpi, suggesting
that other factors may be involved in the regulation of proteasomes as disease
progresses.
Although the reduction of Nrf1 in acute EAE seems to be due to its upstream
effector, PBX1, the reason for the decrease in the levels of the latter remains
unknown. PBX1 is recognized as a downstream target of other transcription
factors, such as ecotropic virus integration site-1 (EVI-1) and notch receptor 3
(NOTCH3) (Park et al., 2008; Shimabe et al., 2009). EVI-1 binds to the promoter
region of PBX-1, particularly in the context of leukemia (Shimabe et al., 2009), but
its expression has not been measured in EAE or MS tissues. NOTCH-3 is probably
not involved in PBX1 impairment since it is upregulated in EAE (Jurynczyk et al.,
2008). There is one other pathway that could be involved in the downregulation of
PBX1 – the RE1 silencing transcription factor/neuron-restrictive silencer factor
complex / polypyrimidine tract binding protein 1 (PTBP1) pathway has been
implicated in control of PBX1 splice isoform expression (Linares et al., 2015; Tyler
et al., 2017). Perhaps there is an overabundance of PTBP1 in EAE, leading to a
decrease in both PBX1a (the isoform measured in our experiments) and Nrf1.
Additionally, multiple micro RNAs have been identified that modulate the
expression of PBX1 (Xu et al., 2013). One of these, miR-486-5p, is upregulated in
serum samples from MS patients (Regev et al., 2018).
Finally, while our findings do suggest the participation of the PBX1/Nrf1
signaling pathway in proteasome composition, it will be important to ascertain if
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that is indeed the case by utilizing silencing RNA for each transcription factor in
both neurons and astrocytes in vitro. Moreover, as with many studies, our in vivo
findings would need to be brought back to the disease we are trying to replicate:
MS. A few things to establish in this context will be whether the distribution of
proteasome subunits in neural cells from MS and EAE tissues are similar and
whether PBX1/Nrf1 signaling is also impaired in MS.
Aim

2:

Neuroinflammation

alone

results

in

proteasome

subunit

displacement in neurons and astrocytes in vitro
The second aim investigated the regulation of proteasome subunit
expression in two different neural cell types under inflammatory conditions in vitro.
Our studies in chapter 3 demonstrate that both neurons and astrocytes exposed
to pro-inflammatory cytokines undergo proteasome subunit displacement, which is
different from the combination of dysregulated Nrf1 and subunit displacement that
appears to occur in EAE. We also found that astrocytes have a higher percentage
of i-20S particles as compared to neurons in vitro. This may indicate that, in the
context of acute inflammatory stress, astrocytes have a higher capacity to generate
peptides for antigen presentation compared to neurons. However, our study was
conducted using differentiated tumor cell lines and the situation may be different
in primary cultures of neurons and astrocytes – this will need to be investigated in
the future. Additional studies should also be conducted to determine whether the
pro-inflammatory cytokine mixture that we used is the best to mimic the cellular
environment in EAE. To model oxidative stress, we could employ the glucose /
glucose oxidase system, which leads to continuous production of hydrogen
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peroxide in the medium (Marinho et al., 2013; Panayiotidis et al., 1999), and
determine whether this stressor plays a role in proteasome regulation in these
cells. Also, we could combine the mixture of cytokines with an oxidative stress
condition in culture to determine whether this combination leads to the same
proteasomal dysfunction as observed in EAE.
Just as is the case with EAE, the upregulation of i-20S-specific subunits and
11S subunits in CIII-treated astrocytes and neurons is likely the result of IFN-gtriggered activation of STAT-1. However, the induction of immuno subunits in
astrocytes seems to be independent of IRF-1 – neurons were not studied. We
found that the reduction of NF-kB by IKK-16 in CIII-stimulated astrocytes is enough
to bring IRF-1 levels down to almost normal values, but p-STAT-1 expression
remains elevated along with that of the above-mentioned proteasome subunits.
This finding is contrary to previous studies suggesting that the effects of IFN-g are
produced by the partnership of STAT-1 and IRF-1. However, our conclusion is
supported by the observation that STAT-1 can itself activate transcription of
inducible subunit b1i, while IRF-1 is unable to do so in vitro (Chatterjee-Kishore et
al., 2000).
Another question that arises from the findings of this chapter is why Nrf1
mRNA and protein levels are not affected in vitro like they are in vivo. While Nrf1
expression is reduced in the EAE spinal cord, it is unchanged in both neurons and
astrocytes exposed to cytokines in culture. One explanation could be that there
are stressors in EAE that are not present in the cytokine mixture. Another
possibility is that the 24h exposure is not long enough to produce measurable
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changes in Nrf1 expression. In this regard, it will be interesting to investigate the
effect of a longer period of cytokine exposure (i.e. 72h or more) on PBX1 and Nrf1
levels as well as proteasome composition.
Nrf1 tends to be more involved in controlling homeostatic expression of its
target genes, compared to the more inducible response from Nrf2 (Zhang and
Xiang, 2016). Perhaps this explains why Nrf1 signaling is not affected by the
oxidative stress that likely results from the cytokine exposure. In contrast, the
stress caused by CIII-treatment is enough to induce a strong Nrf2 response in
cultured astrocytes. The lack of changes in Nrf2 levels in stimulated neurons was
an unexpected finding but is consistent with the observation that the Nrf2 pathway
in astrocytes is more active compared to that in neurons and oligodendrocytes
(Draheim et al., 2016). This also agrees with the idea that astrocytes, via Nrf2
signaling, play a role in providing neurons with protection – such as releasing
glutathione for neuronal uptake (Shih et al., 2006).
Cytokines released by activated microglia generate substantial oxidative
stress in astrocytes (Chen et al., 2015), through NF-kB-dependent induction of
NADPH oxidase (NOX). One study found that a 24-hour treatment with IL-1b and
TNF-a is enough to induce high expression of NOX enzymes as well as
intracellular ROS production and lipid peroxidation in human astrocytes (Sheng et
al., 2013). The above studies indicate that cells that respond to IL-1b and TNF-a
and have an active NF-kB signaling pathway (i.e., the differentiated C6 astrocytes)
will produce phagocytic NOX activity (Anrather et al., 2006) and increase Nrf2
transcription. Conversely, cells where inflammatory cytokine treatment fails to
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activate NF-kB (i.e., the differentiated N2a neurons) will not result in either
oxidative stress or upregulation of Nrf2. This places NF-kB at the center of
oxidative stress control and the development of an antioxidant response.
Aim 3: Cellular differences in inflammatory and oxidative stress signaling
may play an important role in the pathophysiology of EAE
The last aim of this dissertation was to explore the link between NF-kB and
Nrf2 signaling and its effect on cellular reactivity in cultured astrocytes exposed to
pro-inflammatory cytokines. The contribution of reactive astrocytes to the CNS
microenvironment in diseases like MS and EAE has become an exciting research
topic. In EAE specifically, the astrocytic transcriptome in both the spinal cord and
cerebellum shows drastically upregulated immune signaling pathways, with the
highest levels being at the peak of disease and declining thereafter (Itoh et al.,
2018). The same group also found that the complement pathway is highly
augmented in the optic nerve as compared to the spinal cord or cerebellum. This
could explain why we only see a smaller subset of A1-reactive astrocytes in the
spinal cords of our EAE mice. Both reactive microglia and astrocytes are found in
the white matter of the lumbar spinal cord in EAE mice starting at 9 dpi, with high
levels of reactivity at 14 and 21 dpi (Valente et al., 2017). This suggests that
inflammation activates microglia early on in EAE, which can then activate
astrocytes to become A1-reactive. However, a recent study also found elevations
in A1-reactive astrocytes present in the EAE spinal cord at 50 dpi, indicating that
these cells are still pertinent even in the chronic stage of the disease (Tassoni et
al., 2019).
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While NF-kB signaling in astrocytes seems to be essential for the
development of tissue damage in EAE, genetic inactivation of neuronal NF-kB –
through suppression of IkB – does not greatly affect the disease course (Lee et
al., 2012). This is consistent with our observations that, in contrast to astrocytes,
neuronal NF-kB signaling is unresponsive to cytokine stimulation.
Nrf2 and NF-kB have been demonstrated to interact under a variety of
contexts, including inflammation, cancer, proteotoxicity, oxidative stress and
others (Sandberg et al., 2014). LPS is known to upregulate gene expression of
Nrf2 and prevent cell death in monocytes, which is blocked by inhibiting
phosphorylation of IkBα (Rushworth et al., 2012). Though the authors suggest that
there could be other signaling partners involved in this regulation, these results
provide convincing evidence for NF-kB-mediated regulation of Nrf2 expression.
Indeed, our own result of diminished NF-kB and Nrf2 expression following the use
of IKK-16 strongly supports this idea. Yet, the crosstalk between Nrf2 and NF-kB
is much more complicated than one triggering the transcription of the other.
Following LPS stimulation, NF-kB can be upregulated by Rac family small GTPase
1 (RAC1)-IκBα which in turn upregulates Nrf2 – conversely, this amplified Nrf2
response then diminishes the NF-kB response (Cuadrado et al., 2014). The
authors speculate that this feedback could be a mechanism to regulate proinflammatory signaling, which could explain the increase in Nrf2 in our model as
an attempt by A1 astrocytes to reduce their NF-kB response. This also follows with
what we described in pan-reactive astrocytes, where NF-kB signaling is already
depressed and therefore the compensatory elevation of Nrf2 is unnecessary.
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Because Nrf2 downregulates NF-kB signaling and NF-kB activation is critical for
astrocyte reactivity, one would expect that abrogation of Nrf2 expression leads to
the formation of the more toxic A1-reactive cells. Indeed, Nrf2 knockout mice with
EAE have higher levels of demyelination as well as increased reactivity of
astrocytes and microglia (Johnson et al., 2010). Furthermore, genetic deletion of
Nrf2 in mice causes widespread demyelination as well as astrogliosis across the
CNS, resulting in spongiform leukoencephalopathy (Hubbs et al., 2007).
In terms of our A1-reactive versus pan-reactive astrocyte study, there are a
few caveats within these experiments that need to be mentioned. The first of these
is that we used GFAP to identify astrocytes, which may not the be the most
comprehensive marker (Liddelow and Barres, 2017). A way to remedy this would
be to use an antibody directed against aldehyde dehydrogenase 1 family member
L1 (Aldh1l1), which has been shown to stain most astrocytes in vivo as well as C6
cells in vitro (Galland et al., 2019). We should also perform similar studies using
primary astrocytes in culture to determine if they would also respond
heterogeneously to the cytokine mixture. One reason for this is that C6 cells are
technically cancer cells, and most tumor cell lines are known to have higher basal
levels of Nrf2 (Tebay et al., 2015), so the Nrf2 response of primary astrocytes could
be different.
Although we have established that there are at least two populations of
reactive astrocytes in EAE and in vitro, we did not assess the presence of A2reactive astrocytes. Because these astrocytes are theorized to be beneficial to the
greater CNS environment, it will be essential to determine whether they are
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present in EAE as well as in vitro. We would first need to perform IHC on EAE
spinal cord tissue using markers for A2 astrocytes, such as TNF superfamily
member 12 (TWEAK) receptor, sphingosine-1-phosphate receptor 3 (S1Pr3) or
Ptx3 (Zamanian et al., 2012), and determine whether this ischemia-driven cell
subtype is present in EAE. Additionally, it would be of interest to establish whether
Nrf2 expression is also elevated in A2-reactive astrocytes generated in vitro. In this
regard, hyperbaric oxygen preconditioning (HBO-PC) of mice has been reported
to increase Nrf2 levels in spinal cord astrocytes and to be protective following
ischemic injury. Furthermore, HBO-PC combined with glucose-oxygen deprivation
in vitro causes a similar Nrf2 boost in primary astrocytes that has been shown to
protect co-cultured primary neurons through astroglial release of glutathione (Xu
et al., 2014). A separate study discovered that Nrf2 increases in rat brain exposed
to hypoxia-ischemia and even more so following HBO-PC (Zhai et al., 2016).
Therefore, we could use an in vitro model of ischemia, such as an oxygen
deprivation or glucose-oxygen deprivation, to assess A2 reactivity markers in our
C6 astrocytes as well as to determine if Nrf2 increases similarly to what we found
in our A1 phenotype.
Scientific Impact
The findings reported in this dissertation help to interpret and extend our
previous investigations suggesting that differential changes in composition and
activity of the proteasome occur within cellular populations in EAE. These data
provide more insight into how the proteasome functions in individual cell types
during acute inflammation in the CNS, which will hopefully translate into MS. In
182

addition, we discovered that astrocytes are more than just part of the first response
in the CNS, but that their reactions can be as diverse as the cells themselves.
Determining whether pan-reactive or A1-reactive cells are harmful could be
essential to understanding how astrocytes behave during complex diseases like
MS. By appreciating how individual populations of cells react to inflammation,
perhaps we will be able to tailor future treatments for regulation of both proteasome
function as well as astrocyte reactivity to help patients suffering from MS.
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Appendix A – List of Abbreviations and Acronyms
a7 (Psma7): 20S subunit a7
ActD: actinomycin D
AD: Alzheimer’s disease
ALS: amyotrophic lateral sclerosis
β5 (Psmb5): c-20S subunit β5
β5i (Psmb8): i-20S inducible subunit β5
C3 (C3): complement C3
c-20S: constitutive-20S particle
CFA: complete Freund’s adjuvant
CHX: cycloheximide
CNC-bZIP: cap’n collar basic leucine zipper
CNS: central nervous system
Cul3: cullin-3
Dpi: days post immunization
EAE: experimental autoimmune encephalomyelitis
eIF2a: eukaryotic initiation factor 2 alpha
EpRE: electrophile response element
ER: endoplasmic reticulum
EVI-1: ecotropic virus integration site-1
GAPDH: glyceraldehyde 3-phosphate dehydrogenase
GAS: gamma interferon activated site
Gclc, g-glutamylcysteine ligase
GFAP: glial fibrillary acidic protein
GSH: glutathione
GSK-3b: glycogen synthase kinase 3b
H3: histone H3
HBO-PC: hyperbaric oxygen preconditioning
HD: Huntington’s disease
HDAC2: histone deacetylase 2
Hprt1: hypoxanthine phosphoribosyltransferase 1
i-20S: immuno-20S particle
IL-1b: interleukin-1b
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IFN-g: interferon-g
IHC: immunohistochemistry
IKK: IkB kinase
IRF-1: interferon regulatory factor-1
ISRE: interferon-stimulated response element
kDA: kilodalton
Keap1: kelch-like ECH associated protein 1
LPS: lipopolysaccharide
MHC: major histocompatibility complex
MOG: myelin oligodendrocyte glycoprotein
mTOR: mammalian target of rapamycin
mTORC: mammalian target of rapamycin complex
MS: multiple sclerosis
NAD(P)H: nicotinamide adenine dinucleotide phosphate
NF-kB: nuclear factor kappa-light-chain-enhancer of activated B cells
NOTCH3: notch receptor 3
NOX: NADPH oxidase
Nqo1: NAD(P)H quinone dehydrogenase 1
Nrf1 (Nfe2l1): nuclear factor (erythroid-derived 2)-like 1
Nrf2 (Nfe2l2): nuclear factor (erythroid-derived 2)-like 2
Nrf3 (Nfe2l3): nuclear factor (erythroid-derived 2)-like 3
p62: sequestosome 1
PA28: 11S regulatory particle
PA28a (Psme1): PA28 subunit a
PA28b (Psme2): PA28 subunit b
PA700: 19S regulatory particle
PBX1: pre-B-cell leukemia homeobox-1 transcription factor
PD: Parkinson’s disease
PI31: proteasome inhibitor 31 kDa
POMP: proteasome maturation protein
PTBP1: polypyrimidine tract binding protein 1
Ptx3: pentraxin 3
Rn18s: 18S ribosomal RNA
ROS: reactive oxygen species
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Rplp0: ribosomal protein lateral stalk subunit P0
Rpt5 (Psmc3): 19S regulatory subunit 6A
RRID: research resource identifier
RT-qPCR: reverse transcription quantitative polymerase chain reaction
sMaf: small musculoaponeurotic fibrosarcoma
SREBP: sterol responsive element binding protein
STAT-1: signal transducer and activator of transcription 1
Tbp: TATA-box binding protein
TNF-a: tumor necrosis factor-a
UPR: unfolded protein response
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